Tumor-specific cleavable linker
Patent Information
- Application Number
- JP2023531600
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-06
- Filing Date
- 2021-11-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-11-24
AI Technical Summary
Current cytokine therapies for cancer, such as aldesleukin, have short half-lives and require frequent administration, leading to systemic side effects due to systemic immune activation, necessitating the development of therapeutic agents that can target tumors specifically without these side effects.
The use of tumor-specific proteolytically cleavable peptide linkers in polypeptide drug constructs that are activated only in the tumor cell environment, allowing for targeted delivery of therapeutic moieties and reducing systemic toxicity by masking the therapeutic agent until activation in the tumor microenvironment.
This approach enhances the therapeutic efficacy by precisely targeting the tumor site, reducing systemic side effects and extending the half-life of cytokines, thereby improving treatment outcomes for cancer.
Smart Images

Figure 2022115865000001 
Figure 2022115865000002 
Figure 2022115865000003
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 118,585, filed November 25, 2020, and U.S. Provisional Patent Application No. 63 / 253,090, filed October 6, 2021, each of which is incorporated by reference herein in its entirety.
[0002] Submission of sequence listing as an ASCII text file The contents of the following submission on an ASCII text file are incorporated herein by reference in their entirety: Sequence Listing Computer Readable Form (CRF) (Filename: 737762003040SEQLIST.TXT, Recorded: November 22, 2021, Size: 961 KB).
[0003] The present invention relates to tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutic agents to the tumor cell environment. The invention also relates to cleavage products of the drugs and prodrugs and methods related to their use. [Background technology]
[0004] Cancer is the second leading cause of death in the United States, accounting for more deaths than the next five leading causes (chronic respiratory disease, stroke, accidents, Alzheimer's disease, and diabetes). While significant progress has been made, particularly in targeted therapies, much research remains in this field. Immunotherapy and its branch, immuno-oncology, are yielding viable and exciting therapeutic options for treating malignancies. In particular, it is now recognized that one hallmark of cancer is immune evasion, and significant efforts have been made to identify targets and develop therapies directed against these targets to reactivate the immune system to recognize and treat cancer.
[0005] Cytokine therapy is an effective strategy for stimulating the immune system to induce antitumor cytotoxicity. In particular, aldesleukin, a recombinant form of interleukin-2 (IL-2), has been approved by the FDA for the treatment of metastatic renal cell carcinoma and melanoma. Unfortunately, cytokines administered to patients generally have very short half-lives and therefore require frequent administration. For example, the product label for aldesleukin, marketed under the brand name Proleukin, states that the drug has been shown to have a half-life of 85 minutes in patients receiving a 5-minute intravenous (IV) administration. Furthermore, the administration of high-dose cytokines can cause health hazards, such as vascular leakage, due to systemic immune activation. These findings highlight the need for the development of therapeutic agents, such as cytokine therapy, that effectively target tumors without the side effects associated with systemic immune activation.
[0006] Prodrugs, in which the cytokine therapeutic agent is masked by a masking moiety and the therapeutic agent is activated only after cleavage of the masking moiety in the tumor cell environment, are one of the methods envisioned to address this need. Summary of the Invention
[0007] The present invention provides novel tumor-specific proteolytically cleavable peptide linkers, including tumor-specific proteolytically cleavable peptides, and their use in polypeptide drug constructs for delivering therapeutic moieties to the tumor cell environment. The portion of the construct other than the therapeutic moiety can be considered a carrier moiety.
[0008] The tumor-specific proteolytically cleavable peptide acts as a substrate for proteases present in the tumor cell environment. A proteolytically cleavable peptide linker is placed within a polypeptide drug construct such that the linker is cleaved by protease action in the tumor cell environment and the polypeptide drug construct separates to form cleavage products, one of which contains a therapeutic moiety. The present invention also relates to the cleavage products of the drug construct, as well as methods related to their use.
[0009] Provided herein are polypeptide drug constructs comprising (i) a therapeutic moiety, (ii) a carrier moiety, and (iii) a proteolytically cleavable peptide linker comprising a tumor-specific proteolytically cleavable peptide having the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
[0010] In some embodiments, the proteolytically cleavable peptide (CP) is flanked on both sides by spacer domains (SD1 and SD2) as shown in the formula below: TIFF2023553323000002.tif4170
[0011] In some embodiments, the spacer domain is rich in the amino acid residues G, S and P.
[0012] In some embodiments, the proteolytically cleavable peptide linker is 10 to 25 amino acids in length.
[0013] In some embodiments, the spacer domain comprises only amino acid residue types selected from the group consisting of G, S and P.
[0014] In some embodiments, the first spacer domain (SD1) is 3 to 6 amino acids in length.
[0015] In some embodiments, the second spacer domain (SD2) is 3 to 6 amino acids in length.
[0016] In some embodiments, SD2 comprises the amino acid sequence SGP.
[0017] In some embodiments, SD2 has the amino acid sequence SGP.
[0018] In some embodiments, the proteolytically cleavable peptide linker is Includes TIFF2023553323000003.tif5170.
[0019] In some embodiments, the proteolytically cleavable peptide linker is Includes TIFF2023553323000004.tif5170.
[0020] In some embodiments, the proteolytically cleavable peptide linker is Includes TIFF2023553323000005.tif5170.
[0021] In some embodiments, the proteolytically cleavable peptide linker is Includes TIFF2023553323000006.tif5170.
[0022] In some embodiments, the proteolytic cleavable peptide linker is Includes TIFF2023553323000007.tif5170.
[0023] In some embodiments, the proteolytically cleavable peptide linker is Includes TIFF2023553323000008.tif5170.
[0024] In some embodiments, the proteolytically cleavable linker is Includes TIFF2023553323000009.tif5170.
[0025] In some embodiments, the proteolytically cleavable linker is Includes TIFF2023553323000010.tif5170.
[0026] In some embodiments, the proteolytically cleavable linker is Includes TIFF2023553323000011.tif5170.
[0027] In some embodiments, the proteolytically cleavable linker is Includes TIFF2023553323000012.tif5170.
[0028] In some embodiments, the proteolytically cleavable peptide linker is directly covalently attached to the therapeutic moiety.
[0029] In some embodiments, a proteolytically cleavable peptide linker is positioned within the drug construct between the therapeutic moiety and the carrier moiety.
[0030] In some embodiments, the proteolytically cleavable peptide linker is located within the carrier moiety.
[0031] In some embodiments, the polypeptide drug construct comprises a single polypeptide chain, meaning that the therapeutic moiety, the carrier moiety, and the proteolytically cleavable peptide linker are present on the same polypeptide chain.
[0032] In some embodiments, the polypeptide drug construct comprises two or more polypeptide chains. In some embodiments, the proteolytically cleavable peptide linker is present in the same polypeptide chain as the therapeutic moiety. In some embodiments, the proteolytically cleavable peptide linker is present in a different polypeptide chain than the therapeutic moiety.
[0033] In some embodiments, the polypeptide drug construct is a prodrug. In some embodiments, the polypeptide drug construct is a prodrug, and the remainder of the molecule (from which the therapeutic moiety is separated after cleavage of the proteolytically cleavable peptide linker) comprises a masking moiety that inhibits the biological activity of the therapeutic moiety of the prodrug, such that the therapeutic moiety becomes biologically active only after cleavage of the proteolytically cleavable peptide linker in the tumor cell environment. In some embodiments, the masking moiety is present on the same polypeptide chain as the therapeutic moiety. In some embodiments, the masking moiety is present on a different polypeptide chain from the therapeutic moiety.
[0034] In some embodiments, the masking moiety is present on the same polypeptide chain as the therapeutic moiety.
[0035] In some embodiments, the masking moiety is present in a first polypeptide chain and the therapeutic moiety is present in a second polypeptide chain.
[0036] In some embodiments, the drug construct comprises a half-life extending moiety.
[0037] In some embodiments, the half-life extending moiety comprises an antibody or a fragment thereof.
[0038] In some embodiments, the half-life extending moiety comprises a first and a second half-life extending moiety.
[0039] In some embodiments, the prodrug is a cytokine prodrug and the therapeutic moiety is a cytokine moiety.
[0040] In some embodiments, the masking moiety comprises a domain of the extracellular domain of a cytokine receptor.
[0041] The cytokine prodrugs described herein, in which the therapeutic moiety is a cytokine moiety and the masking moiety comprises a domain of the extracellular domain of a cytokine receptor, are referred to herein as "masked cytokines."
[0042] In some embodiments, provided herein are masked cytokines comprising a masking moiety in a first polypeptide chain and a cytokine moiety in a second polypeptide chain. Such masked cytokines may be referred to as "heterodimeric" masked cytokines.
[0043] In some embodiments, the masked cytokine is a protein heterodimer comprising:
[0044] a) a first polypeptide chain comprising a masking moiety linked to a first half-life extending moiety via a first linker;
[0045] b) a second polypeptide chain comprising the cytokine portion linked to a second half-life extending moiety via a second linker;
[0046] a first half-life extending moiety associated with a second half-life extending moiety;
[0047] The present invention includes a protein heterodimer, wherein at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
[0048] In some embodiments, in the first polypeptide chain, the first half-life prolonging domain is linked to the amino terminus of a first linker and the carboxy terminus of the first linker is linked to the amino terminus of the masking moiety, and in the second polypeptide chain, the second half-life prolonging domain is linked to the amino terminus of a second linker and the carboxy terminus of the second linker is linked to the amino terminus of the cytokine moiety.
[0049] In some embodiments, the first polypeptide chain is TIFF2023553323000013.tif4170, The second polypeptide chain is TIFF2023553323000014.tif4170, wherein HL1 is a first half-life extending domain, L1 is a first linker, MM is a masking moiety, HL2 is a second half-life extending domain, L2 is a second linker, and C is a cytokine moiety; a first half-life extending moiety associated with a second half-life extending moiety; At least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
[0050] In some embodiments, the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker. This configuration is described herein as "Structure A."
[0051] In some embodiments, the first polypeptide chain is TIFF2023553323000015.tif5170, The second polypeptide chain is Includes TIFF2023553323000016.tif5170.
[0052] In some embodiments, the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker. This configuration is described herein as "Structure B."
[0053] In some embodiments, the first polypeptide chain is TIFF2023553323000017.tif5170, The second polypeptide chain is Includes TIFF2023553323000018.tif5170.
[0054] In some embodiments, provided herein is a masked cytokine comprising a masking moiety and its cytokine moiety linked by a single polypeptide chain. In some embodiments, the masked cytokine has the following formula: TIFF2023553323000019.tif4170, including polypeptide chains wherein HL is a half-life extending domain, L1 is a first linker, MM is a masking moiety, L2 is a second linker, and C is a cytokine moiety, and wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described elsewhere herein. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the first linker is a proteolytically cleavable peptide linker and the second linker is non-cleavable. The non-cleavable linker may be as described elsewhere herein.
[0055] In some embodiments, the masked cytokine has the following formula: TIFF2023553323000020.tif4170, including polypeptide chains; wherein HL is a half-life extending domain, L1 is a first linker, MM is a masking moiety, L2 is a second linker, and C is the cytokine portion thereof, and wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described elsewhere herein. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the first linker is a proteolytically cleavable peptide linker and the second linker is non-cleavable. The non-cleavable linker may be as described elsewhere herein.
[0056] In some embodiments, the non-cleavable linker is between 3 and 25 amino acids in length.
[0057] In some embodiments, the non-cleavable linker is rich in the amino acid residues G, S, and P.
[0058] In some embodiments, the non-cleavable linker comprises the amino acid sequence of SEQ ID NO:14.
[0059] In some embodiments, the non-cleavable linker comprises the amino acid sequence of SEQ ID NO:23.
[0060] In some embodiments, the half-life prolonging domain comprises a first half-life prolonging domain and a second half-life prolonging domain.
[0061] In some embodiments, the first half-life prolonging domain comprises a first Fc domain or a fragment thereof, and the second Fc domain comprises an Fc domain or a fragment thereof.
[0062] In some embodiments, the first Fc domain comprises a CH3 domain or a fragment thereof, and the second Fc domain comprises a CH3 domain or a fragment thereof.
[0063] In some embodiments, the first and second half-life prolonging domains are each an IgG1 Fc domain or fragment thereof.
[0064] In some embodiments, the first and / or second Fc domain each contain one or more modifications that facilitate non-covalent association of the first and second half-life prolonging domains.
[0065] In some embodiments, the first half-life prolonging domain comprises an IgG1 Fc domain or a fragment thereof comprising the mutations Y349C;T366S;L38A and Y407V, numbered according to the Kabat EU numbering system, forming a "hole" in the first half-life prolonging domain, and the second half-life prolonging domain comprises an IgG1 Fc domain or a fragment thereof comprising the mutations S354C and T366W, forming a "knob" in the second half-life prolonging domain.
[0066] In some embodiments, the first and second half-life prolonging domains are each an IgG1 Fc domain or fragment thereof, each comprising an amino substitution at position 297 numbered according to the Kabat EU numbering system.
[0067] In some embodiments, the first and second half-life prolonging domains are each an IgG1 Fc domain or fragment thereof, each comprising an amino substitution of N297A numbered according to the Kabat EU numbering system.
[0068] In some embodiments, the first and second half-life prolonging domains are each an IgG1 Fc domain or fragment thereof, each comprising an amino substitution at position 253 numbered according to the Kabat EU numbering system.
[0069] In some embodiments, the first and second half-life prolonging domains are each an IgG1 Fc domain or fragment thereof, each comprising an amino substitution of I253A numbered according to the Kabat EU numbering system.
[0070] In some embodiments, the first half-life prolonging domain comprises the amino acid sequence of SEQ ID NO:9 and the second half-life prolonging domain comprises the amino acid sequence of SEQ ID NO:12.
[0071] In some embodiments, the first half-life prolonging domain comprises the amino acid sequence of SEQ ID NO:10 and the second half-life prolonging domain comprises the amino acid sequence of SEQ ID NO:13.
[0072] In some embodiments, the half-life prolonging domain (HL) comprises the Fc region of an antibody (i.e., the C-terminal region of an immunoglobulin heavy chain) or a fragment thereof comprising a dimerized Fc domain (HL1-HL2). Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the Fc region of a human IgG heavy chain is usually defined to stretch from an amino acid residue at position Cys226, or from an amino acid residue at position Pro230, to its carboxyl-terminus. In some embodiments, the dimerized Fc domain of an antibody (HL1-HL2) comprises a first half-life prolonging domain and a second half-life prolonging domain, as described elsewhere herein, wherein the first half-life extending moiety comprises a first Fc domain or fragment thereof, and the second half-life extending moiety comprises a second Fc domain or fragment thereof. In some embodiments, HL2 is a component of a polypeptide chain, and HL1 dimerizes to HL2.
[0073] In some embodiments, the first and second half-life extending moieties are each an IgG1 Fc domain or fragment thereof.
[0074] In some embodiments, the first half-life extending moiety comprises an IgG1 Fc domain or a fragment thereof comprising the mutation 1253A, and the second half-life extending moiety comprises an IgG1 Fc domain or a fragment thereof comprising the mutation 1253A. In some embodiments, the first and second half-life extending moieties are derived from the sequence of human IgG1 immunoglobulin heavy chain constant gamma 1 having SEQ ID NO: 6 (the "parent sequence"), such that the first and second half-life extending moieties each comprise SEQ ID NO: 7 or a fragment thereof with one or more amino acid modifications. In some embodiments, the first and second half-life extending moieties comprise SEQ ID NO: 7 with amino substitutions to promote association of the first and second half-life extending moieties according to a "knob-into-hole" approach. In some embodiments, sequence SEQ ID NO:7 contains the mutations Y349C; T366S; L38A, and Y407V (numbered according to the Kabat EU numbering system) to form a "hole" in the first half-life extending portion, and the mutations S354C and T366W (numbered according to the Kabat EU numbering system) to form a "knob" in the second half-life extending portion. In some embodiments, the first and second half-life extending portions each further comprise an amino substitution of N297A numbered according to the Kabat EU numbering system. In some embodiments, the first and second half-life extending portions each further comprise an amino substitution of I253A numbered according to the Kabat EU numbering system. In some embodiments, the first and second half-life extending portions each further comprise both amino substitutions N297A and I253A numbered according to the Kabat EU numbering system. In some embodiments, the first half-life extending moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences in any one of SEQ ID NOs: 7, 8, 9, and 10.In some embodiments, the second half-life extending moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences in any one of SEQ ID NOs: 7, 11, 12, and 13.
[0075] In some embodiments, the cytokine moiety comprises a wild-type cytokine moiety or a variant cytokine moiety.
[0076] In some embodiments, the cytokine moiety is an IL-2 cytokine moiety described anywhere herein.
[0077] In some embodiments, the IL-2 cytokine moiety comprises a wild-type IL-2 cytokine moiety or a variant thereof.
[0078] In some embodiments, the IL-2 cytokine portion comprises an IL-2 cytokine or a fragment thereof.
[0079] In some embodiments, the IL-2 cytokine or functional fragment thereof is modified compared to the sequence of mature IL-2 having SEQ ID NO:2.
[0080] In some embodiments, the modified IL-2 cytokine or functional fragment thereof comprises the modifications R38A, F42A, Y45A, and E62A relative to the sequence of mature IL-2 having SEQ ID NO:2.
[0081] In some embodiments, the modified IL-2 cytokine or functional fragment thereof comprises the modification C125A relative to the sequence of mature IL-2 having SEQ ID NO:2.
[0082] In some embodiments, the modified IL-2 cytokine or functional fragment thereof comprises R38A, F42A, Y45A, E62A, and C125A relative to the sequence of mature IL-2 having SEQ ID NO:2.
[0083] In some embodiments, the IL-2 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO:3.
[0084] In some embodiments, the masking moiety comprises IL-2Rβ or a fragment, portion, or variant thereof.
[0085] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof comprises the amino acid sequence of SEQ ID NO:4.
[0086] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has a mutation at amino acid position C122 compared to the IL-2β of SEQ ID NO:4.
[0087] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has a mutation at amino acid position C168 compared to the IL-2β of SEQ ID NO:4.
[0088] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has mutations at amino acid positions C122 and C168 compared to the IL-2β of SEQ ID NO:4.
[0089] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has the mutations C122S and C168S compared to the IL-2β of SEQ ID NO:4.
[0090] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof comprises the amino acid sequence of SEQ ID NO:5.
[0091] In some embodiments, the cytokine moiety is an IL-12 cytokine moiety described anywhere herein.
[0092] In some embodiments, the IL-12 cytokine moiety comprises a wild-type IL-12 cytokine moiety or a variant thereof.
[0093] In some embodiments, the IL-12 cytokine portion comprises an IL-12 cytokine or a fragment thereof.
[0094] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an IL-12p40 polypeptide or functional fragment thereof covalently linked to an IL-12p35 polypeptide or functional fragment thereof.
[0095] In some embodiments, the IL-12p40-IL-12p35 linker is between 5 and 20 amino acids in length.
[0096] In some embodiments, the IL-12p40-IL-12p35 linker is rich in G and S amino acid residues.
[0097] In some embodiments, the IL-12p40-IL-12p35 linker comprises SEQ ID NO: 116 (GGGGSGGGGSGGGGS).
[0098] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO:204 (as set forth in the IL-12 cytokine subtable herein), or an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO:204 (as set forth in the IL-12 cytokine subtable herein).
[0099] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 204 (as shown in the IL-12 cytokine sub-table herein).
[0100] In some embodiments, the IL-12p40 polypeptide comprises at least one amino acid modification to the GAG binding domain (KSKREKKDRV) compared to the amino acid sequence of SEQ ID NO: 204 (as set forth in the IL-12 cytokine subtable herein).
[0101] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 205 (as shown in the IL-12 cytokine sub-table herein).
[0102] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 206 (as shown in the IL-12 cytokine sub-table herein).
[0103] In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having one or more cysteine substitution mutations compared to the amino acid sequence of SEQ ID NO: 204 (as set forth in the IL-12 cytokine sub-table herein).
[0104] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 207 (as shown in the IL-12 cytokine sub-table herein).
[0105] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO: 208 (as shown in the IL-12 cytokine sub-table herein).
[0106] In some embodiments, the IL-12p35 polypeptide comprises SEQ ID NO:209 (as set forth in the IL-12 cytokine subtable herein), or an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO:209 (as set forth in the IL-12 cytokine subtable herein).
[0107] In some embodiments, the IL-12p35 polypeptide comprises SEQ ID NO: 209 (as shown in the IL-12 cytokine sub-table herein).
[0108] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 210 (as shown in the IL-12 cytokine sub-table herein).
[0109] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 211 (as shown in the IL-12 cytokine sub-table herein).
[0110] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 212 (as shown in the IL-12 cytokine sub-table herein).
[0111] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 213 (as shown in the IL-12 cytokine sub-table herein).
[0112] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 214 (as shown in the IL-12 cytokine sub-table herein).
[0113] In some embodiments, the masking moiety comprises an IL-12 cytokine receptor, or a subunit or functional fragment thereof.
[0114] In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ1, or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-12.
[0115] In some embodiments, the masking moiety comprises residues 24-237 of human IL-12Rβ1, ie, the sequence having SEQ ID NO: 215 (as shown in the IL-12 Masking Moiety Table herein).
[0116] In some embodiments, the masking moiety comprises residues 24-545 of human IL-12Rβ1, ie, the sequence having SEQ ID NO: 216 (as shown in the IL-12 Masking Moiety Table herein).
[0117] In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ2, or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-12.
[0118] In some embodiments, the masking moiety comprises residues 24-212 of human IL-12Rβ2, ie, the sequence having SEQ ID NO: 217 (as shown in the IL-12 Masking Moiety Table herein).
[0119] In some embodiments, the masking moiety comprises residues 24-222 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 218 (as set forth in the IL-12 Masking Subpart Table herein), or the masking moiety comprises residues 24-227 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 222 (as set forth in the IL-12 Masking Subpart Table herein).
[0120] In some embodiments, the masking moiety comprises residues 24-319 of human IL-12Rβ2, ie, a sequence having SEQ ID NO: 219 (as shown in the IL-12 Masking Moiety Table herein).
[0121] In some embodiments, the masking moiety comprises at least one amino acid modification compared to the sequence of SEQ ID NO: 219 (as shown in the IL-12 Masking Moiety Table herein), optionally, the modification is a cysteine substitution mutation.
[0122] In some embodiments, the masking moiety comprises SEQ ID NO: 220 (as shown in the IL-12 Masking Moiety Table herein).
[0123] In some embodiments, the masking moiety comprises residues 24-622 of human IL-12Rβ2, ie, the sequence having SEQ ID NO: 221 (as shown in the IL-12 Masking Moiety Table herein).
[0124] In some embodiments, the cytokine moiety is an IL-15 cytokine moiety described anywhere herein.
[0125] In some embodiments, the IL-15 cytokine moiety comprises a wild-type IL-15 cytokine moiety or a variant thereof.
[0126] In some embodiments, the cytokine moiety is an IL-15 cytokine moiety and the masked cytokine further comprises a domain comprising an IL-15Rα subunit or a functional fragment thereof (the "IL-15Rα domain"). In some embodiments, the cytokine moiety is an IL-15 cytokine moiety and the masked cytokine further comprises a domain comprising an IL-15Rα subunit or a functional fragment thereof (the "IL-15Rα domain"), wherein the IL-15Rα domain and the IL-15 cytokine moiety are present on different polypeptide chains in the construct, and wherein the IL-15Rα domain is non-covalently linked to the IL-15 cytokine moiety.
[0127] As used herein, an "IL-15Rα domain" can consist of the sequence of wild-type sushi domain sIL-15Rα or a variant thereof, such as the sequence of wild-type sushi domain sIL-15Rα having one or more, e.g., one, two, three, or four, amino acid substitutions. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R26. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R26N. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R26S. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R35. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R35Q. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R35S. In some embodiments, the IL-15Rα domain comprises amino acid substitutions at positions R26 and R35. In some embodiments, the IL-15Rα domain comprises the amino acid substitutions R26S or R26N, and R35Q or R35S. In some embodiments, the IL-15Rα domain comprises the amino acid substitutions R26N and R35Q.
[0128] In some embodiments, the IL-15 cytokine portion comprises an IL-15 cytokine or a fragment thereof.
[0129] In some embodiments, the IL-15 cytokine or fragment thereof comprises SEQ ID NO: 224 (as set forth in the IL-15 cytokine sub-table herein) or a functional fragment thereof.
[0130] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine sub-table herein).
[0131] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0132] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53 compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0133] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53, N71, N79, or N112 compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0134] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N71 and N79 compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0135] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N71 and N112 compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0136] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N79 and N112 compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0137] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N71, N79 and N112 compared to the amino acid sequence of SEQ ID NO: 224 (as set forth in the IL-15 cytokine subtable herein).
[0138] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 225 (as set forth in the IL-15 cytokine sub-table herein).
[0139] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 226 (as set forth in the IL-15 cytokine sub-table herein).
[0140] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 227 (as set forth in the IL-15 cytokine sub-table herein).
[0141] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 228 (as set forth in the IL-15 cytokine sub-table herein).
[0142] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 229 (as set forth in the IL-15 cytokine sub-table herein).
[0143] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 230 (as set forth in the IL-15 cytokine sub-table herein).
[0144] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 233 (as set forth in the IL-15 cytokine sub-table herein).
[0145] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 234 (as set forth in the IL-15 cytokine sub-table herein).
[0146] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 235 (as set forth in the IL-15 cytokine sub-table herein).
[0147] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 236 (as set forth in the IL-15 cytokine sub-table herein).
[0148] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 237 (as set forth in the IL-15 cytokine sub-table herein).
[0149] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 238 (as set forth in the IL-15 cytokine sub-table herein).
[0150] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 239 (as set forth in the IL-15 cytokine sub-table herein).
[0151] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an additional mutation at position N71.
[0152] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an additional mutation at position S73.
[0153] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises additional mutations at one or more amino acid positions N72, N79, V80, T81, and N112.
[0154] In some embodiments, the masking moiety comprises IL-15Rβ or a fragment or variant thereof.
[0155] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 (as shown in the IL-15 Masking Moiety Table herein).
[0156] In some embodiments, the masking moiety comprises an IL-15Rβ variant or a fragment thereof having an amino acid substitution at position C122.
[0157] In some embodiments, the masking moiety comprises an IL-15Rβ variant or fragment thereof having the amino acid substitution C122S.
[0158] In some embodiments, the masking moiety comprises an IL-15Rβ variant or a fragment thereof having an amino acid substitution at position C168.
[0159] In some embodiments, the masking moiety comprises an IL-15Rβ variant or fragment thereof having the amino acid substitution C168S.
[0160] In some embodiments, the masking moiety comprises an IL-15Rβ variant or fragment thereof having amino acid substitutions at positions C122 and C168.
[0161] Provided herein are cleavage products comprising an active therapeutic moiety, preparable by proteolytic cleavage of a proteolytically cleavable linker in a polypeptide drug construct described anywhere herein.
[0162] Provided herein are nucleic acids encoding any one of the polypeptide drug constructs described anywhere herein.
[0163] Provided herein are nucleic acids encoding one of the chains of any one of the polypeptide drug constructs described anywhere herein.
[0164] Provided herein are vectors comprising the nucleic acids described herein.
[0165] Provided herein are vectors comprising nucleic acids encoding the polypeptide drug constructs described anywhere herein.
[0166] Provided herein are vectors containing a nucleic acid encoding one of the chains of a polypeptide drug construct described anywhere herein.
[0167] Provided herein are host cells containing the nucleic acids described herein.
[0168] In one embodiment, the host cell is a HEK cell. In another embodiment, the host cell is a CHO cell.
[0169] Provided herein are compositions comprising any one of the polypeptide drug constructs described anywhere herein.
[0170] Provided herein is a pharmaceutical composition comprising any one of the polypeptide drug constructs described anywhere herein and a pharmaceutically acceptable carrier.
[0171] Provided herein are kits that include any one of the polypeptide drug constructs described anywhere herein, or any composition or pharmaceutical composition described herein.
[0172] Provided herein is a method of making any one of the polypeptide drug constructs described anywhere herein, comprising culturing a host cell described herein under conditions to produce the polypeptide drug construct.
[0173] Provided herein are nucleic acids encoding any one of the cleavage products described herein.
[0174] Provided herein are compositions comprising any one of the cleavage products described herein.
[0175] Provided herein are pharmaceutical compositions comprising any one of the cleavage products described herein and a pharmaceutically acceptable carrier.
[0176] Provided herein are polypeptide drug constructs as described herein for use in medicine.
[0177] Provided herein are cleavage products described herein for use in medicine.
[0178] Provided herein are methods for treating or preventing cancer in a subject, the methods comprising administering to the subject an effective amount of a polypeptide drug construct described herein.
[0179] Provided herein are methods for treating or preventing cancer in a subject, the methods comprising administering to the subject an effective amount of a composition described herein.
[0180] Provided herein are methods for treating or preventing cancer in a subject, the methods comprising administering to the subject an effective amount of a pharmaceutical composition described herein.
[0181] Provided herein are methods for treating or preventing cancer in a subject, the methods comprising administering to the subject an effective amount of a polypeptide drug construct described herein, whereby the polypeptide drug construct is proteolytically cleaved in vivo to produce a cleavage product described herein.
[0182] Provided herein are methods for treating or preventing cancer in a subject, the methods comprising generating in vivo cleavage products capable of binding to the target protein, wherein the cleavage products are as described herein.
[0183] Provided herein is a polypeptide drug construct as described herein for use in the treatment or prevention of cancer.
[0184] Provided herein are polypeptide drug constructs described herein for use in methods for treating or preventing cancer, the method comprising administering to a subject an effective amount of the polypeptide drug construct, whereby the polypeptide drug construct is proteolytically cleaved in vivo to produce a cleavage product described herein.
[0185] Provided herein are the cleavage products described herein for use in the treatment or prevention of cancer.
[0186] Provided herein are cleavage products described herein for use in the treatment or prevention of cancer, the method comprising administering to a patient a polypeptide drug construct described herein, thereby producing the cleavage product by proteolytic cleavage of the masked cytokine in vivo.
[0187] Provided herein are cleavage products described herein for use in a method for treating or preventing cancer in a subject, the method comprising producing the cleavage product by in vivo proteolytic cleavage from a polypeptide drug construct described herein administered to the subject. [Brief explanation of the drawings]
[0188] [Figure 1]FIG. 1 shows the structure of exemplary embodiments of masked cytokines comprising a masking moiety, a cytokine or functional fragment thereof ("cytokine"), a half-life extending moiety, and a first linker comprising a first cleavable peptide ("1CP"), a first N-terminal spacer domain ("1NSD"), and a first C-terminal spacer domain ("1CSD"). These exemplary embodiments also comprise a second linker comprising a second cleavable peptide ("2CP"), a second N-terminal spacer domain ("2NSD"), and a second C-terminal spacer domain ("2CSD"). As indicated by the arrows, the exemplary embodiments show that the masking moiety is linked to the first linker and the cytokine or functional fragment thereof is linked to the first and second linkers, but that the masking moiety and cytokine or functional fragment thereof can be interchanged, such that the cytokine or functional fragment thereof is linked to the first linker and the masking moiety is linked to the first and second linkers. FIG. 1 shows the structure of exemplary embodiments of masked cytokines as monomers. [Figure 2]Figure 2 shows the structure of an exemplary embodiment of a masked cytokine, including a masking moiety, a cytokine or functional fragment thereof ("cytokine"), a first half-life extending moiety, and a second half-life extending moiety. The exemplary embodiment shown in Figure 2 also includes a first linker ("1CP") comprising a first cleavable peptide, a first N-terminal spacer domain ("1NSD"), and a first C-terminal spacer domain ("1CSD"), as well as a second linker ("2CP") comprising a second cleavable peptide, a second N-terminal spacer domain ("2NSD"), and a second C-terminal spacer domain ("2CSD"). The exemplary first and second half-life extending moieties include "knob-into-hole" modifications that facilitate association of the first half-life extending moiety with the second half-life extending moiety, as indicated by the "hole" of the first half-life extending moiety and the "knob" of the second half-life extending moiety. The first half-life extending moiety and the second half-life extending moiety are also shown to be associated, at least in part, by the formation of disulfide bonds. Although the "hole" is shown as part of the first half-life extending moiety (linked to the masking moiety) and the "knob" as part of the second half-life extending moiety (linked to the cytokine), it will be understood that the "hole" and "knob" may alternatively be comprised in the second half-life extending moiety and the first half-life extending moiety, respectively, such that the "hole" is part of the second half-life extending moiety (linked to the cytokine) and the "knob" is part of the first half-life extending moiety (linked to the masking moiety). [Figure 3A] 3A-3B show exemplary embodiments of a masked cytokine before (left) and after (right) cleavage by a protease, such as in a tumor microenvironment. Figures 3A-3B show exemplary embodiments of a masked IL-2 cytokine. Protease cleavage releases a masking moiety (e.g., IL-2Rβ, shown in FIG. 3B) or releases IL-2 (FIG. 3A). [Figure 3B] Same as above. [Figure 4]Figure 4 shows SDS-PAGE analysis of flow-through (FT) samples (i.e., proteins that did not bind to the Protein A column) and elution (E) samples (i.e., proteins that bound to and eluted from the Protein A column) following production and purification of IL-2 constructs (AK304, AK305, AK307, AK308, AK309, AK310, AK311, AK312, AK313, AK314, and AK315). [Figure 5A] Figures 5A-5D show the results of SPR analyses testing the binding of an exemplary masked IL-2 polypeptide construct (AK168) or a rhIL-2 control to CD25-Fc. Figure 5A shows the interaction between AK168 and CD25-Fc, Figure 5B shows the interaction between MMP-activated AK168 and CD25-Fc, and Figure 5C shows the interaction between a recombinant human IL-2 (rhIL2) control and CD25-Fc. Figure 5D provides a table summarizing the data obtained for the association constant (k), dissociation constant (kd), equilibrium dissociation constant (KD), and Chi2 and U values for each interaction. [Figure 5B] Same as above. [Figure 5C] Same as above. [Figure 5D] Same as above. [Figure 6A] Figures 6A-6D show the results of SPR analyses testing the binding of an exemplary masked IL-2 polypeptide construct (AK111) or a rhIL2 control to CD122-Fc. Figure 6A shows the interaction between AK111 and CD122-Fc, Figure 6B shows the interaction between protease-activated AK111 and CD122-Fc, and Figure 6C shows the interaction between a recombinant human IL-2 (rhIL-2) control and CD122-Fc. Figure 6D provides a table summarizing the data obtained for the association constant (k), dissociation constant (kd), equilibrium dissociation constant (KD), and Chi2 and U values for each interaction. [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above. [Figure 7A] Figure 7A shows an exemplary embodiment of a masked cytokine before (left) and after (right) cleavage by a protease, such as in a tumor microenvironment. Figure 7B shows an SDS-PAGE analysis of an exemplary masked IL-2 polypeptide construct incubated in the absence (left lane) or presence (right lane) of MMP10 protease, demonstrating the release of IL-2 from the Fc portion. [Figure 7B] Same as above. [Figure 8A] Figures 8A-8D show % STAT5 activation in PBMCs treated with constructs AK032, AK035, AK041, or rhIL-2 as a control. The levels of STAT5 activation (%) are shown for NK cells, CD8+ T cells, effector T cells (Teff), and regulatory T cells (Treg) determined after incubation with rhIL-2 (Figure 8A), AK032 (Figure 8B), AK035 (Figure 8C), or AK041 (Figure 8D). [Figure 8B] Same as above. [Figure 8C] Same as above. [Figure 8D] Same as above. [Figure 9A] Figures 9A-9C show % STAT5 activation in PBMCs treated with constructs AK081 or AK032. The AK081 construct was tested with or without prior exposure to MMP10. An isotype control and an IL-2 negative control were also tested. The levels of STAT5 activation (%) are shown for NK cells (Figure 9A), CD8+ T cells (Figure 9C), and CD4+ T cells (Figure 9B). [Figure 9B] Same as above. [Figure 9C] Same as above. [Figure 10A]Figures 10A-10D show the results of STAT5 activation studies in PBMCs using the AK081 and AK111 constructs, as well as controls including rhIL-2 and anti-RSV antibody. An untreated control was also tested. EC50 (pM) is also shown for rhIL-2, AK081, and AK111 treatment. STAT5 activation (%) is shown for CD4+FoxP3+CD25+ cells (Figure 10A), CD8+ cells (Figure 10B), and CD4+FoxP3-CD25- cells (Figure 10C). Figure 10D provides the EC50 (pM) and fold-change data for the AK081 and AK111 constructs, and the rhIL-2 control. [Figure 10B] Same as above. [Figure 10C] Same as above. [Figure 10D] Same as above. [Figure 11A] Figures 11A-11D show the results of STAT5 activation studies in PBMCs using constructs AK167 and AK168, as well as controls including rhIL-2 and anti-RSV antibody. An untreated control was also tested. EC50 (pM) is also shown for rhIL-2, AK167, and AK168 treatment. STAT5 activation (%) is shown for CD4+FoxP3+CD25+ cells (Figure 11A), CD8+ cells (Figure 11B), and CD4+FoxP3-CD25- cells (Figure 11C). Figure 11D provides EC50 (pM) and fold-change data for the AK167 and AK168 constructs and the rhIL-2 control. [Figure 11B] Same as above. [Figure 11C] Same as above. [Figure 11D] Same as above. [Figure 12A]Figures 12A-12D show % STAT5 activation in PBMCs treated with constructs AK165 or AK166, or an isotype control or IL-2-Fc control, that were (+MMP10) or not previously exposed to MMP10 protease. The key shown in Figure 12A also applies to Figure 12B, and the key shown in Figure 12C also applies to Figure 12D. % STAT5 activation is shown for CD4+FoxP3+ T regulatory cells (Figure 12A), CD4+FoxP3- T helper cells (Figure 12B), CD8+ cytotoxic T cells (Figure 12C), and CD56+ NK cells (Figure 12D). [Figure 12B] Same as above. [Figure 12C] Same as above. [Figure 12D] Same as above. [Figure 13A] Figures 13A-C show % STAT5 activation in PBMCs treated with constructs AK109 or AK110, or an isotype control or IL-2-Fc control, that were (+MMP10) or not previously exposed to MMP10 protease. The key shown in Figure 12B also applies to Figure 13A. % STAT5 activation is shown for NK cells (Figure 13A), CD8 cells (Figure 13B), and CD4 cells (Figure 17C). [Figure 13B] Same as above. [Figure 13C] Same as above. [Figure 14A] Figures 14A-14D show the results of STAT5 activation studies in PBMCs using constructs AK211, AK235, AK253, AK306, AK310, AK314, and AK316, as well as rhIL-2 control. % STAT5 activation is shown for CD3+CD4+FoxP3+ cells (Figure 14A), CD3+CD4+FoxP3- cells (Figure 14B), and CD3+CD8+ cells (Figure 14C). Figure 14D provides EC50 data for each of the tested constructs and the rhIL-2 control. [Figure 14B] Same as above. [Figure 14C] Same as above. [Figure 14D] Same as above. [Figure 15A] Figures 15A-15D show the results of STAT5 activation studies in PBMCs using protease-activated constructs AK081, AK167, AK216, AK218, AK219, AK220, and AK223, as well as rhIL-2 control. % STAT5 activation is shown for CD4 FoxP3 CD25 regulatory T cells (Figure 15A), CD4 FoxP3 CD25 cells (Figure 15B), and CD8 cells (Figure 15C). Figure 15D provides EC50 data for each of the tested constructs and the rhIL-2 control. [Figure 15B] Same as above. [Figure 15C] Same as above. [Figure 15D] Same as above. [Figure 16A] Figures 16A-16C show STAT5 activation (%) in PBMCs treated with constructs AK081, AK189, AK190, or AK210, or an anti-RSV control. The key shown in Figure 16A also applies to Figures 16B and 16C. STAT5 activation (%) is shown for regulatory T cells (Figure 16A), CD4 helper T cells (Figure 16B), and CD8 cells (Figure 16C). [Figure 16B] Same as above. [Figure 16C] Same as above. [Figure 17A] Figures 17A-17C show % STAT5 activation in PBMCs treated with constructs AK167, AK191, AK192, or AK193, or an anti-RSV control. The key shown in Figure 17A also applies to Figures 17B and 17C. % STAT5 activation is shown for regulatory T cells (Figure 17A), CD4 helper T cells (Figure 17B), and CD8 cells (Figure 17C). [Figure 17B] Same as above. [Figure 17C] Same as above. [Figure 18A]Figures 18A-18D show the results of pharmacokinetic studies conducted in tumor-bearing mice using constructs AK032, AK081, AK111, AK167, or AK168, or an anti-RSV control. Figure 18A provides a simple depiction of the structure of each construct tested. Figure 18B shows Fc levels (μg / mL) in plasma by detecting human IgG, Figure 18C shows Fc-CD122 levels (μg / mL) in plasma by detecting human CD122, and Figure 18D shows Fc-IL2 levels (μg / mL) in plasma by detecting human IL-2. Prior to the detection step, anti-human IG was used as a capture antibody. [Figure 18B] Same as above. [Figure 18C] Same as above. [Figure 18D] Same as above. [Figure 19A] Figures 19A-19D show the results of pharmacokinetic studies conducted in tumor-bearing mice using constructs AK167, AK191, AK197, AK203, AK209, or AK211, or an anti-RSV control. Figure 19A provides a simple depiction of the structure of each construct tested. Figure 19B shows Fc levels (μg / mL) in plasma by detecting human IgG, Figure 19C shows Fc-IL2 levels (μg / mL) in plasma by detecting human IL-2, and Figure 19D shows Fc-CD122 levels (μg / mL) in plasma by detecting human CD122. Prior to the detection step, anti-human IG was used as a capture antibody. [Figure 19B] Same as above. [Figure 19C] Same as above. [Figure 19D] Same as above. [Figure 20A]Figures 20A-20L show the results of a study examining the in vivo response of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumors using AK032, AK081, AK111, AK167, or AK168 constructs, or an anti-RSV IgG control. For spleen tissue, the CD8 cell percentage of CD3 cells (Figure 20A), the CD4 cell percentage of CD3 cells (Figure 20B), the NK cell percentage of CD3- cells (Figure 20C), and the FoxP3 cell percentage of CD4 cells (Figure 20D) are shown. For blood, the CD8 cell percentage of CD3 cells (Figure 20E), the CD4 cell percentage of CD3 cells (Figure 20F), the NK cell percentage of CD3- cells (Figure 20G), and the FoxP3 cell percentage of CD4 cells (Figure 20H) are shown. For tumor tissues, the CD8 cell % of CD3 cells (Fig. 20I), the CD4 % of CD3 cells (Fig. 20J), the NK cell % of CD3- cells (Fig. 20K), and the FoxP3 % of CD4 cells (Fig. 20L) are shown. [Figure 20B] Same as above. [Figure 20C] Same as above. [Figure 20D] Same as above. [Figure 20E] Same as above. [Figure 20F] Same as above. [Figure 20G] Same as above. [Figure 20H] Same as above. [Figure 20I] Same as above. [Figure 20J] Same as above. [Figure 20K] Same as above. [Figure 20L] Same as above. [Figure 21A]Figures 21A-21L show the results of a study examining the in vivo response of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumors using the AK167, AK168, AK191, AK197, AK203, AK209, or AK211 constructs, or an anti-RSV IgG control. For spleen tissue, the CD8 cell percentage of CD3 cells (Figure 21A), the CD4 cell percentage of CD3 cells (Figure 21B), the NK cell percentage of CD3 cells (Figure 21C), and the FoxP3 cell percentage of CD4 cells (Figure 21D) are shown. For blood, the CD8 cell percentage of CD3 cells (Figure 21E), the CD4 cell percentage of CD3 cells (Figure 21F), the NK cell percentage of CD3 cells (Figure 21G), and the FoxP3 cell percentage of CD4 cells (Figure 21H) are shown. For tumor tissues, the % CD8 cells among CD3 cells (Fig. 21I), % CD4 cells among CD3 cells (Fig. 21J), % NK cells among CD3- cells (Fig. 21K), and % FoxP3 cells among CD4 cells (Fig. 21L) are shown. [Figure 21B] Same as above. [Figure 21C] Same as above. [Figure 21D] Same as above. [Figure 21E] Same as above. [Figure 21F] Same as above. [Figure 21G] Same as above. [Figure 21H] Same as above. [Figure 21I] Same as above. [Figure 21J] Same as above. [Figure 21K] Same as above. [Figure 21L] Same as above. [Figure 22A]Figures 22A-22L show the results of a study examining the in vivo response of CD4, CD8, NK, and Treg percentages in spleen, blood, and tumors using AK235, AK191, AK192, AK193, AK210, AK189, AK190, or AK211 constructs, or an anti-RSV IgG control. For spleen tissue, the CD8 cell percentage of CD3 cells (Figure 22A), the CD4 cell percentage of CD3 cells (Figure 22B), the NK cell percentage of CD3 cells (Figure 22C), and the FoxP3 cell percentage of CD4 cells (Figure 22D) are shown. For blood, the CD8 cell percentage of CD3 cells (Figure 22E), the CD4 cell percentage of CD3 cells (Figure 22F), the NK cell percentage of CD3 cells (Figure 22G), and the FoxP3 cell percentage of CD4 cells (Figure 22H) are shown. For tumor tissues, the % CD8 cells among CD3 cells (Fig. 22I), % CD4 cells among CD3 cells (Fig. 22J), % NK cells among CD3- cells (Fig. 22K), and % FoxP3 cells among CD4 cells (Fig. 22L) are shown. [Figure 22B] Same as above. [Figure 22C] Same as above. [Figure 22D] Same as above. [Figure 22E] Same as above. [Figure 22F] Same as above. [Figure 22G] Same as above. [Figure 22H] Same as above. [Figure 22I] Same as above. [Figure 22J] Same as above. [Figure 22K] Same as above. [Figure 22L] Same as above. [Figure 23A]Figures 23A-23I show the results of in vivo T cell activation in spleen, blood, and tumors using the AK235, AK191, AK192, AK193, AK210, AK189, AK190, or AK211 constructs. T cell activation was measured as the mean fluorescence intensity (MFI) of CD25 in CD8+ T cells (Figure 23A; Figure 23D; Figure 23G), CD4+ T cells (Figure 23B; Figure 23E; Figure 23H), or Foxp3+ cells (Figure 23C; Figure 23F; Figure 23I) in spleen, blood, and tumors. Statistical analysis was performed using one-way ANOVA in comparison with the non-cleavable AK211 construct. [Figure 23B] Same as above. [Figure 23C] Same as above. [Figure 23D] Same as above. [Figure 23E] Same as above. [Figure 23F] Same as above. [Figure 23G] Same as above. [Figure 23H] Same as above. [Figure 23I] Same as above. [Figure 24A] Figures 24A-24D show the results of a study examining the in vivo cleavage of exemplary masked IL-2 polypeptide constructs AK168 (cleavable peptide sequence: MPYDLYHP, SEQ ID NO: 24) and AK209 (cleavable peptide sequence: VPLSLY, SEQ ID NO: 28). [Figure 24B] Same as above. [Figure 24C] Same as above. [Figure 24D] Same as above. [Figure 24E] FIG. 24E shows the results of a pharmacokinetic study of total plasma IgG concentration (μg / mL) for combined levels of the AK167, AK168, and AK209 constructs, as well as levels of the uncleaved form of each construct. [Figure 25A]Figures 25A-25D show the results of in vivo studies assessing vascular leakage using exemplary masked IL-2 polypeptide constructs AK111 or AK168, or unmasked IL-2 polypeptide constructs AK081 or AK167, or an anti-RSV control. [Figure 25B] Same as above. [Figure 25C] Same as above. [Figure 25D] Ibid. Figure 25A shows the percent weight loss, and Figures 25B, 25C, and 25D show the weights of the liver, lungs, and spleen, respectively, in grams. [Figure 26A] Figures 26A and 26B show the results of an in vivo study evaluating vascular leakage by measuring the degree of dye leakage into liver and lung tissue after administration of the AK081, AK111, AK167, or AK168 construct, or an anti-RSV control. The degree of dye leakage into the liver (Figure 26A) and lung (Figure 26B) was measured based on absorbance at 650 nm. [Figure 26B] Same as above. [Figure 27A] Figures 27A and 27B show the results of an in vivo study evaluating vascular leakage, as measured by the degree of perivascular infiltration of mononuclear cells into liver and lung tissue after administration of the AK081, AK111, AK167, or AK168 construct, or an anti-RSV control. The mean number of mononuclear cells in the liver (Figure 27A) and lung (Figure 27B) are shown, respectively. [Figure 27B] Same as above. [Figure 28A] Figures 28A and 28B show the results of a syngeneic tumor model study in which tumor volume and body weight were assessed over the course of treatment with AK032, AK081, AK111, AK167, or AK168 constructs, or an anti-RSV control. Figure 28A shows data on tumor volume over the course of treatment, and Figure 28B shows data on the percentage change in body weight over the course of treatment. [Figure 28B] Same as above. [Figure 29A]Figures 29A and 29B show that AK471 with the I253A FcRn mutation induces robust CD8 T cell expansion in the TME while remaining inactive in the periphery. [Figure 29B] Same as above. [Figure 30A] Figures 30A to 30C show that AK471 has a slightly shorter half-life compared to aglyco-hIgG1. [Figure 30B] Same as above. [Figure 30C] Same as above. [Figure 31A] Figures 31A-C show that there is no evidence of cleavage or decapitation by AK471 in plasma. [Figure 31B] Same as above. [Figure 31C] Same as above. [Figure 32A] 32A and 32B show the results of Example 5. [Figure 32B] Same as above. [Figure 33A] 33A to 33D show the results of Example 5. [Figure 33B] Same as above. [Figure 33C] Same as above. [Figure 33D] Same as above. [Figure 34A] Figures 34A and 34B show the results of Example 6i. [Figure 34B] Same as above. [Figure 35A] Figures 35A and 35B show the results of Example 6ii. [Figure 35B] Same as above. [Figure 36A] Figures 36A and 36B show the results of Example 6iii. [Figure 36B] Same as above. [Figure 37A] Figures 37A and 37B show the results of Example 6iv. [Figure 37B] Same as above. [Figure 38A] Figures 38A and 38B show the results of Example 6v. [Figure 38B] Same as above. [Figure 39A] Figures 39A and 39B show the results of Example 6vi. [Figure 39B] Same as above. [Figure 40A] 40A to 40D show the results of Example 6vii. [Figure 40B] Same as above. [Figure 40C] Same as above. [Figure 40D] Same as above. [Figure 41A] Figures 41A and 41B show the results of Example 6viii. [Figure 41B] Same as above. [Figure 42A] Figures 42A and 42B show the results of Example 6ix. [Figure 42B] Same as above. [Figure 43A] Figures 43A and 43B show the results of Example 6x. [Figure 43B] Same as above. [Figure 44A] Figures 44A-44D and 45A-45F show the results of SDS-PAGE and HEK-Blue IL-2 bioassays using exemplary IL-15 constructs AK904 and AK910 without peptide substrate, and constructs AK932, AK938, AK930, and AK936 with peptide substrate. Figures 44A-44D show the results of the SDS-PAGE gel. Figures 45A-45F show the results of the HEK-Blue IL-2 bioassay. [Figure 44B] Same as above. [Figure 44C] Same as above. [Figure 44D] Same as above. [Figure 45A] Same as above. [Figure 45B] Same as above. [Figure 45C] Same as above. [Figure 45D] Same as above. [Figure 45E] Same as above. [Figure 45F] Same as above. [Figure 46]46 to 54 show the results of Example 9. [Figure 47] Same as above. [Figure 48A] Same as above. [Figure 48B] Same as above. [Figure 49A] Same as above. [Figure 49B] Same as above. [Figure 50A] Same as above. [Figure 50B] Same as above. [Figure 50C] Same as above. [Figure 50D] Same as above. [Figure 50E] Same as above. [Figure 50F] Same as above. [Figure 50G] Same as above. [Figure 50H] Same as above. [Figure 50I] Same as above. [Figure 50J] Same as above. [Figure 50K] Same as above. [Figure 51A] Same as above. [Figure 51B] Same as above. [Figure 52A] Same as above. [Figure 52B] Same as above. [Figure 52C] Same as above. [Figure 52D] Same as above. [Figure 52E] Same as above. [Figure 52F] Same as above. [Figure 52G] Same as above. [Figure 53] Same as above. [Figure 54A] Same as above. [Figure 54B] Same as above. [Figure 54C] Same as above. [Figure 54D] Same as above. [Figure 54E] Same as above. [Figure 55A]Figures 55-65 show the results of Example 10. Figures 55A-55D show the results of pharmacokinetic studies conducted in CT26 tumor-bearing mice using constructs AK904, AK910, AK930, or AK936. Figure 55A shows the percentage of body weight loss, Figure 55B shows tumor volume in mm, and Figures 55C and 55D show lung and spleen weights in grams, respectively, 5 days after treatment. Statistical analysis was performed using one-way ANOVA compared to the vehicle group (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001). [Figure 55B] Same as above. [Figure 55C] Same as above. [Figure 55D] Same as above. [Figure 56A] Figures 56A-C show the results of a study examining the in vivo response of NK cells as a percentage of CD45+ cells in blood, spleen, and tumor. [Figure 56B] Same as above. [Figure 56C] Same as above. [Figure 57A] Figures 57A-C show the results of a study examining the in vivo response of NK cell proliferation as MFI of Ki67 in blood, spleen, and tumor. [Figure 57B] Same as above. [Figure 57C] Same as above. [Figure 58A] Figures 58A-C show the results of a study examining the in vivo response of CD8 T cells as a percentage of CD45+ cells in blood, spleen, and tumor. [Figure 58B] Same as above. [Figure 58C] Same as above. [Figure 59A] Figures 59A-C show the results of a study examining the in vivo response of CD8 T cell proliferation as MFI of Ki67 in blood, spleen, and tumor. [Figure 59B] Same as above. [Figure 59C] Same as above. [Figure 60A]Figures 60A-60C show the results of a study examining the in vivo response of CD8 / Treg ratios in blood, spleen, and tumor. [Figure 60B] Same as above. [Figure 60C] Same as above. [Figure 61A] Figures 61A-61D show the results of a pharmacokinetic study conducted in B16F10 tumor-bearing mice using constructs AK904, AK910, AK930, and AK936. Figure 61A shows the percentage of body weight loss, Figure 61B shows tumor volume in mm, and Figures 61C and 61D show lung and spleen weights in grams, respectively, 5 days after treatment. Statistical analysis was performed using one-way ANOVA compared to the vehicle group (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001). [Figure 61B] Same as above. [Figure 61C] Same as above. [Figure 61D] Same as above. [Figure 62A] Figures 62A-62D show the results of a pharmacokinetic study performed as described in Example 10 in B16F10 tumor-bearing mice using constructs AK904, AK910, AK930, and AK936. Figure 62A shows the Fc levels (ng / mL) in plasma by detecting human IgG. Figures 62B-62D show the half-life, Cmax, and AUC(0-last) calculated by WinNonlin software from the results of Figure 62A. [Figure 62B] Same as above. [Figure 62C] Same as above. [Figure 62D] Same as above. [Figure 63A] Figures 63A-C show the results of a study examining the in vivo response of NK cells as a percentage of CD45+ cells in blood, spleen, and tumor. [Figure 63B] Same as above. [Figure 63C] Same as above. [Figure 64A]Figures 64A-C show the results of a study examining the in vivo response of CD8 T cells as a percentage of CD45+ cells in blood, spleen, and tumor. [Figure 64B] Same as above. [Figure 64C] Same as above. [Figure 65A] Figures 65A-C show the results of a study examining the in vivo response of CD8 / Treg ratios in blood, spleen, and tumor. [Figure 65B] Same as above. [Figure 65C] Same as above. [Figure 66] 66 and 67 show the results of Example 11. [Figure 67] Same as above. DETAILED DESCRIPTION OF THE INVENTION
[0189] 1. Polypeptide Drug Constructs The present invention provides novel tumor-specific proteolytically cleavable peptide linkers and their use in polypeptide drug constructs for delivering therapeutic moieties to the tumor cell environment. The proteolytically cleavable peptide linker is placed within the polypeptide drug construct so that the polypeptide drug construct is released when the linker is cleaved by protease action in the tumor cell environment. The present invention also relates to cleavage products of the drug constructs, as well as methods related to their use.
[0190] The protease substrate amino acid sequences DLLAVVAAS and ISSGLLSGRS have been found to exhibit highly specific cleavage in tumor cell environments compared to non-tumor cell environments. Therefore, these proteolytically cleavable peptides can be advantageously used as proteolytically cleavable peptide linkers in polypeptide drug constructs, and any systemic side effects of administered protein therapeutic agents can be reduced.
[0191] The proteolytically cleavable peptide linker may be directly or indirectly attached to the therapeutic moiety within the polypeptide drug construct. If the polypeptide drug construct comprises multiple polypeptide chains, the proteolytically cleavable peptide linker may be present within the same polypeptide chain as the therapeutic moiety or within a different polypeptide chain.
[0192] The portion of the construct other than the therapeutic moiety can be considered a carrier moiety. When the proteolytically cleavable peptide linker is directly covalently bonded to the therapeutic moiety, the proteolytically cleavable peptide linker is located within the drug construct between the therapeutic moiety and the carrier moiety. Alternatively, the proteolytically cleavable peptide linker may be located within the carrier moiety so that the separated molecule after cleavage contains a portion of the therapeutic moiety and the carrier moiety.
[0193] A polypeptide drug construct comprising a tumor-specific proteolytically cleavable peptide linker may be a prodrug. When a tumor-specifically cleavable linker is used in a prodrug to deliver a therapeutic moiety to a tumor cell environment, the remaining molecule separated after cleavage of the therapeutic moiety may contain a masking moiety, which inhibits the biological activity of the therapeutic moiety in the prodrug, so that the therapeutic moiety is only biologically active after cleavage of the proteolytically cleavable peptide linker in the tumor cell environment. The masking moiety may be present in the same polypeptide chain as the therapeutic moiety. Alternatively, the masking moiety may be present in the first polypeptide chain, and the therapeutic moiety may be present in the second polypeptide chain. The proteolytically cleavable peptide linker may be present in either the first or second polypeptide chain.
[0194] By using a masking moiety, the systemic side effects of administered protein therapeutics can be reduced by interfering with the binding ability of the therapeutic. By masking a therapeutic agent using a proteolytically cleavable peptide linker, the binding ability that is interfered with by using the masking moiety can be restored by cleavage of the proteolytically cleavable peptide linker in the tumor microenvironment. Thus, the prodrugs provided herein are engineered to precisely target pharmacological activity to the tumor microenvironment by taking advantage of the high local concentration of active proteases, one of the hallmarks of cancer. This characteristic of the tumor microenvironment is used to transform systemically inactive molecules into locally active molecules in the form of cleavage products. Activation of the therapeutic moiety in the tumor microenvironment significantly reduces the systemic toxicity that can be associated with drugs administered to a subject in their active form.
[0195] In some embodiments, the drug constructs provided herein comprise a half-life extending moiety. A long half-life in vivo is important for therapeutic proteins. Unfortunately, therapeutic agents administered to a subject can have a short half-life because they are usually rapidly removed from the subject by mechanisms including renal clearance and endocytic degradation. Therefore, the drug constructs provided herein may comprise a half-life extending moiety for the purpose of extending the half-life of the therapeutic moiety in vivo.
[0196] Proteolytically Cleavable Peptide Linker The proteolytically cleavable peptide linkers described herein include proteolytically cleavable peptides (CPs) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
[0197] In some embodiments, the proteolytically cleavable peptide linker is 9 to 25 amino acids in length.
[0198] In some embodiments, the proteolytically cleavable peptide linker is 10 to 25 amino acids in length.
[0199] In some embodiments, the proteolytically cleavable peptide linker is 12 to 18 amino acids in length.
[0200] In some embodiments, the proteolytically cleavable peptide linker comprises a proteolytically cleavable peptide (CP) flanked on both sides by spacer domains (SD1 and SD2) as shown below. TIFF2023553323000021.tif4170
[0201] In some embodiments, the proteolytically cleavable peptide (CP) consists of the amino acid sequence DLLAVVAAS.
[0202] In some embodiments, the proteolytically cleavable peptide (CP) consists of the amino acid sequence ISSGLLSGRS.
[0203] The spacer domain may consist of one or more amino acids. The function of the spacer domain, if present, is to link the proteolytically cleavable peptide (CP) to other functional components in the constructs described herein.
[0204] It will be understood that the spacer domain does not alter the biological interaction of the proteolytically cleavable peptide with proteases in a tumor cell environment or a non-tumor cell environment, in other words, even in the presence of a spacer domain, the inventive proteolytically cleavable peptides disclosed herein retain their advantageous tumor specificity.
[0205] In some embodiments, the spacer domains flanking the proteolytically cleavable peptide are different.
[0206] In some embodiments, the spacer domain is rich in the amino acid residues G, S and P.
[0207] In some embodiments, the spacer domain comprises only amino acid residue types selected from the group consisting of G, S and P.
[0208] In some embodiments, the first spacer domain (SD1) is 3 to 10 amino acids in length. In some embodiments, the first spacer domain (SD1) is 4 to 9 amino acids in length. In some embodiments, the first spacer domain (SD1) is 3 to 6 amino acids in length.
[0209] An exemplary SD1 sequence is shown below. [Table 1]
[0210] In some embodiments, the first spacer domain (SD1) has a sequence shown in the table above.
[0211] In some embodiments, the C-terminal sequence of SD2 is -GP C'.
[0212] In some embodiments, the C-terminal sequence of SD2 is SEQ ID NO:29.
[0213] In some embodiments, the second spacer domain (SD2) is 3 to 6 amino acids in length.
[0214] In some embodiments, SD2 comprises the amino acid sequence SGP.
[0215] In some embodiments, SD2 has the amino acid sequence SGP.
[0216] Exemplary combinations of SD1 and SD2 in cleavable linkers are shown below: [Table 2]
[0217] In some embodiments, the second spacer domain (SD2) has a sequence shown in the table above.
[0218] In some embodiments, the proteolytically cleavable linker comprises SD1-CP-SD2, where SD1 is a first spacer domain, CP is a cleavable peptide having the amino acid sequence DLLAVVAAS, and SD2 is a second spacer domain. In some embodiments, the spacer domain is rich in amino acid residues G, S, and P. In some embodiments, the spacer domain comprises only amino acid residue types selected from the group consisting of G, S, and P. In some embodiments, SD2 has the amino acid sequence SGP.
[0219] In some embodiments, the proteolytically cleavable linker comprises SD1-CP-SD2, where SD1 is a first spacer domain, CP is a cleavable peptide having the amino acid sequence ISSGLLSGRS, and SD2 is a second spacer domain. In some embodiments, the spacer domain is rich in amino acid residues G, S, and P. In some embodiments, the spacer domain comprises only amino acid residue types selected from the group consisting of G, S, and P. In some embodiments, SD2 has the amino acid sequence SGP.
[0220] An exemplary cleavable linker using TIFF2023553323000024.tif5170 is shown below. [Table 3]
[0221] In some embodiments, the cleavable linker is Includes TIFF2023553323000026.tif5170.
[0222] In some embodiments, the cleavable linker is Includes TIFF2023553323000027.tif5170.
[0223] In some embodiments, the cleavable linker is Includes TIFF2023553323000028.tif5170.
[0224] In some embodiments, the cleavable linker is Includes TIFF2023553323000029.tif5170.
[0225] In some embodiments, the cleavable linker is Includes TIFF2023553323000030.tif5170.
[0226] In some embodiments, the cleavable linker is Includes TIFF2023553323000031.tif5170.
[0227] In some embodiments, the cleavable linker is I have TIFF2023553323000032.tif5170.
[0228] In some embodiments, the cleavable linker is I have TIFF2023553323000033.tif5170.
[0229] In some embodiments, the cleavable linker is I have TIFF2023553323000034.tif5170.
[0230] In some embodiments, the cleavable linker is I have TIFF2023553323000035.tif5170.
[0231] In some embodiments, the cleavable linker is I have TIFF2023553323000036.tif5170.
[0232] In some embodiments, the cleavable linker is I have TIFF2023553323000037.tif5170.
[0233] In some embodiments, the cleavable linker is I have TIFF2023553323000038.tif5170.
[0234] In some embodiments, the cleavable linker is I have TIFF2023553323000039.tif5170.
[0235] An exemplary cleavable linker using TIFF2023553323000040.tif5170 is shown below. [Table 4]
[0236] In some embodiments, the cleavable linker is I have TIFF2023553323000042.tif5170.
[0237] In some embodiments, the cleavable linker is I have TIFF2023553323000043.tif5170.
[0238] In some embodiments, the cleavable linker is I have TIFF2023553323000044.tif5170.
[0239] In some embodiments, the cleavable linker is I have TIFF2023553323000045.tif5170.
[0240] The linker combinations disclosed in the exemplary AK molecules may be used with any cytokine moiety disclosed herein. The linker combinations disclosed in the exemplary AK molecules may be used with any masking moiety disclosed herein. The linker combinations disclosed in the exemplary AK molecules may be used with any half-life extending moiety. In other words, the linkers disclosed in the exemplary AK molecules may be used in combination with any cytokine moiety, masking moiety, and / or half-life extending moiety disclosed herein.
[0241] Half-life extension moiety A long half-life in vivo is important for therapeutic proteins.
[0242] The term "half-life extending moiety" includes, for example, PEG, albumin, antibodies and antibody fragments.
[0243] The half-life extending moiety may comprise an antibody or a fragment thereof.
[0244] An antibody or fragment thereof capable of FcRn-mediated recycling may reduce or otherwise delay clearance of the drug construct from a subject, thereby extending the half-life of the administered drug construct. In some embodiments, the antibody or fragment thereof is any antibody or fragment thereof capable of FcRn-mediated recycling, such as any heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) capable of FcRn-mediated recycling.
[0245] The antibody or fragment thereof may be any antibody or fragment thereof. However, in some embodiments of a drug construct comprising a first half-life extending moiety and a second half-life extending moiety, either the first half-life extending moiety or the second half-life extending moiety may comprise an antibody or fragment thereof that does not bind to the FcRn receptor, such as a light chain polypeptide. For example, in some embodiments of a drug construct, the first half-life extending moiety comprises an antibody or fragment thereof comprising a light chain polypeptide or portion thereof that does not directly interact with the FcRn receptor, but the drug construct nevertheless has an extended half-life due to the inclusion of a second half-life extending moiety that can interact with the FcRn receptor, e.g., comprising a heavy chain polypeptide. It is recognized in the art that FcRn-mediated recycling requires binding of the FcRn receptor to the Fc region of an antibody or fragment thereof. For example, studies have shown that residues I253, S254, H435, and Y436 (numbered according to the Kabat EU index numbering system) are important for the interaction between the human Fc region and the human FcRn complex. See, for example, Firan, M., et al., Int. Immunol. 13 (2001) 993-1002; Shields, RL, et al., J. Biol. Chem. 276 (2001) 6591-6604. Various mutants of residues 248-259, 301-317, 376-382, and 424-437 (numbered according to the Kabat EU index numbering system) have also been investigated and reported. Yeung, YA, et al. (J. Immunol. 182 (2009) 7667-7671).
[0246] In some embodiments, the antibody or fragment thereof comprises either a heavy chain polypeptide or a light chain polypeptide. In some embodiments, the antibody or fragment thereof comprises a portion of either a heavy chain polypeptide or a light chain polypeptide. In some embodiments, the antibody or fragment thereof comprises an Fc domain or a fragment thereof. In some embodiments, the antibody or fragment thereof comprises a CH2 and CH3 domain or a fragment thereof. In some embodiments, the antibody or fragment thereof comprises a constant domain of a heavy chain polypeptide. In some embodiments, the antibody or fragment thereof comprises a constant domain of a light chain polypeptide. In some embodiments, the antibody or fragment thereof comprises a heavy chain polypeptide or a fragment thereof (e.g., an Fc domain or a fragment thereof). In some embodiments, the antibody or fragment thereof comprises a light chain polypeptide.
[0247] In some embodiments, the first half-life extending moiety comprises a first Fc domain or fragment thereof and the second half-life extending moiety comprises a second Fc domain or fragment thereof.
[0248] In some embodiments, the first and / or second Fc domain each contain one or more modifications that facilitate non-covalent attachment of the first and second half-life extending moieties. In some embodiments, the first half-life extending moiety comprises an IgG1 Fc domain or a fragment thereof comprising the mutations Y349C; T366S; L38A and Y407V, forming a "hole" in the first half-life extending moiety, and the second half-life extending moiety comprises an IgG1 Fc domain or a fragment thereof comprising the mutations S354C and T366W, forming a "knob" in the second half-life extending moiety.
[0249] In some embodiments, the first and second half-life extending moieties are, respectively, an IgG1, IgG2, or IgG4 Fc domain or fragment thereof. In some embodiments, the first and second half-life extending moieties are, respectively, an IgG1 Fc domain or fragment thereof. Human IgG1 immunoglobulin heavy chain constant gamma 1 has the following sequence: TIFF2023553323000046.tif35170
[0250] In some embodiments, the first and second half-life extending moieties are derived from the sequence of human IgG1 immunoglobulin heavy chain constant gamma 1 having SEQ ID NO: 6 (the "parent sequence"), such that the first and second half-life extending moieties each comprise SEQ ID NO: 6 or a fragment thereof having one or more amino acid modifications.
[0251] In some embodiments, the first and second half-life extending moieties each comprise the portion of SEQ ID NO:6 shown in bold above, and optionally have one or more amino acid modifications: DKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSNKALAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 7)
[0252] In some embodiments, the first and second half-life extending moieties comprise SEQ ID NO: 7, which has amino substitutions to promote association of the first and second half-life extending moieties according to a "knob-into-hole" approach. In some embodiments, the sequence SEQ ID NO: 7 contains the mutations Y349C; T366S; L38A, and Y407V (numbered according to the Kabat EU numbering system) to form a "hole" in the first half-life extending moiety, and the mutations S354C and T366W (numbered according to the Kabat EU numbering system) to form a "knob" in the second half-life extending moiety. These modified sequences have SEQ ID NOs: 8 and 11, as shown below: First half-life extending moiety (Y349C; T366S; L38A; and Y407V) SEQ ID NO: 8: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Second half-life extending moiety (S354C and T366W) SEQ ID NO: 11: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTK NQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
[0253] In some embodiments, the first and second half-life extending moieties each further comprise an amino substitution at N297A, numbered according to the Kabat EU numbering system.
[0254] First half-life extending moiety (Y349C; T366S; L38A; Y407V and N297A) SEQ ID NO: 9: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKL TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Second half-life extending moiety (S354C, T366W and N297A) SEQ ID NO: 12: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTK NQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
[0255] In some embodiments, the first and second half-life extending moieties each further comprise an amino substitution of I253A, numbered according to the Kabat EU numbering system.
[0256] In some embodiments, the first and second half-life extending moieties each further comprise both amino substitutions N297A and I253A, numbered according to the Kabat EU numbering system.
[0257] First half-life extending moiety (Y349C; T366S; L38A; Y407V, N297A and I253A) SEQ ID NO: 10: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE YKCKVSNKALAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCA VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG Second half-life extending moiety (S354C, T366W, N297A and I253A) SEQ ID NO: 13: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEY KCKVSNKALAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG
[0258] In some embodiments, the first half-life extending moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences in any one of SEQ ID NOs: 7, 8, 9, and 10.
[0259] In some embodiments, the second half-life extending moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences in any one of SEQ ID NOs: 7, 11, 12, and 13.
[0260] In some embodiments, the first half-life extending moiety comprises an amino acid sequence having one or more modifications, such as one or more amino acid substitutions, additions, or deletions, compared to the amino acid sequence of any one of SEQ ID NOs: 7, 8, 9, and 10. In some embodiments, the second half-life extending moiety comprises an amino acid sequence having one or more modifications, such as one or more amino acid substitutions, additions, or deletions, compared to the amino acid sequence of any one of SEQ ID NOs: 7, 11, 12, and 13. The one or more modifications may be any modification or alteration described herein, and in some embodiments include any modification or alteration that promotes heterodimerization of polypeptide chains and / or inhibits homodimerization of polypeptide chains, alters effector function, or enhances effector function.
[0261] In some embodiments, the Fc domain or fragment thereof comprises one or more amino acid substitutions that alter effector function. In some embodiments, the half-life extending moiety is an IgG1 Fc domain or fragment thereof comprising one or more amino acid substitutions selected from the group consisting of N297A, N297G, N297Q, L234A, L235A, C220S, C226S, C229S, P238S, E233P, L234V, L234F, L235E, P331S, S267E, L328F, D265A, and P329G, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extending moiety is an IgG2 Fc domain or a fragment thereof and comprises the following amino acid substitutions: V234A and G237A; H268Q, V309L, A330S, and A331S; and / or V234A, G237A, P238S, H268A, V309L, and A330S, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extending moiety is an IgG2 Fc domain or a fragment thereof and comprises one or more amino acid substitutions selected from the group consisting of V234A, G237A, H268Q, V309L, A330S, A331S, P238S, H268A, and V309L, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extending moiety is an IgG4 Fc domain or a fragment thereof and comprises the following amino acid substitutions: L235A, G237A, and E318A; S228P, L234A, and L235A; H268Q, V309L, A330S, and P331S, and / or S228P and L235A, numbered according to the Kabat EU numbering system. In some embodiments, the half-life extending moiety is an IgG2 Fc domain or a fragment thereof and comprises one or more amino acid substitutions selected from the group consisting of L235A, G237A, E318A, S228P, L234A, H268Q, V309L, A330S, and P331S, numbered according to the Kabat EU numbering system.
[0262] In some embodiments, the half-life extending moiety comprises an Fc domain or a fragment thereof comprising one or more amino acid substitutions that enhance effector function. In some embodiments, the half-life extending moiety is an IgG1 Fc domain or a fragment thereof comprising the following amino acid substitutions: S298A, E333A, and K334A; S239D and I332E; S239D, A330L, and I332E; P247I and A339D or A339Q; D280H and K290S; D280H, K290S, and either S298D or S298V; F243L, R292P, and Y300L; F243L, R292P, Y300L, and P396L; F243L, R292P, Y300L, V3 05I, and P396L;G236A, S239D, and I332E;K326A and E333A;K326W and E333S;K290E, S298G, and T299A;K290E, S298G, T299A, and K326E;K290N, S298G, and T299A;K290N, S298G, T299A, and K326E;K334V;L235S, S239D, and K334V;K334V and Q331M, S239D, F243V, E294L, or or S298T; E233L, Q311M, and K334V; L234I, Q311M, and K334V; K334V and S298T, A330M, or A330F; K334V, Q311M, and either A330M or A330F; K334V, S298T, and either A330M or A330F; K334V, S239D, and either A330M or S298T; L234Y, Y296W, and K290Y, F243V, or E294L; Y 296W and either L234Y or K290Y;S239D, A330S, and I332E, V264I;F243L and V264I;L328M;I332E;L328M and I332E;V264I and I332E;S239E and I332E;S239Q and I332E;S239E;A330Y;I332D;L328I and I332E;L328Q and I332E;V264T;V240I;V266I;S239D;S239D and I332D;S239D and I332N;S239D and I332Q;S239E and I332D;S239E and I332N;S239E and I332Q;S239N and I332D;S239N and I332E;S239Q and I332D;A330Y and I332E;V264I, A330Y, and I332E;A330L and I332E;V264I, A330L, and I332E;L234E, L234Y, or L234I;L235D, L23 5S, L235Y, or L235I;S239T;V240M;V264Y;A330I;N325T;I332E and L328D, L328V, L328T, or L328I;V264I, I332E, and either S239E or S239Q;S239E, V264I, A330Y, and I332E;A330Y, I332E, and either S239D or S239N;A330L, I332E, and either S239D or S239N; V264I, S298A, and I332E; S298A, I332E, and either S239D or S239N; S239D, V264I, and I332E; S239D, V264I, S298A, and I332E; S239D, V264I, A330L, and I332E; S239D, I332E, and A330I; P230A; P230A, E233D, and I332E; E272Y; K274T, K274E, K274R, K274L, or K 274Y;F275W;N276L;Y278T;V302I;E318R;S324D, S324I or S324V;K326I or K326T;T335D, T335R, or T335Y;V240I and V266I;S239D, A330Y, I332E, and L234I;S239D, A330Y, I332E, and L235D;S239D, A330Y, I332E, and V240I;S239D, A330Y, I332E, and V264T;and / or S239D, A330Y, I332E, and either K326E or K326T. In some embodiments, the half-life extending moiety is an IgG1 Fc domain or a fragment thereof comprising one or more amino acid substitutions selected from the group consisting of: P230A, E233D, L234E, L234Y, L234I, L235D, L235S, L235Y, L235I, S239D, S239E, S239N, S239Q, S239T, V240I, V240M, F243L, V264I, V264T, V264Y, V266I, E272Y, K274T, K 274E, K274R, K274L, K274Y, F275W, N276L, Y278T, V302I, E318R, S324D, S324I, S324V, N325T, K326I, K326T, L328M, L328I, L328Q, L328D, L328V, L328T, A330Y, A330L, A330I, I332D, I332E, I332N, I332Q, T335D, T335R, and T335Y;
[0263] In some embodiments, the half-life extending moiety comprises one or more amino acid substitutions that enhance binding of the half-life extending moiety to FcRn, hi some embodiments, the one or more amino acid substitutions increase the binding affinity of the Fc-containing polypeptide (e.g., heavy chain polypeptide or Fc domain or fragment thereof) to FcRn at acidic pH. In some embodiments, the half-life extending moiety comprises one or more amino acid substitutions selected from the group consisting of M428F; T250Q and M428F; M252Y, S254T, and T256E; P257I and N434H; D376V and N434H; P257I and Q3111; N434A; N434W; M428F and N434S; V259I and V308F; M252Y, S254T, and T256E; V259I, V308F and M428F; T307Q and N434A; T307Q and N434S; T307Q, E380A, and N434A; V308P and N434A; N434H; and V308P.
[0264] For manufacturing purposes, a signal peptide can be engineered upstream of the half-life domain to improve protein secretion. The signal peptide is selected according to the requirements of the cell line as known in the art. Of course, the signal peptide is not expressed as part of the protein to be purified and formulated as a pharmaceutical.
[0265] 1.1.1 Heterodimerization modification The half-life extending moieties described herein may contain one or more modifications that promote heterodimerization of two different half-life extending moieties. In some embodiments, it is desirable to promote heterodimerization of the first and second half-life extending moieties so that production of the drug construct in its correct heterodimeric form is efficiently produced. Thus, one or more amino acid modifications can be made to the first half-life extending moiety and one or more amino acid modifications can be made to the second half-life extending moiety using any strategy available in the art, including any of the strategies described below. Klein et al. (2012), MAbs, 4(6):653-663. Exemplary strategies and modifications are described in detail below.
[0266] 1.1.2 Knob-into-hole approach One strategy to promote heterodimerization of two different half-life extending moieties is an approach called "knobs-into-holes."
[0267] In some embodiments, the drug construct comprises a first half-life extending moiety and a second half-life extending moiety, each of which comprises a CH3 domain. In some embodiments, the half-life extending moiety comprising a CH3 domain is a heavy chain polypeptide or a fragment thereof (e.g., an Fc domain or a fragment thereof). The CH3 domains of the two half-life extending moieties can be altered by "knob-into-hole" technology, which is described in detail in some examples below, for example: WO1996 / 027011; Ridgway, JB et al, Protein Eng. (1996) 9(7):617-621; Merchant, AM, et al, Nat. Biotechnol. (1998) 16(7):677-681. See also Klein et al. (2012), MAbs, 4(6):653-663. The knob-into-hole method is used to modify the interaction surfaces of two CH3 domains to increase heterodimerization of two half-life extenders containing two modified CH3 domains. This occurs by introducing bulky residues into the CH3 domain of one of the half-life extenders, which acts as a "knob." Then, to accommodate the bulky residue, a "hole" is formed in the other half-life extender that can accommodate the knob. One of the modified CH3 domains can be the "knob" and the other the "hole." The introduction of disulfide bridges further stabilizes the heterodimer (Merchant, AM, et al., Nat. Biotechnol. (1998) 16(7); Atwell, S., et al., J. Mol. Biol. (1997) 270(1):26-35) and also increases yield.
[0268] It has been reported that heterodimerization yields of over 97% can be achieved by introducing S354C and T366W mutations into the heavy chain to create a "knob" and Y349C, T366S, L368A, and Y407V mutations into the heavy chain to create a "hole" (residue numbering according to the Kabat EU numbering system). Carter et al. (2001), J. Immunol. Methods, 248: 7-15; Klein et al. (2012), MAbs, 4(6): 653-663.
[0269] In some embodiments comprising a first half-life extending moiety and a second half-life extending moiety, the first half-life extending moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) comprising the amino acid mutations S354C and T366W (numbered according to the Kabat EU numbering system), and the second half-life extending moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) comprising the amino acid mutations Y349C, T366S, L368A, and Y407V (numbered according to the Kabat EU numbering system). In some embodiments comprising a first half-life extending moiety and a second half-life extending moiety, the first half-life extending moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) comprising the amino acid mutations Y349C, T366S, L368A, and Y407V (numbered according to the Kabat EU numbering system), and the second half-life extending moiety comprises a heavy chain polypeptide or portion thereof (e.g., an Fc domain or fragment thereof) comprising the amino acid mutations S354C and T366W (numbered according to the Kabat EU numbering system).
[0270] Further examples of substitutions that can be made to form knobs and holes include those described in US20140302037A1, the contents of which are incorporated herein by reference. For example, in some embodiments, any of the following amino acid substitutions can be made in a first half-life extender (hereinafter, the first domain) and a paired second half-life extender (hereinafter, the second domain), each containing an Fc domain: (a) Y407T in the first domain and T366Y in the second domain, (b) Y407A in the first domain and T366W in the second domain, (c) F405A in the first domain and T394W in the second domain, (d) F405W in the first domain and T394S in the second domain, (e) Y407T in the first domain and T366Y in the second domain, numbered according to the Kabat EU numbering system. 6Y, (f) T366Y and F405A in the first domain, and T394W and Y407T in the second domain, (g) T366W and F405W in the first domain, and T394S and Y407A in the second domain, (h) F405W and Y407A in the first domain, and T366W and T394S in the second domain, or (i) T366W in the first domain, and T366S, L368A, and Y407V in the second domain.
[0271] In some embodiments, any of the following amino acid substitutions may be made in a first half-life extender (hereinafter the first domain) and a paired second half-life extender (hereinafter the second domain), each containing an Fc domain: (a) Y407T in the second domain and T366Y in the first domain; (b) Y407A in the second domain and T366W in the first domain; (c) F405A in the second domain and T394W in the first domain; (d) F405W in the second domain and T394S in the first domain; (e) Y407T in the second domain and T366Y in the first domain; (f) Y407T in the second domain and T366Y in the first domain, numbered according to the Kabat EU numbering system. (g) T366W and F405W in the second domain and T394S and Y407A in the first domain; (h) F405W and Y407A in the second domain and T366W and T394S in the first domain; or (i) T366W in the second domain and T366S, L368A, and Y407V in the first domain.
[0272] In embodiments comprising a first half-life extending moiety and a second half-life extending moiety, each comprising an Fc domain, any of the heterodimerization modifications described herein can be used in the Fc domain to promote heterodimerization of any of the drug constructs described herein.
[0273] treatment part In some embodiments, provided herein are cytokine prodrugs, wherein the therapeutic moiety is a cytokine moiety. The masking moiety of the cytokine prodrug may comprise a domain of the extracellular domain of a cytokine receptor. Thus, the cytokine prodrug may be considered a masked cytokine.
[0274] The cytokine moiety may comprise a wild-type cytokine moiety or a variant cytokine moiety.
[0275] Cytokines exemplified herein are IL-2, IL-12, and IL-15.
[0276] Cytokine Prodrugs Cytokines play a role in cell signaling, particularly in cells of the immune system. Provided herein are cytokine portions, including cytokines (e.g., IL-2, IL-15, or IL-12 cytokines) or functional fragments thereof, for use in masking cytokines or cleavage products thereof.
[0277] 1.1 "Heterodimeric" masked cytokines In some embodiments, provided herein are masked cytokines comprising a masking moiety in a first polypeptide chain and a cytokine moiety in a second polypeptide chain. Such masked cytokines may be referred to as "heterodimeric" masked cytokines.
[0278] In some embodiments, the masked cytokine is a protein heterodimer comprising: c) a first polypeptide chain comprising a masking moiety linked to a first half-life extending moiety via a first linker; d) a second polypeptide chain comprising the cytokine portion linked to a second half-life extending moiety via a second linker; a first half-life extending moiety associated with a second half-life extending moiety; The present invention includes a protein heterodimer, wherein at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS.
[0279] In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described anywhere herein. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the first linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the first linker is a proteolytically cleavable peptide linker and the second linker is a non-cleavable linker. The non-cleavable linker may be as described anywhere herein.
[0280] In some embodiments, the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS. The proteolytically cleavable peptide linker may be as described anywhere herein. In some embodiments, the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS. In some embodiments, the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS. In some embodiments, the second linker is a proteolytically cleavable peptide linker and the first linker is non-cleavable. The non-cleavable linker may be as described anywhere herein.
[0281] The proteolytically cleavable peptide linker may be as described anywhere herein.
[0282] The half-life extending moiety may be as described anywhere herein.
[0283] The combination of the masking moiety and the cytokine moiety may be as described anywhere herein.
[0284] In some embodiments, in the first polypeptide chain, the first half-life prolonging domain is linked to the amino terminus of a first linker and the carboxy terminus of the first linker is linked to the amino terminus of the masking moiety, and in the second polypeptide chain, the second half-life prolonging domain is linked to the amino terminus of a second linker and the carboxy terminus of the second linker is linked to the amino terminus of the cytokine moiety.
[0285] In some embodiments, the first polypeptide chain is TIFF2023553323000047.tif4170, The second polypeptide chain is TIFF2023553323000048.tif4170, wherein HL1 is a first half-life extending domain, L1 is a first linker, MM is a masking moiety, HL2 is a second half-life extending domain, L2 is a second linker, and C is the cytokine portion thereof; In some embodiments, the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker. This configuration is described herein as "Structure A." In some embodiments, the first polypeptide chain is TIFF2023553323000049.tif5170, The second polypeptide chain is Includes TIFF2023553323000050.tif5170.
[0286] In some embodiments, the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker. This configuration is described herein as "Structure B." In some embodiments, the first polypeptide chain is TIFF2023553323000051.tif5170, The second polypeptide chain is Includes TIFF2023553323000052.tif5170.
[0287] 1.2 "Linear" masked cytokines In some embodiments, provided herein is a masked cytokine comprising a masking moiety and its cytokine moiety linked by a single polypeptide chain. In some embodiments, the masked cytokine has the following formula: TIFF2023553323000053.tif4170, including polypeptide chains wherein HL is a half-life extending domain, L1 is a first linker, MM is a masking moiety, L2 is a second linker, C is the cytokine portion, and at least the first linker comprises a proteolytically cleavable peptide.
[0288] In some embodiments, the masked cytokine has the following formula: TIFF2023553323000054.tif4170, including polypeptide chains; wherein HL is a half-life prolonging domain, L1 is a first linker, MM is a masking moiety, L2 is a second linker, and C is the cytokine portion, and at least the first linker comprises a proteolytically cleavable peptide. In some embodiments, the first linker is a cleavable linker described elsewhere herein. In some embodiments, the second linker is a non-cleavable linker described elsewhere herein. In some embodiments, the cytokine portion is as described elsewhere herein. In some embodiments, the half-life prolonging domain (HL) comprises an Fc region of an antibody (i.e., the C-terminal region of an immunoglobulin heavy chain) or a fragment thereof comprising a dimerized Fc domain (HL1-HL2). Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the Fc region of a human IgG heavy chain is usually defined to stretch from the amino acid residue at position Cys226, or from the amino acid residue at position Pro230, to the carboxyl terminus thereof. In some embodiments, the dimerized Fc domain of the antibody (HL1-HL2) comprises a first half-life prolonging domain and a second half-life prolonging domain, as described anywhere herein, wherein the first half-life extending moiety comprises a first Fc domain or fragment thereof, and the second half-life extending moiety comprises a second Fc domain or fragment thereof. In some embodiments, HL2 is a component of a polypeptide chain, and HL1 dimerizes to HL2.
[0289] 1.1 Cytokine and masking moieties The cytokine moieties and masking moieties disclosed herein (eg, IL-2, IL-12, and IL-15 cytokine moieties and masking moieties) may be used in any of the polypeptide drug constructs disclosed herein.
[0290] The cytokine moieties and masking moieties disclosed herein can be used in the heterodimeric masked cytokine of structure A disclosed herein.
[0291] The cytokine moieties and masking moieties disclosed herein can be used in the heterodimeric masked cytokines of structure B disclosed herein.
[0292] The cytokine moieties and masking moieties disclosed herein can be used in the linear masked cytokines disclosed herein.
[0293] 1.1.1 IL-2 Cytokine Moiety and IL-2 Masking Moiety (a) IL-2 cytokine portion In some embodiments, the therapeutic moiety comprises an IL-2 cytokine or a functional fragment thereof. IL-2 is an interleukin, a type of cytokine signaling molecule of the immune system that regulates the activity of white blood cells.
[0294] In eukaryotic cells, naturally occurring IL-2 is synthesized as a 153-amino acid precursor polypeptide having SEQ ID NO: 1. This is then processed to mature IL-2 by removing amino acid residues 1-20. This results in the mature form of IL-2 consisting of 133 amino acids (amino acid residues 21-153) having SEQ ID NO: 2. A "functional fragment" of the IL-2 cytokine includes a portion of the full-length cytokine protein that retains or modifies cytokine receptor binding ability (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the activity of the full-length cytokine protein). Cytokine receptor binding ability can be demonstrated, for example, by the ability of the cytokine to bind to its cognate receptor or a component thereof (e.g., one or more chains of a heterotrimeric receptor complex).
[0295] In some embodiments, the IL-2 cytokine or functional fragment thereof is any naturally occurring interleukin-2 (IL-2) protein or modified variant thereof capable of binding to the interleukin-2 receptor, particularly the IL-2Rα chain. In the context of IL-2 cytokine binding, the target protein can be IL-2R (including the IL-2Rα, IL-2Rβ, and IL-2Rγ chains), the IL-2Rα chain, the IL-2Rβ chain, or the IL-2Rα / β dimeric complex. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises the amino acid sequence of amino acid residues 21-153 of SEQ ID NO:1. In some embodiments, the IL-2 polypeptide or functional fragment thereof comprises the amino acid sequence of mature IL-2, SEQ ID NO:2.
[0296] In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO: 2. Each of the at least one amino acid modification may be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having at least 5 amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 2.
[0297] In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions compared to the amino acid sequence of wild-type IL-2 of SEQ ID NO: 2, which decrease the affinity of the IL-2 peptide or functional fragment thereof for IL-2Rα (CD25). In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 2, such that one or more amino acid residues 38, 42, 45, and 62 are alanine (A). In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 2, such that one or more amino acid residues 38, 42, 45, and 62 are alanine (A).
[0298] In some embodiments, the IL-2 cytokine or functional fragment thereof comprises the amino acid sequence substitution C125A compared to the amino acid sequence of SEQ ID NO:2.
[0299] In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 2, such that amino acid residues 38, 42, 45, and 62 are alanine (A) and amino acid residue 125 is alanine (A). In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid residues R38, F42, Y45, and E62 substituted with alanine (A) in the amino acid sequence of SEQ ID NO: 2. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid residues R38, F42, Y45, and E62 substituted with alanine (A) and amino acid residue C125 substituted with alanine (A) in the amino acid sequence of SEQ ID NO: 2.
[0300] In some embodiments, the IL-2 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the IL-2 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 3.
[0301] In some embodiments, the IL-2 cytokine or functional fragment thereof has one or more amino acid residues, e.g., residues 1-3, deleted relative to the amino acid sequence of mature IL-2 of SEQ ID NO: 2 to remove an O-glycosylation site. In some embodiments, the IL-2 cytokine or functional fragment thereof has one or more amino acid residues substituted relative to the amino acid sequence of mature IL-2 of SEQ ID NO: 2 to remove an O-glycosylation site. In some embodiments, the IL-2 cytokine or functional fragment thereof has one or more amino acid residues inserted relative to the amino acid sequence of mature IL-2 of SEQ ID NO: 2 to remove an O-glycosylation site, e.g., in the region of residues 1-3. In some embodiments, the IL-2 cytokine or functional fragment thereof does not have an O-glycosylation site within residues 1-3.
[0302] (b) IL-2 masking moiety Provided herein are masking moieties for use in masking therapeutic moieties comprising the IL-2 cytokine or functional fragments thereof.
[0303] It will be understood that the masking moiety is cleaved from the masked cytokine to form its cleavage product. The masking moiety masks the IL-2 cytokine or a functional fragment thereof in the masked cytokine, thereby reducing or preventing the binding of the IL-cytokine or a functional fragment thereof to its cognate receptor. In some embodiments, the masking moiety reduces or prevents the binding of the IL-2 cytokine or a functional fragment thereof to IL-2Rα (CD25). In some embodiments, the masking moiety provided herein refers to a moiety capable of binding to or otherwise exhibiting affinity for the IL-2 cytokine or a functional fragment thereof, such as an anti-IL-2 antibody or an IL-2 cognate receptor protein. Methods for determining the degree of binding of a protein (e.g., a cytokine) to a cognate protein (e.g., a cytokine receptor) are well known in the art.
[0304] In some embodiments, the masking moiety comprises an IL-2 cytokine receptor, or a subunit or functional fragment thereof.
[0305] In some embodiments, the masking moiety comprises IL-2Rβ (also called CD122) or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-2.
[0306] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 4 with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions.
[0307] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has a mutation at amino acid position C122 compared to the IL-2β of SEQ ID NO:4.
[0308] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has a mutation C122S at amino acid position 122 compared to the IL-2β of SEQ ID NO:4.
[0309] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 4 with a C122 mutation.
[0310] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 4 with a C122S mutation.
[0311] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has a mutation at amino acid position C168 compared to the IL-2β of SEQ ID NO:4.
[0312] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has a mutation C168S at amino acid position 168 compared to the IL-2β of SEQ ID NO:4.
[0313] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 4 with a C168 mutation.
[0314] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 4 with a C168S mutation.
[0315] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has mutations at amino acid positions C122 and C168 compared to the IL-2β of SEQ ID NO:4.
[0316] In some embodiments, the IL-2Rβ or fragment, portion, or variant thereof has the mutations C122S and C168S compared to the IL-2Rβ of SEQ ID NO:4.
[0317] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO:5.
[0318] In some embodiments, when (i) the masked cytokine is a heterodimeric masked cytokine of structure A, and (ii) the cytokine moiety is an IL-2 cytokine moiety, the proteolytically cleavable peptide linker does not have the amino acid sequence GGSGISSGLLSGRSSSGP or GISSGLLSGRSSSGP.
[0319] 1.1.2 IL-12 Cytokine Moiety and IL-12 Masking Moiety (a) IL-12 cytokine portion In some embodiments, the therapeutic moiety comprises an IL-12 cytokine or a functional fragment thereof.
[0320] IL-12 is an interleukin, a type of cytokine signaling molecule of the immune system that regulates the activity of white blood cells.
[0321] Endogenous IL-12 exists as two distinct molecules, IL-12 p40 and IL-12 p35, which dimerize intracellularly during biosynthesis.
[0322] The full sequences of IL-12 p40 and IL-12 p35 are as follows (the propeptide cleaved during biosynthesis is shown in bold): IL-12 p40 subunit: TIFF2023553323000055.tif28170IL-12 p35 subunit: TIFF2023553323000056.tif18170The mature form is as follows: IL-12 p40 subunit: IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKN LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVIC RKNASISVRAQDRYYSSSWSEWASVPCS IL-12 p35 subunit: RNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMM ALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQK SSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNAS
[0323] They are expressed as two chains that covalently dimerize during biosynthesis via a disulfide bond between the two subunits: cysteine C199 of the p40 subunit associates with cysteine C96 of the p35 subunit.
[0324] A "functional fragment" of an IL-12 cytokine includes a portion of the full-length cytokine protein that retains or modifies cytokine receptor binding ability (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the activity compared to the full-length cytokine protein). Cytokine receptor binding ability can be demonstrated, for example, by the ability of the cytokine to bind to its cognate receptor or a component thereof.
[0325] In some embodiments, the IL-12 cytokine or functional fragment thereof is any naturally occurring interleukin-2 (IL-12) protein or modified variant thereof capable of binding to the interleukin-2 receptor.
[0326] In some embodiments, the IL-12 polypeptide or functional fragment thereof comprises an IL-12p40 polypeptide or functional fragment thereof covalently linked to an IL-12p35 polypeptide or functional fragment thereof.
[0327] The IL-12p40 polypeptide or functional fragment thereof may have a first polypeptide chain of the formula: TIFF2023553323000057.tif4170, the second polypeptide chain having the formula: TIFF2023553323000058.tif5170, wherein "IL-12p40" is an IL-12p40 polypeptide or a functional fragment thereof, and "IL-12p35" is an IL-12p35 polypeptide or a functional fragment thereof.
[0328] In some embodiments, the IL-12p40 polypeptide comprises SEQ ID NO:204 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO:204 as set forth in the IL-12 cytokine subtable below. Each of the at least one amino acid modification may be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten amino acid substitutions compared to the amino acid sequence of SEQ ID NO:204 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least five amino acid substitutions compared to the amino acid sequence of SEQ ID NO:204 as set forth in the IL-12 cytokine subtable below.
[0329] The IL-12p40 polypeptide contains a glycosaminoglycan (GAG)-binding domain (KSKREKKDRV). GAGs, such as heparin and heparan sulfate, have been shown to bind to numerous growth factors and cytokines, including IL-12. The physiological significance of this binding is twofold. First, GAGs can function as coreceptors on the cell surface, maintaining high local concentrations of cytokines. Second, GAGs can regulate the biological activity of growth factors and cytokines through multiple mechanisms, including dimerization and protection from proteolysis.
[0330] The GAG-binding domain of the mature form of the IL-12 p40 subunit is shown below in bold. TIFF2023553323000059.tif28170
[0331] Modifications to the GAG-binding domain (KSKREKKDRV) are shown herein to increase the PK profile of constructs containing IL-12 cytokines with mutated GAG-binding domains without reducing cytokine activity. Thus, in some embodiments, the IL-12p40 polypeptide comprises at least one amino acid modification to the GAG-binding domain. In some embodiments, the modification to the GAG-binding domain is a deletion mutation. In some embodiments, the modification to the GAG-binding domain is a deletion mutation and at least one substitution mutation.
[0332] In some embodiments, the GAG binding domain comprises the amino acid sequence KDNTERV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence shown in the IL-12 cytokine subtable below, SEQ ID NO: 205. In some embodiments, the GAG binding domain comprises the amino acid sequence KDNTEGRV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence shown in the IL-12 cytokine subtable below, SEQ ID NO: 206.
[0333] In some embodiments, the GAG-binding domain consists of the amino acid sequence KDNTERV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence shown in the IL-12 cytokine subtable below, SEQ ID NO: 205. In some embodiments, the GAG-binding domain consists of the amino acid sequence KDNTEGRV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence shown in the IL-12 cytokine subtable below, SEQ ID NO: 206.
[0334] In some embodiments, an IL-12p40 polypeptide comprises an amino acid sequence having one or more cysteine substitutions compared to the amino acid sequence of SEQ ID NO: 204 as set forth in the IL-12 cytokine subtable below. In some embodiments, an IL-12p40 polypeptide comprises an amino acid sequence having an amino acid substitution at position C252 compared to the amino acid sequence of SEQ ID NO: 204 as set forth in the IL-12 cytokine subtable below. In some embodiments, the amino acid substitution at position C252 is C252S. In some embodiments, an IL-12p40 polypeptide comprises the amino acid sequence of SEQ ID NO: 207 as set forth in the IL-12 cytokine subtable below. In some embodiments, an IL-12p40 polypeptide comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 207 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12p40 polypeptide consists of the amino acid sequence of SEQ ID NO: 207, as shown in the IL-12 cytokine subtable below.
[0335] In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having one or more cysteine substitutions compared to the amino acid sequence of SEQ ID NO: 204 set forth in the IL-12 cytokine subtable below, and at least one amino acid modification to the GAG-binding domain. In some embodiments, the IL-12p40 polypeptide comprises an amino acid substitution at position C252S compared to the amino acid sequence of SEQ ID NO: 204 set forth in the IL-12 cytokine subtable below, and the GAG-binding domain comprises the amino acid sequence KDNTERV. In some embodiments, the IL-12p40 polypeptide comprises an amino acid substitution at position C252S compared to the amino acid sequence of SEQ ID NO: 204 set forth in the IL-12 cytokine subtable below, and the GAG-binding domain comprises the amino acid sequence KDNTEGRV. In some embodiments, the IL-12p40 polypeptide comprises the amino acid sequence of SEQ ID NO: 208 set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12p40 polypeptide comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 208 as set forth in the IL-12 cytokines subtable below. In some embodiments, the IL-12p40 polypeptide consists of the amino acid sequence of SEQ ID NO: 208 as set forth in the IL-12 cytokines subtable below.
[0336] In some embodiments, the IL-12p35 polypeptide comprises SEQ ID NO: 209 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12p35 polypeptide comprises an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO: 209 as set forth in the IL-12 cytokine subtable below. Each of the at least one amino acid modification may be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 209 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least five amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 209 as set forth in the IL-12 cytokine subtable below.
[0337] In some embodiments, the IL-12p40-IL-12p35 linker is between 5 and 20 amino acids in length.
[0338] In some embodiments, the IL-12p40-IL-12p35 linker is rich in G and S amino acid residues.
[0339] In some embodiments, the IL-12p40-IL-12p35 linker comprises only amino acid residue types selected from the group consisting of G and S.
[0340] In some embodiments, the IL-12p40-IL-12p35 linker is [(G) n S], where n=4 or 5.
[0341] In some embodiments, the IL-12p40-IL-12p35 linker comprises (GGGGS) repeats.
[0342] In some embodiments, the IL-12p40-IL-12p35 linker comprises SEQ ID NO: 116 (GGGGSGGGGSGGGGS).
[0343] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises SEQ ID NO: 210 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification compared to the amino acid sequences of SEQ ID NOs: 204 and 209 as set forth in the IL-12 cytokine subtable below. Each of the at least one amino acid modification may be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten amino acid substitutions compared to the amino acid sequences of SEQ ID NOs: 204 and 209 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having at least five amino acid substitutions compared to the amino acid sequences of SEQ ID NOs: 204 and 209 as set forth in the IL-12 cytokine subtable below.
[0344] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 210 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 210 as set forth in the IL-12 cytokine subtable below.
[0345] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 211 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 211 as set forth in the IL-12 cytokine subtable below.
[0346] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 212. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 212 as shown in the IL-12 cytokine subtable below.
[0347] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 213 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 213 as set forth in the IL-12 cytokine subtable below.
[0348] In some embodiments, the IL-12 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 214 as set forth in the IL-12 cytokine subtable below. In some embodiments, the IL-12 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 214 as set forth in the IL-12 cytokine subtable below. [Table 5] TIFF2023553323000061.tif229170TIFF2023553323000062.tif232170TIFF2023553323000063.tif69170
[0349] In some embodiments, the IL-12 cytokine portion has an amino acid sequence set forth by one of the sequences in the table above.
[0350] (b) IL-12 masking moiety Provided herein are masking moieties for use in masking therapeutic moieties comprising the IL-12 cytokine or functional fragments thereof.
[0351] It will be understood that the masking moiety is cleaved from the masked cytokine to form a cleavage product thereof. The masking moiety masks the IL-12 cytokine or functional fragment thereof in the masked cytokine, thereby reducing or preventing binding of the IL-cytokine or functional fragment thereof to its cognate receptor.
[0352] IL-12 receptor, beta 1, or IL-12Rβ1, is a subunit of the IL-12 receptor complex. IL-12Rβ1 is also known as CD212. This protein binds interleukin-12 (IL-12) with low affinity. The protein forms disulfide-linked oligomers, which are required for IL-12 binding activity. IL-12 receptor, beta 2, or IL-12Rβ2, is a subunit of the IL-12 receptor complex. Coexpression of IL-12Rβ1 and IL-12Rβ2 proteins has been shown to lead to the formation of a high-affinity IL-12 binding site.
[0353] Methods for determining the degree of binding of a protein (eg, a cytokine) to a cognate protein (eg, a cytokine receptor) are well known in the art.
[0354] In some embodiments, the masking moiety comprises the extracellular domain of the IL-12 cytokine receptor, or a subunit or functional fragment thereof.
[0355] The interleukin-12 receptor subunit beta-1, also called CD212, has the following sequence: TIFF2023553323000064.tif58170
[0356] The interleukin-12 receptor subunit beta-2 has the following sequence: TIFF2023553323000065.tif72170
[0357] Bold indicates the propeptide, underlined italics indicates the extracellular domain, italics indicates the transmembrane domain, and underlined bold indicates the cytoplasmic domain.
[0358] In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ1, or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-12.
[0359] In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of human IL-12Rβ1 with one to four amino acid substitutions, hi some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of human IL-12Rβ1 with one or two amino acid substitutions.
[0360] In some embodiments, the masking moiety comprises residues 24-237 of human IL-12Rβ1, i.e., the sequence having SEQ ID NO:215 as set forth in the IL-12 Masking Subpart Table below, or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-12. In some embodiments, the masking moiety comprises IL-12Rβ1 having SEQ ID NO:215 as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO:215, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO:215, as set forth in the IL-12 Masking Subpart Table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 215, as shown in the IL-12 Masking Moiety Table below, with one or two amino acid substitutions.
[0361] In some embodiments, the masking moiety comprises residues 24-545 of human IL-12Rβ1, i.e., the sequence having SEQ ID NO:216 as set forth in the IL-12 Masking Subpart Table below, or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-12. In some embodiments, the masking moiety comprises IL-12Rβ1 having SEQ ID NO:216 as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO:216, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO:216, as set forth in the IL-12 Masking Subpart Table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 216, as shown in the IL-12 Masking Moiety Table below, with one or two amino acid substitutions.
[0362] In some embodiments, the masking moiety comprises the extracellular domain of human IL-12Rβ2, or a fragment, portion, or variant thereof, that retains or otherwise exhibits affinity for IL-12. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of human IL-12Rβ2 with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of human IL-12Rβ2 with one or two amino acid substitutions.
[0363] In some embodiments, the masking portion comprises residues 24-212 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 217, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking portion comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO: 217, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 217, as set forth in the IL-12 Masking Subpart Table below, with one to four amino acid substitutions. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 217, as set forth in the IL-12 Masking Subpart Table below, with one or two amino acid substitutions.
[0364] In some embodiments, the masking portion comprises residues 24-222 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 218, as set forth in the IL-12 Masking Portion Table below. In some embodiments, the masking portion comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO: 218, as set forth in the IL-12 Masking Portion Table below. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 218, as set forth in the IL-12 Masking Portion Table below, with one to four amino acid substitutions. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 218, as set forth in the IL-12 Masking Portion Table below, with one or two amino acid substitutions.
[0365] In some embodiments, the masking portion comprises residues 24-319 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 219, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking portion comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO: 219, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 219, as set forth in the IL-12 Masking Subpart Table below, with one to four amino acid substitutions. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 219, as set forth in the IL-12 Masking Subpart Table below, with one or two amino acid substitutions.
[0366] In some embodiments, the masking moiety comprises residues 24-319 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO:219, as set forth in the IL-12 Masking Subpart Table below, with one or more cysteine substitutions. In some embodiments, the masking moiety comprises residues 24-319 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO:219, as set forth in the IL-12 Masking Subpart Table below, with an amino acid substitution at position C242. In some embodiments, the amino acid substitution at position C242 is C242S. In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO:220, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 220, as set forth in the IL-12 Masking Moiety Table below. In some embodiments, the masking moiety consists of the amino acid sequence of SEQ ID NO: 220, as set forth in the IL-12 Masking Moiety Table below. In some embodiments, the masking moiety comprises residues 24 to 622 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 221, as set forth in the IL-12 Masking Moiety Table below. In some embodiments, the masking moiety comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO: 221, as set forth in the IL-12 masking moiety table below. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 221, as set forth in the IL-12 masking moiety table below, with one to four amino acid substitutions. In some embodiments, the masking moiety comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 221, as set forth in the IL-12 masking moiety table below, with one or two amino acid substitutions.
[0367] In some embodiments, the masking portion comprises residues 24-227 of human IL-12Rβ2, i.e., the sequence having SEQ ID NO: 222, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking portion comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the amino acid sequences of SEQ ID NO: 222, as set forth in the IL-12 Masking Subpart Table below. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 222, as set forth in the IL-12 Masking Subpart Table below, with one to four amino acid substitutions. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 222, as set forth in the IL-12 Masking Subpart Table below, with one or two amino acid substitutions. [Table 6] TIFF2023553323000067.tif30170
[0368] In some embodiments, the IL-12 masking moiety has an amino acid sequence set forth by one of the sequences in the table above.
[0369] 1.1.3 IL-15 Cytokine Moiety and IL-15 Masking Moiety (a) IL-15 cytokine portion In some embodiments, the therapeutic moiety comprises an IL-15 cytokine or a functional fragment thereof.
[0370] IL-15 is an interleukin, a type of cytokine signaling molecule of the immune system that regulates the activity of white blood cells.
[0371] In eukaryotic cells, IL-15 is synthesized as a 162 amino acid precursor polypeptide, which is then processed to mature IL-15 by removal of amino acid residues 1 to 48. This results in the mature form of IL-15 consisting of 114 amino acids (amino acid residues 49 to 162) that is secreted in its mature, active form.
[0372] IL-15 precursor polypeptide: MRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS IL-15 mature polypeptide: NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0373] As used herein, the term "IL-15" or "IL-15 polypeptide" refers to any interleukin-15 (IL-15) protein, or a functional fragment or variant thereof. The term encompasses any naturally occurring IL-15 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., rats and mice). The term encompasses unprocessed IL-15 (e.g., the full-length precursor form of IL-15 consisting of amino acid residues 1-162), as well as any form of IL-15 resulting from intracellular processing (e.g., the mature form of IL-15 consisting of amino acid residues 49-162). Thus, the term encompasses the protein encoded by the amino acid sequence of SEQ ID NO: 224, as shown in the IL-15 Cytokine Subtable below, as well as sequence variants thereof. The term also encompasses naturally occurring variants of IL-15. The term also encompasses non-naturally occurring variants of IL-15, such as truncations, deletions, forms in which IL-15 is linked to another molecule, and variants caused by at least one amino acid change to the amino acid sequence (e.g., by substitution, addition, or deletion). In some embodiments, a variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, or 114 contiguous amino acid portion) compared to a naturally occurring IL-15 polypeptide, such as the IL-15 polypeptide encoded by the amino acid sequence of SEQ ID NO:223 or 224, as set forth in the IL-15 cytokine subtable below. Thus, the term "IL-15" or "IL-15 polypeptide" includes an IL-15 protein comprising the amino acid sequence of SEQ ID NO: 223 or 224 as set forth in the IL-15 cytokine subtable below, and includes variants thereof, such as variants made by one or more amino acid substitutions relative to the amino acid sequence of SEQ ID NO: 223 or 224 as set forth in the IL-15 cytokine subtable below.
[0374] A "functional fragment" of an IL-15 cytokine includes a portion of a full-length cytokine protein that retains or modifies cytokine receptor binding ability (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the activity compared to the full-length cytokine protein). Cytokine receptor binding ability can be demonstrated, for example, by the ability of the cytokine to bind to its cognate receptor or a component thereof (e.g., one or more chains of a heterotrimeric receptor complex).
[0375] In some embodiments, the IL-15 cytokine or functional fragment thereof is any naturally occurring interleukin-2 (IL-15) protein or modified variant thereof capable of binding to the interleukin-2 receptor, particularly the IL-15Rα chain.
[0376] In some embodiments, the IL-15 cytokine or fragment thereof comprises SEQ ID NO: 224, or a functional fragment thereof, as set forth in the IL-15 cytokine subtable below.
[0377] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises the amino acid sequence of SEQ ID NO: 224, as shown in the IL-15 cytokine subtable below.
[0378] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least one amino acid modification compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below. Each of the at least one amino acid modification may be any amino acid modification, such as a substitution, insertion, or deletion. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having at least five amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0379] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0380] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below. In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having one or more amino acid substitutions at positions D22, E46, E53, N71, N79, N112 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0381] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position D22 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0382] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position E46 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0383] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position E53 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0384] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N71 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0385] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N79 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0386] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having an amino acid substitution at position N112 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0387] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions E46 and E53 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0388] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N71 and N79 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0389] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N71 and N112 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0390] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N79 and N112 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0391] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions at positions N71, N79 and N112 compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0392] In some embodiments, the amino acid substitution at position D22 is D22A.
[0393] In some embodiments, the amino acid substitution at position E46 is E46A.
[0394] In some embodiments, the amino acid substitution at position E46 is E46R.
[0395] In some embodiments, the amino acid substitution at position E46 is E46S.
[0396] In some embodiments, the amino acid substitution at position E53 is E53A.
[0397] In some embodiments, the amino acid substitution at position E53 is E53R.
[0398] In some embodiments, the amino acid substitution at position E53 is E53S.
[0399] In some embodiments, the amino acid substitution at position N71 is N71Q.
[0400] In some embodiments, the amino acid substitution at position N79 is N79Q.
[0401] In some embodiments, the amino acid substitution at position N112 is N112Q.
[0402] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having the amino acid substitution D22A compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0403] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having the amino acid substitution E46A compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0404] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions E46A and E53A compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0405] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions E46R and E53R compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0406] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions E46S and E53S compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0407] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having the amino acid substitution E53A compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0408] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having the amino acid substitution N71Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0409] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having the amino acid substitution N79Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0410] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having the amino acid substitution N112Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0411] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions N71Q and N79Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0412] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions N71Q and N112Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0413] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions N79Q and N112Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below.
[0414] In some embodiments, the IL-15 cytokine or functional fragment thereof comprises an amino acid sequence having amino acid substitutions N71Q, N79Q, and N112Q compared to the amino acid sequence of SEQ ID NO: 224 shown in the IL-15 cytokine subtable below. [Table 7] TIFF2023553323000069.tif253170TIFF2023553323000070.tif79170
[0415] In some embodiments, the IL-15 cytokine portion has an amino acid sequence set forth by one of the sequences in the table above.
[0416] In some embodiments, an additional mutation may be included in any of the above sequences at position N71. In some embodiments, the mutation is N71A, N71R, N71W, N71F, N71P, N71M, N71L, N71T, N71S, or N71Y.
[0417] In some embodiments, an additional mutation may be included in any of the above sequences at position S73. In some embodiments, the mutation is S73A, S73W, S73V, or S73M.
[0418] In some embodiments, additional mutations may be included in any of the above sequences at one or more amino acid positions N72, N79, V80, T81, and N112. In some embodiments, one or more additional mutations selected from N72A, N79A, V80A, T81A, and N112R may be included in any of the above sequences.
[0419] In some embodiments, additional mutations may be included in any of the above sequences at one or more amino acid positions N72, S73, N79, V80, T81, and N112. In some embodiments, one or more additional mutations N72A, S73A, N79A, V80A, T81A, and N112 may be included in any of the above sequences.
[0420] In some embodiments, the IL-15 cytokine or functional fragment thereof has one or more amino acid residues, e.g., residues 1-3, removed compared to the amino acid sequence of mature IL-15 of SEQ ID NO: 224 set forth in the IL-15 cytokine subtable above, to remove an O-glycosylation site. In some embodiments, the IL-15 cytokine or functional fragment thereof has one or more amino acid residues substituted compared to the amino acid sequence of mature IL-15 of SEQ ID NO: 224 set forth in the IL-15 cytokine subtable above, to remove an O-glycosylation site. In some embodiments, the IL-15 cytokine or functional fragment thereof has one or more amino acid residues inserted in the region of residues 1-3 compared to the amino acid sequence of mature IL-15 of SEQ ID NO: 224 set forth in the IL-15 cytokine subtable above, to remove an O-glycosylation site. In some embodiments, the IL-15 cytokine or functional fragment thereof does not have an O-glycosylation site within residues 1-3.
[0421] In some embodiments, the masked IL-15 cytokine further comprises a domain comprising the IL-15Rα subunit or a functional fragment thereof (the "IL-15Rα domain"). Incorporation of the "IL-15Rα domain" into a masked IL-15 cytokine construct has been demonstrated to increase the potency of the cytokine to activate CD8 T cells and NK cells.
[0422] The IL-15Rα subunit (also called CD215) is structurally similar to IL-2Rα. The ectodomain of IL-15Rα consists of a single protein-binding sushi domain, a membrane-proximal proline-threonine-rich (PT) region, and a linker / hinge region connecting the sushi domain and the PT region. The IL-15Rα subunit specifically binds IL-15 with very high affinity and can bind IL-15 independently of the β and γ subunits.
[0423] Interleukin (IL)-15 is a cytokine that acts on a wide range of cell types, but is most important for the development, homeostasis, and function of specific immune cell populations, including CD8 T cells, NK cells, NKT cells, and CD8αα intraepithelial lymphocytes. IL-15 signals via the IL-2 / 15Rβ and common γ (γC) chains, but the delivery of IL-15 to these signaling components is quite unique. In contrast to other secreted cytokines, IL-15 exists primarily bound to the high-affinity IL-15Rα. Once the IL-15 / IL-15Rα complex is translocated to the cell surface, it can stimulate opposing cells via the β / γC receptor complex. This novel mechanism of IL-15 delivery is called transpresentation (SW Stonier and KS Schluns, 'Trans-presentation: a novel mechanism regulating IL-15 delivery and responses', Immunol Lett Jan 4 2010;127(2):85-92, the contents of which are incorporated herein by reference).
[0424] The IL-15Rα subunit contains a conserved protein-binding motif called the sushi domain. The sushi domain, sIL-15Rα, encompassing amino acids 31-95 of the IL-15Rα subunit, is responsible for interacting with IL-15 and is essential for IL-15 / IL-15Rα function (Wei X et al. 'The Sushi Domain of Soluble IL-15 Receptor α Is Essential for Binding IL-15 and Inhibiting Inflammatory and Allogenic Responses In Vitro and In Vivo', J Immunol July 1 2001;167(1) 277-282, the contents of which are incorporated herein by reference).
[0425] The sequence of the wild-type IL-15Rα subunit is shown below, along with a breakdown of the major domains. [Table 8]
[0426] As used herein, an "IL-15Rα domain" can include the sequence of the extracellular domain of a wild-type IL-15Rα subunit or a variant thereof, such as the sequence of the extracellular domain of a wild-type IL-15Rα subunit having one or more, e.g., one, two, three, or four, amino acid substitutions.
[0427] As used herein, an "IL-15Rα domain" can include the sequence of wild-type sushi domain sIL-15Rα or a variant thereof, such as the sequence of wild-type sushi domain sIL-15Rα having one or more, e.g., one, two, three, or four, amino acid substitutions.
[0428] As used herein, an "IL-15Rα domain" can consist of the sequence of wild-type sushi domain sIL-15Rα or a variant thereof, such as the sequence of wild-type sushi domain sIL-15Rα having one or more, e.g., one, two, three, or four, amino acid substitutions.
[0429] In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R26. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R26N. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R26S. In some embodiments, the IL-15Rα domain comprises an amino acid substitution at position R35. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R35Q. In some embodiments, the IL-15Rα domain comprises the amino acid substitution R35S. In some embodiments, the IL-15Rα domain comprises amino acid substitutions at positions R26 and R35. In some embodiments, the IL-15Rα domain comprises the amino acid substitutions R26S or R26N and R35Q or R35S. In some embodiments, the IL-15Rα domain comprises the amino acid substitutions R26N and R35Q.
[0430] An exemplary sequence of the IL-15Rα domain is shown below. [Table 9]
[0431] In some embodiments, the IL-15Rα domain has an amino acid sequence set forth by one of the sequences in the table above.
[0432] (b) IL-15 masking moiety Provided herein are masking moieties for use in masking therapeutic moieties comprising an IL-15 cytokine or functional fragment thereof.
[0433] It will be understood that the masking moiety is cleaved from the masked cytokine to form its cleavage product. The masking moiety masks the IL-15 cytokine or a functional fragment thereof in the masked cytokine, thereby reducing or preventing the binding of the IL-cytokine or a functional fragment thereof to its cognate receptor. In some embodiments, the masking moiety reduces or prevents the binding of the IL-15 cytokine or a functional fragment thereof to IL-15Rα. In some embodiments, the masking moiety provided herein refers to a moiety that can bind to or otherwise exhibit affinity for the IL-15 cytokine or a functional fragment thereof, such as an anti-IL-15 antibody or an IL-15 cognate receptor protein. Methods for determining the degree of binding of a protein (e.g., a cytokine) to a cognate protein (e.g., a cytokine receptor) are well known in the art.
[0434] In some embodiments, the masking moiety comprises an IL-15 cytokine receptor, or a subunit thereof or a functional fragment thereof.
[0435] In some embodiments, the masking moiety comprises IL-15Rβ (also called CD122) or a fragment, portion, or variant thereof that retains or otherwise exhibits affinity for IL-15.
[0436] The wild-type sequence of IL-15Rβ is shown in SEQ ID NO: 240 in the IL-15 Masking Subtable below.
[0437] In some embodiments, the masking portion comprises the amino acid sequence of SEQ ID NO: 240 as set forth in the IL-15 masking subtable below. In some embodiments, the masking portion comprises an amino acid sequence having about or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 240 in the IL-15 masking subtable below. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 240 in the IL-15 masking subtable below with one to four amino acid substitutions. In some embodiments, the masking portion comprises an amino acid sequence having the amino acid sequence of SEQ ID NO: 240 in the IL-15 masking subtable below with one or two amino acid substitutions.
[0438] In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), wherein the IL-15Rβ has an amino acid substitution at position C122.
[0439] In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), wherein the IL-15Rβ has the amino acid substitution C122S.
[0440] In some embodiments, the IL-15Rβ or fragment, portion, or variant thereof has an amino acid substitution at position C122 compared to the IL-15β of SEQ ID NO: 240 in the IL-15 Masking Subgroup Table below.
[0441] In some embodiments, the IL-15Rβ or fragment, portion, or variant thereof has a mutation C122S at amino acid position 122 compared to the IL-15β of SEQ ID NO: 240 in the IL-15 Masking Subgroup Table below.
[0442] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 of the IL-15 masking moiety table below, with the C122 mutation.
[0443] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 of the IL-15 masking moiety table below, with the C122S mutation.
[0444] In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), wherein the IL-15Rβ has an amino acid substitution at position C168.
[0445] In some embodiments, the masking moiety comprises IL-15Rβ (or a functional fragment, portion, or variant thereof), wherein the IL-15Rβ has the amino acid substitution C168S.
[0446] In some embodiments, the IL-15Rβ or fragment, portion, or variant thereof has a mutation at amino acid position C168 compared to the IL-15β of SEQ ID NO: 240 in the IL-15 Masking Subgroup Table below.
[0447] In some embodiments, the IL-15Rβ or fragment, portion, or variant thereof has a mutation C168S at amino acid position 168 compared to the IL-15β of SEQ ID NO: 240 in the IL-15 Masking Subgroup Table below.
[0448] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 of the IL-15 masking moiety table below, with the C168 mutation.
[0449] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 240 of the IL-15 masking moiety table below, with the C168S mutation.
[0450] In some embodiments, the IL-15Rβ or fragment, portion, or variant thereof has mutations at amino acid positions C122 and C168 compared to the IL-15β of SEQ ID NO: 240 in the IL-15 Masking Subgroup Table below.
[0451] In some embodiments, the IL-15Rβ or fragment, portion, or variant thereof has the mutations C122S and C168S compared to the IL-15β of SEQ ID NO: 240 in the IL-15 Masking Subgroup Table below.
[0452] In some embodiments, the masking moiety comprises the amino acid sequence of SEQ ID NO: 241, as shown in the IL-15 Masking Moiety Table below. [Table 10] TIFF2023553323000074.tif107170
[0453] In some embodiments, the IL-15 masking moiety has an amino acid sequence set forth by one of the sequences in the table above.
[0454] 1.2 Non-cleavable peptide linkers Provided herein are non-cleavable peptide linkers for use in the drug constructs described herein or their cleavage products. The non-cleavable linkers provided herein refer to peptides of two additional amino acids that are used to link two functional components together in the masked cytokines described herein.
[0455] The masked cytokine comprises a first linker and a second linker, wherein at least the first linker or the second linker comprises a proteolytically cleavable peptide.
[0456] In some embodiments, the second linker comprises a proteolytically cleavable peptide (a linker referred to herein as a "proteolytically cleavable linker") and the first linker does not comprise a proteolytically cleavable peptide (a linker referred to herein as a "non-cleavable linker"). This configuration is described herein as "Structure A". In some embodiments, the first polypeptide chain has the formula: TIFF2023553323000075.tif5170 included, the second polypeptide chain having the formula: Includes TIFF2023553323000076.tif5170.
[0457] In some embodiments, the first linker comprises a proteolytically cleavable peptide (a linker referred to herein as a "proteolytically cleavable linker" or "cleavable linker") and the second linker does not comprise a proteolytically cleavable peptide (a linker referred to herein as a "non-cleavable linker"). This configuration is described herein as "Structure B". In some embodiments, the first polypeptide chain has the formula: TIFF2023553323000077.tif5170, the second polypeptide chain having the formula: Includes TIFF2023553323000078.tif5170.
[0458] Non-cleavable and cleavable linkers of some embodiments are described in more detail below.
[0459] In some embodiments, the non-cleavable linker is between 3 and 25 amino acids in length.
[0460] In some embodiments, the non-cleavable linker is 3 to 18 amino acids in length.
[0461] In some embodiments, the non-cleavable linker is 3 to 8 amino acids in length.
[0462] In some embodiments, the non-cleavable linker is 4 to 6 amino acids in length.
[0463] In some embodiments, the non-cleavable linker is rich in the amino acid residues G, S, and P.
[0464] In some embodiments, the non-cleavable linker comprises only amino acid residue types selected from the group consisting of G, S, and P.
[0465] In some embodiments, the non-cleavable linker comprises "GS" repeats.
[0466] In some embodiments, the non-cleavable linker comprises an N'-terminal "P" residue.
[0467] In some embodiments, the non-cleavable linker comprises the amino acid sequence PGSGS (SEQ ID NO: 14).
[0468] In some embodiments, the non-cleavable linker consists of the amino acid sequence PGSGS.
[0469] In some embodiments, the non-cleavable linker comprises the amino acid sequence GGSSPPGGGSSGGGSGP (SEQ ID NO: 23).
[0470] In some embodiments, the non-cleavable linker consists of the amino acid sequence GGSSPPGGGSSGGGSGP.
[0471] In some embodiments, the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker, wherein the non-cleavable linker comprises PGSGS. In some embodiments, the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker, wherein the non-cleavable linker consists of the amino acid sequence PGSGS.
[0472] In some embodiments, the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, wherein the non-cleavable linker comprises GGSSPPGGGSSGGGSGP. In some embodiments, the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, wherein the non-cleavable linker consists of the amino acid sequence GGSSPPGGGSSGGGSGP.
[0473] In some embodiments, the second linker is a proteolytically cleavable linker and the first linker is a non-cleavable linker, and the non-cleavable linker is 3 to 8 amino acids in length. In some embodiments, the non-cleavable linker is 4 to 6 amino acids in length. In some embodiments, the non-cleavable linker comprises the amino acid sequence set forth in SEQ ID NO: 14 (PGSGS).
[0474] In some embodiments, the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, wherein the non-cleavable linker is 3 to 18 amino acids in length. In some embodiments, the first linker is a proteolytically cleavable linker and the second linker is a non-cleavable linker, wherein the non-cleavable linker is 10 to 18 amino acids in length. In some embodiments, the non-cleavable linker comprises the amino acid sequence set forth in SEQ ID NO: 23 (GGSSPPGGGSSGGGSGP).
[0475] In some embodiments, the first and second polypeptide chains are desirably the same or similar length to facilitate association of the first half-life prolonging domain with the second half-life prolonging domain and masking of the cytokine or functional fragment thereof in the assembled construct. Thus, if the masking moiety is a shorter amino acid sequence than the cytokine or functional fragment thereof, the difference in length can be fully or partially compensated for by using a longer linker L1.
[0476] In some embodiments, the first polypeptide chain has the formula: TIFF2023553323000079.tif5170, the second polypeptide chain having the formula: Includes TIFF2023553323000080.tif4170. In some embodiments, the first polypeptide chain has the formula: TIFF2023553323000081.tif4170, the second polypeptide chain having the formula: Includes TIFF2023553323000082.tif5170.
[0477] The linker combinations disclosed in the exemplary AK molecules may be used with any cytokine moiety disclosed herein. The linker combinations disclosed in the exemplary AK molecules may be used with any masking moiety disclosed herein. The linker combinations disclosed in the exemplary AK molecules may be used with any half-life extending moiety. In other words, the linkers disclosed in the exemplary AK molecules may be used in combination with any cytokine moiety, masking moiety, and / or half-life extending moiety disclosed herein.
[0478] 2. Cleavage Products Provided herein are cleavage products comprising an active therapeutic moiety, preparable by proteolytic cleavage of a proteolytically cleavable linker in a polypeptide drug construct described anywhere herein.
[0479] Provided herein are cleavage products of the "heterodimeric" masked cytokines described anywhere herein.
[0480] The masked cytokine described herein comprises a cleavable linker.When the protein is cleaved at the cleavage site of the cleavable linker, a cleavage product comprising a cytokine portion is formed.The cytokine portion in the cleavage product is no longer masked by the masking portion, and is therefore activated.Therefore, the cytokine portion in the cleavage product can bind to a target protein.
[0481] The tumor cell environment is complex and can contain multiple different proteases. Therefore, the exact site at which a given cleavable peptide in a masked cytokine is cleaved in the tumor cell environment may vary between tumor types, between patients with the same tumor type, and even between cleavage products formed within the same tumor. Furthermore, even after cleavage, further modification of the initial cleavage product, for example, by removal of one or two terminal amino acids, can occur through the additional action of proteases in the tumor cell environment. Therefore, the distribution of cleavage products formed in the tumor cell environment of a patient after administration of a masked cytokine as described herein can be predicted.
[0482] As referred to herein, a cleavage site is understood to refer to a site between two specific amino acid residues within a cleavable peptide that is a target of a protease known to be associated with the tumor cell environment. In this sense, there may be multiple cleavage sites within a cleavable peptide described herein, where different proteases cleave the cleavable peptide at different cleavage sites. It is also possible that multiple proteases act on the same cleavage site within a cleavable peptide. Discussions of protease cleavage sites can be found in the art.
[0483] Thus, the cleavable peptides disclosed herein may be cleaved by one or more proteases.
[0484] Provided herein are cleavage products comprising a cytokine portion capable of binding to a cognate receptor, preparable by proteolytic cleavage of a proteolytically cleavable linker in a masked cytokine, as described elsewhere herein.
[0485] Also provided herein is a distribution of cleavage products obtained or obtainable from a single structure of a masked cytokine, wherein each cleavage product within the distribution of cleavage products (i) is capable of binding to a target protein and (ii) comprises a cytokine (e.g., an IL-2, IL-15, or IL-12 cytokine) portion as defined anywhere herein.
[0486] Also provided herein are cleavage products of masked cytokines, wherein the cleavage products are capable of binding to a target protein, and the cleavage products have the following formula: TIFF2023553323000083.tif4170, where PCP is the proteolytically cleavable peptide portion, SD is the spacer domain, and C is the cytokine portion.
[0487] Further provided herein are cleavage products of masked cytokines, wherein the cleavage products are capable of binding to a target protein, and the cleavage products are a) a first polypeptide chain comprising a first half-life extending moiety; b) Formula: a second polypeptide chain comprising a polypeptide comprising TIFF2023553323000084.tif4170, and a second polypeptide chain, wherein HL2 is a second half-life extending moiety, L2 is a non-cleavable linker, C is a cytokine moiety, and the first half-life extending moiety is associated with the second half-life extending moiety. Also provided herein is a distribution of cleavage products obtained or obtainable from a single structure of a masked cytokine, wherein each cleavage product within the distribution of cleavage products (i) is capable of binding to a target protein, and (ii) is one of the following: a) a first polypeptide chain comprising a first half-life extending moiety; b) Formula: a second polypeptide chain comprising a polypeptide comprising TIFF2023553323000085.tif4170, wherein HL2 is a second half-life extending moiety, L2 is a non-cleavable linker, C is a cytokine moiety, and the first half-life extending moiety is associated with the second half-life extending moiety.
[0488] Further provided herein are cleavage products of masked cytokines, wherein the cleavage products are capable of binding to a target protein, and the cleavage products are a) Formula: a first polypeptide chain comprising a polypeptide comprising TIFF2023553323000086.tif4170, a first polypeptide chain, wherein HL1 is a first half-life extending moiety, SD is a spacer domain, and PCP is a portion of a proteolytically cleavable peptide; b) Formula: a second polypeptide chain comprising a polypeptide comprising TIFF2023553323000087.tif4170, wherein HL2 is a second half-life extending moiety, L2 is a non-cleavable linker, C is a cytokine moiety, and the first half-life extending moiety is associated with the second half-life extending moiety.
[0489] Within the cleavage products, the masking moiety, half-life extending moiety, cytokine moiety, linker, space domain may be any one of those described herein, and any combination of those described herein.
[0490] The location of the cleavable peptide determines the structure of the resulting cleavage product containing the cytokine moiety.
[0491] A "proteolytically cleavable peptide portion" refers to a portion of the original proteolytically cleavable peptide sequence after cleavage at the cleavage site. After cleavage, further modification of the initial cleavage product, for example, by removal of one or two terminal amino acids, may occur through the further action of proteases in the tumor cell environment. Thus, cleavage products within the distribution of cleavage products that may be formed in the tumor cell environment of a patient after administration of a masked cytokine may not contain any portion of the proteolytically cleavable peptide.
[0492] In some embodiments, a "portion" refers to 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, or 6 amino acids of the original proteolytically cleavable peptide sequence. In some embodiments, a "portion" refers to 2 amino acids of the original proteolytically cleavable peptide sequence. In some embodiments, a "portion" refers to 3 amino acids of the original proteolytically cleavable peptide sequence. In some embodiments, a "portion" refers to 4 amino acids of the original proteolytically cleavable peptide sequence.
[0493] In some embodiments, a "portion" of a proteolytically cleavable peptide is 3 to 6 amino acids in length. In some embodiments, a "portion" of a proteolytically cleavable peptide is 3 or 4 amino acids in length.
[0494] Exemplary cleavage sites for the cleavable linkers disclosed herein are disclosed below (* indicates a known or observed protease cleavage site within the cleavable peptide): TIFF2023553323000088.tif10170
[0495] Thus, disclosed herein are cleavage products of any one of the polypeptide drug constructs or masked cytokines disclosed herein.
[0496] 3. Binding Assay The strength, or affinity, of an immunological binding interaction, such as between a cytokine or its functional fragment and a binding partner (e.g., a target protein such as a cytokine receptor) for which the cytokine or its functional fragment is specific, can be expressed in terms of the dissociation constant (Kd) of the interaction, with a smaller Kd representing a higher affinity. The binding of a cytokine to a cytokine receptor can be expressed in terms of Kd. In some embodiments, the immunological binding interaction is between a masked cytokine (in the presence or absence of a protease) and a target protein, such as a cytokine receptor. In the context of IL-2 cytokine binding, the target protein can be IL-2R (including the IL-2Rα, IL-2Rβ, and IL-2Rγ chains), the IL-2Rα chain, the IL-2Rβ chain, or the IL-2Rα / β dimeric complex. The immunological binding properties of a protein can be quantified using methods well known in the art. For example, one method involves measuring the rates of cytokine receptor (e.g., IL-2R) / cytokine (e.g., IL-2) complex formation and dissociation, which depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that affect the rates in both directions equally. Both the "on rate constant" (Kon) and the "off rate constant" (Koff) can be determined by calculating the concentrations and the actual rates of association and dissociation. The rate Koff / Kon allows for the elimination of all parameters not related to affinity and is equal to the dissociation constant Kd. See Davies et al., Annual Rev Biochem. 59:439-473, (1990).
[0497] In some aspects, the masked cytokines described herein bind to a target protein with approximately the same or higher affinity upon cleavage by a protease compared to a parent cytokine that includes a masking moiety but does not include a cleavable peptide. The target protein may be any cytokine receptor. In some embodiments, the target protein is IL-2R (including the IL-2Rα, IL-2Rβ, and IL-2Rγ chains). In some embodiments, the target protein is IL-2Rα. In some embodiments, the target protein is IL-2Rβ. In some embodiments, the target protein is the IL-2Rα / β2 dimeric complex.
[0498] In some embodiments, a masked cytokine provided herein that does not include a cleavable peptide in the linker has a dissociation constant (Kd) with a target protein of ≦1 M, ≦150 nM, ≦100 nM, ≦50 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 M or less, e.g., 10 M to 10 M, e.g., 10 M to 10 M). In some embodiments, a masked cytokine provided herein comprising a cleavable peptide in a linker has a dissociation constant (Kd) with a target protein prior to protease cleavage of ≦1 M, ≦150 nM, ≦100 nM, ≦50 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or 0.001 nM (e.g., 10 M or less, e.g., 10 M to 10 M, e.g., 10 M to 10 M). In some embodiments, a masked cytokine provided herein comprising a cleavable peptide in a linker has a dissociation constant (Kd) with a target protein upon cleavage by a protease of ≦1 M, ≦150 nM, ≦100 nM, ≦50 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or 0.001 nM (e.g., 10 M or less, e.g., 10 M to 10 M, e.g., 10 M to 10 M). In some embodiments, the cytokine or functional fragment thereof of the masked cytokine provided herein has a dissociation constant (Kd) with the masking moiety of the masked cytokine of ≧500M, ≧250M, ≧200M, ≧150M, ≧100M, ≧50M, ≧10M, ≧1M, ≧500nM, ≧250nM, ≧150nM, ≧100nM, ≧50nM, ≧10nM, ≧1nM, ≧0.1nM, ≧0.01nM, or ≧0.001nM.In some embodiments, the cytokine or functional fragment thereof of the masked cytokine provided herein has a dissociation constant (Kd) of about 200 M to about 50 nM, e.g., about or at least about 175 M, about or at least about 150 M, about or at least about 125 M, about or at least about 100 M, about or at least about 75 M, about or at least about 50 M, about or at least about 25 M, about or at least about 5 M, about or at least about 1 M, about or at least about 750 nM, about or at least about 500 nM, about or at least about 250 nM, about or at least about 150 nM, about or at least about 100 nM, about or at least about 75 nM, or about or at least about 50 nM. Assays for assessing binding affinity are well known in the art.
[0499] In some embodiments, masked cytokines exhibiting a desired occlusion ratio are provided. As used herein, the term "occlusion ratio" refers to the ratio between (a) the maximum detectable level of a parameter under a first set of conditions and (b) the minimum detectable value of that parameter under a second set of conditions. In the context of a masked IL-2 polypeptide, for example, the occlusion ratio refers to the ratio of (a) the maximum detectable level of a target protein (e.g., IL-2R protein) that binds to the masked IL-2 polypeptide in the presence of at least one protease capable of cleaving a cleavable peptide of the masked IL-2 polypeptide to (b) the minimum detectable level of a target protein (e.g., IL-2R protein) that binds to the masked IL-2 polypeptide in the presence of the protease. Thus, the occlusion ratio of a masked cytokine can be calculated by dividing the EC50 of the masked cytokine before cleavage by the EC50 of the masked cytokine after cleavage. The occlusion ratio of a masked cytokine can also be calculated as the ratio of the dissociation constant of the masked cytokine before cleavage by the protease to the dissociation constant of the masked cytokine after cleavage by the protease. In some embodiments, a greater occlusion ratio for the masked cytokine indicates that the target protein bound by the masked cytokine occurs more frequently (e.g., occurs primarily) in the presence of a protease capable of cleaving the cleavable peptide of the masked cytokine than in the absence of the protease.
[0500] In some embodiments, masked cytokines having an optimal occlusion ratio are provided herein. In some embodiments, the optimal occlusion ratio of a masked cytokine indicates that the masked cytokine has desirable properties useful in the methods or compositions contemplated herein. In some embodiments, the masked cytokines provided herein exhibit an optimal occlusion ratio of about 2 to about 10,000, for example, about 80 to about 100. In further embodiments of any of the masked cytokines provided herein, the occlusion ratio is about 2 to about 7,500, about 2 to about 5,000, about 2 to about 2,500, about 2 to about 2,000, about 2 to about 1,000, about 2 to about 900, about 2 to about 800, about 2 to about 700, about 2 to about 600, about 2 to about 500, about 2 to about 400, about 2 to about 300, about 2 to about 500, about 2 to about 500, about 2 to about 600, about 2 to about 700, about 2 to about 800, about 2 to about 9 ... to about 200, about 2 to about 100, about 2 to about 50, about 2 to about 25, about 2 to about 15, about 2 to about 10, about 5 to about 10, about 5 to about 15, about 5 to about 20, about 10 to about 100, about 20 to about 100, about 30 to about 100, about 40 to about 100, about 50 to about 100, about 60 to about 100, about 70 to about 100, about 80 to about 100, or about 100 to about 1,000. In some embodiments, the masked cytokines provided herein exhibit an optimal occlusion ratio of about 2 to about 1,000. Binding of the masked cytokine to the target protein before and / or after protease cleavage can be determined using techniques well known in the art, such as ELISA.
[0501] In some embodiments, the masking moieties described herein bind to the cytokines or functional fragments thereof described herein with an affinity lower than the affinity between the cytokines or functional fragments thereof and the target protein (e.g., cytokine receptor). In certain embodiments, the masking moieties provided herein bind to the cytokines or functional fragments thereof described herein with an affinity lower than the affinity between the cytokines or functional fragments thereof and the target protein (e.g., cytokine receptor).
[0502] binds with a dissociation constant (Kd) of ≥500M, ≥250M, ≥200M, ≥150M, ≥100M, ≥50M, ≥10M, ≥1M, ≥500nM, ≥250nM, ≥150nM, ≥100nM, ≥50nM, ≥10nM, ≥1nM, ≥0.1nM, ≥0.01nM, or ≥0.001nM.
[0503] 4. Masked cytokine production The masked cytokines described herein are prepared using techniques available in the art, exemplary methods of which are described.
[0504] 4.1 Antibody production Some embodiments of the masked cytokines include antibodies or fragments thereof. The following sections provide further details on the production of antibodies and antibody fragments, variants, and derivatives thereof that may be used in some embodiments of the masked cytokines provided herein. In some embodiments, the masked cytokine is in the form of a dimer, produced by two copies of the masked cytokine linked via a disulfide bond.
[0505] 1. Antibody fragment In some embodiments, the present invention encompasses antibody fragments. Antibody fragments may be any antibody fragment, such as an Fc domain, a portion of a heavy chain, a portion of a light chain, Fab, Fv, or scFv. Antibody fragments may be produced by conventional means, such as enzymatic digestion, or by recombinant technology. In certain circumstances, it may be advantageous to link an antibody fragment, rather than a whole antibody, to the masked cytokines described herein. For a review of certain antibody fragments, see Hudson et al. (2003) Nat. Med. 9:129-134.
[0506] Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science, 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv, and ScFv antibody fragments can all be expressed in and secreted from E. coli and other cell types, such as HEK293 and CHO cells, thus allowing the facile production of large amounts of these fragments. Alternatively, Fab-SH fragments can be directly recovered from the culture medium and chemically coupled to form F(ab)2 fragments (Carter et al., Bio / Technology 10:163-167 (1992)). According to another approach, F(ab)2 fragments can be directly isolated from recombinant host cell culture. Fab and F(ab)2 fragments with increased in vivo half-lives containing FcRN / salvage receptor binding epitope residues are described in U.S. Pat. No. 5,869,046. Other techniques for generating antibody fragments for use with masked cytokines will be apparent to those skilled in the art. In certain embodiments, the masked cytokine comprises a single-chain Fv fragment (scFv). See WO 93 / 16185, U.S. Pat. Nos. 5,571,894, and 5,587,458. scFv fusion proteins may be constructed to provide fusion of an effector protein at either the amino or carboxy terminus of the scFv. See Antibody Engineering, ed. Borrebaeck, supra. Also, in some embodiments, bi-scFvs, comprising two scFvs linked via a polypeptide linker, can be used with masked cytokines.
[0507] In some embodiments, the present invention includes linear antibodies (e.g., as described in U.S. Pat. No. 5,641,870) or single-chain immunoglobulins comprising antibody heavy and light chain sequences linked via a suitable linker. Such linear antibodies or immunoglobulins may be monospecific or bispecific. Such single-chain immunoglobulins can be dimerized, thereby maintaining a structure and activity similar to that of an originally tetrameric antibody. In some embodiments, an antibody or fragment thereof may also be an antibody having a single heavy chain variable region and no light chain sequence. Such antibodies are referred to as single-domain antibodies (sdAbs) or nanobodies. These antibodies are also encompassed within the meaning of functional fragments of antibodies according to the present invention. Antibody fragments may be linked to the masked cytokines described herein according to the guidance provided herein.
[0508] 2. Humanized antibodies In some embodiments, the present invention encompasses humanized antibodies or antibody fragments thereof. In some embodiments, a humanized antibody may be any antibody, including any antibody fragment. Various methods for humanizing non-human antibodies are known in the art. For example, a humanized antibody may have one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are often referred to as "import" residues, typically taken from an "import" variable domain. Humanization can be performed essentially following the method of Winter (Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536) by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Such "humanized" antibodies thus are chimeric antibodies (U.S. Pat. No. 4,816,567) in which substantially less intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies can be linked to the masked cytokines described herein, following the guidance provided herein.
[0509] 3. Human antibodies Human antibodies of some embodiments of the present invention can be constructed by combining Fv clone variable domain sequences selected from a human-derived phage display library with known human constant domain sequences. Alternatively, human monoclonal antibodies of some embodiments of the present invention can be produced, for example, by hybridoma technology using, for example, mouse, rat, bovine (e.g., cow), or rabbit cells to produce human monoclonal antibodies. In some embodiments, human antibodies and human monoclonal antibodies can be antibodies that bind to any antigen. In some embodiments, human monoclonal antibodies of the present invention can be produced by immunizing a non-human animal containing human immunoglobulin loci with a target antigen and isolating antibodies from the immunized animal or cells derived from the immunized animal. Examples of suitable non-human animals include transgenic or transchromosomic animals such as HuMAb Mouse® (Medarex, Inc.), KM Mouse®, "TC Mouse," and Xenomouse™. See, for example, Lonberg, et al. (1994) Nature 368: 856-859; Fishwild, D. et al. (1996) Nature Biotechnology 14: 845-851, WO2002 / 43478, U.S. Patent Nos. 5,939,598, 6,075,181, 6,114,598, 6,150,584, 6,162,963, and Tomizuka et al. (2000) Proc. Natl. Acad. Sci. USA 97:722-727.
[0510] Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor J. Immunol., 133: 3001 (1984), Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987), and Boerner et al., J. Immunol., 147: 86 (1991). Human antibodies can be linked to the masked cytokines described herein following the guidance provided herein.
[0511] 4. Bispecific antibodies Bispecific antibodies are monoclonal antibodies that have binding specificities for at least two different antigens. In certain embodiments, bispecific antibodies are human or humanized. In some embodiments, one of the binding specificities is for a first antigen and the other is for a second antigen, which may be two different epitopes on the same target protein or two different epitopes on two different target proteins. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing the first and / or second antigen. Bispecific antibodies can also be used to recruit cells, such as T cells or natural killer cells, to kill specific cells, such as cancer cells. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies). Bispecific antibodies can be linked to the masked cytokines described herein according to the guidance provided herein.
[0512] Methods for producing bispecific antibodies are known in the art. See Milstein and Cuello, Nature, 305: 537 (1983); WO93 / 08829 published May 13, 1993; Traunecker et al., EMBO J., 10: 3655 (1991); Kontermann and Brinkmann, Drug Discovery Today, 20(7): 838-847. For further details on producing bispecific antibodies, see, for example, Suresh et al., Methods in Enzymology, 121: 210 (1986). Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, while the other can be coupled to biotin. Heteroconjugate antibodies can be produced using any convenient cross-linking method. Suitable cross-linking agents are well known in the art and are disclosed in US Pat. No. 4,676,980, along with several cross-linking techniques.
[0513] 5. Single Domain Antibodies In some embodiments, the single domain antibody is linked to a masked cytokine according to the guidance provided herein. The single domain antibody can be any antibody. A single domain antibody is a single polypeptide chain comprising all or a portion of an antibody heavy chain variable domain or all or a portion of an antibody light chain variable domain. In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Patent No. 6,248,516 B1). In some embodiments, the single domain antibody consists of all or a portion of an antibody heavy chain variable domain. In some embodiments, the single domain antibody is a camel-derived antibody obtained by immunizing a camel with a target antigen. In some embodiments, the single domain antibody is a shark-derived antibody obtained by immunizing a shark with a target antigen. In some embodiments, the single domain antibody is a nanobody (see, e.g., WO2004041865A2 and US20070269422A1).
[0514] 6. Antibody Variants In some embodiments, amino acid sequence modifications of the antibodies or fragments thereof described herein are contemplated. For example, it may be desirable to improve the FcRn binding affinity and / or pH-dependent FcRn binding affinity of the antibody. It may also be desirable to promote heterodimerization of antibody heavy chains by introducing specific amino acid modifications. Methods for promoting heterodimerization of antibody chains, including specific modifications that can be made to promote heterodimerization, are described in Klein et al. (2012), MAbs, 4(6): 653-663.
[0515] Amino acid sequence variants of antibodies can be prepared by introducing appropriate changes into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletion from and / or insertion into and / or substitution of residues within the amino acid sequence of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct retains the desired characteristics. Amino acid changes can be introduced into the subject antibody amino acid sequence at the time the sequence is generated.
[0516] A useful method for identifying specific residues or regions of an antibody that are preferred locations for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a target residue or group of residues is identified (e.g., charged residues such as arg, asp, his, lys, and glu) and substituted with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to affect the interaction of the amino acid with the antigen. Those amino acid locations that demonstrate functional sensitivity to the substitution are then refined by introducing further or other variants at or for the substitution site. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is performed at the target codon or region, and the expressed immunoglobulins are screened for the desired activity.
[0517] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing several hundred or more residues, as well as intersequence insertions of single or multiple amino acid residues. An example of a terminal insertion is an antibody with an N-terminal methionyl residue. Other insertional variants of antibody molecules include the fusion to the N- or C-terminus of the antibody to an enzyme or a polypeptide to extend the serum half-life of the antibody.
[0518] In some embodiments, the masked cytokine is modified to eliminate, reduce, or otherwise inhibit protease cleavage near the hinge region. The "hinge region" of an IgG is generally defined as including E216 and ending at P230 for human IgG1 according to the EU index as in Kabat; however, functionally, the flexible portion of the chain may be considered to include additional residues designated the upper and lower hinge regions, such as E216 to G237 (Roux et al., 1998 J Immunol 161:4083), with the lower hinge designated as residues 233-239 of the Fc region, to which FcyR binding is generally attributed. Modifications to any of the masked cytokines described herein can be made, for example, according to the methods described in US 20150139984A1, incorporated herein by reference, and by incorporating any of the modifications described herein.
[0519] In some embodiments, FcRn mutations that improve pharmacokinetics include, but are not limited to, M428L, T250Q / M428L, M252Y / S254T / T256E, P257I / N434H, D376V / N434H, P257I / Q3111, N434A, N434W, M428L / N434S, V259I / V308F, M252Y / S254T / T256E, V259I / V308F / M428L, T307Q / N434A, T307Q / N434S, T307Q / E380A / N434A, V308P / N434A, N434H, V308P. In some embodiments, such mutations enhance antibody binding to FcRn at low pH but do not alter antibody affinity at neutral pH.
[0520] In certain embodiments, antibodies or fragments thereof of the present invention are modified to increase or decrease the extent of glycosylation of the antibody. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
[0521] Addition or deletion of glycosylation sites to the masked cytokine is conveniently accomplished by altering the amino acid sequence to create or remove one or more of the above-mentioned tripeptide sequences (for N-linked glycosylation sites). Alterations may also be made to the original antibody sequence (for O-linked glycosylation sites) by adding, deleting, or substituting one or more serine or threonine residues.
[0522] If an antibody or fragment thereof contains an Fc region, the carbohydrate attached thereto can be modified. For example, an antibody having a mature carbohydrate structure lacking fucose attached to its Fc region is described in U.S. Application No. US2003 / 0157108 (Presta, L.). See also U.S. Application No. US2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). An antibody having a bisecting N-acetylglucosamine (GlcNAc) in the carbohydrate attached to its Fc region is mentioned in WO2003 / 011878 (Jean-Mairet et al.) and U.S. Patent No. 6,602,684 (Umana et al.). An antibody having at least one galactose residue in the oligosaccharide attached to its Fc region is reported in WO1997 / 30087 (Patel et al.). See also WO1998 / 58964 (Raju, S.) and WO1999 / 22764 (Raju, S.) concerning antibodies with modified carbohydrates attached to the Fc region thereof. See also US2005 / 0123546 (Umana et al.) concerning antigen-binding molecules with modified glycosylation.
[0523] In certain embodiments, the glycosylation variant comprises an Fc region, and the carbohydrate structure attached to the Fc region lacks or has reduced fucose. Such variants have improved ADCC function. Optionally, the Fc region further comprises one or more amino acid substitutions therein that further improve ADCC, e.g., substitutions at positions 298, 333, and / or 334 of the Fc region (Eu numbering of residues). Examples of publications related to "defucosylated" or "fucose-deficient" antibodies include US2003 / 0157108, WO2000 / 61739, WO2001 / 29246, US2003 / 0115614, US2002 / 0164328, US2004 / 0093621, US2004 / 0132140, US2004 / 0110704, US2004 / 0110282, US2004 / 0109865, WO2003 / 085119, WO2003 / 084570, WO2005 / 035586, WO2005 / 035778, WO2005 / 053742, Okazaki et al. J. Mol. Biol. 336:1239-1249(2004), Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614(2004). Examples of cell lines that produce defucosylated antibodies include Lee13 CHO cells, which are deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Application No. US2003 / 0157108 A1, Presta, L; and WO2004 / 056312 A1, Adams et al., especially Example 11), and knockout cell lines such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (Yamane-Ohnuki et al. Biotech. Bioeng. 87:614 (2004)), and cells overexpressing β1,4-N-acetylglucosaminyltransferase III (GnT-III) and Golgi p-mannosidase II (ManII).
[0524] In any of the embodiments herein, the masked cytokine may be engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In some embodiments, the masked cytokine may be produced in a cell line with an alpha 1,6-fucosyltransferase (Fut8) knockout. In some embodiments, the host cell is modified to have reduced intrinsic alpha 1,6-fucosylation activity. Examples of methods for modifying the fucosylation pathway in mammalian host cells can be found, for example, in Yamane-Ohnuki and Satoh, MAbs, 1(3): 230-236 (2009), the contents of which are incorporated herein by reference. Examples of methods and compositions for partially or completely inactivating the expression of the FUT8 gene can be found, for example, in U.S. Publication No. 20160194665A1 and WO2006133148A2, the contents of which are incorporated herein by reference. In some embodiments, the masked cytokine is produced in a Lecl3 variant of CHO cells (see, e.g., Shields et al., J. Biol. Chem., 277(30):26733-40(2002)), or in the YB2 / 0 cell line with reduced FUT8 activity (see, e.g., Shinkawa et al., J. Biol. Chem., 278(5):3466-73 (2003)). In some embodiments, small interfering RNA (siRNA) against genes associated with alpha 1,6-fucosylation may be introduced (see, e.g., Mori et al., Biotechnol. Bioeng. 88(7): 901-908 (2004); Imai-Nishiya et al., BMC Biotechnol. 7: 84 (2007); Omasa et al., J. Biosci. Bioeng., 106(2): 168-173 (2008)). In some further embodiments, the masked cytokine may be produced in a cell line overexpressing β1,4-N-acetylglucosaminyltransferase III (GnT-III). In a further embodiment, the cell line further overexpresses Golgi p-mannosidase II (ManII).In some embodiments herein, the masked cytokine may comprise at least one amino acid substitution in the Fc region that improves ADCC activity.
[0525] In some embodiments, the masked cytokine is modified to improve its serum half-life. To increase the serum half-life of the cytokine, an FcRN / salvage receptor binding epitope can be incorporated into the linked antibody (particularly an antibody fragment), as described in U.S. Pat. No. 5,739,277. As used herein, the term "salvage receptor binding epitope" refers to an epitope in the Fc region of an IgG molecule (e.g., IgG1, IgG2, IgG3, or IgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule (US2003 / 0190311, U.S. Pat. No. 6,821,505, U.S. Pat. No. 6,165,745, U.S. Pat. No. 5,624,821, U.S. Pat. No. 5,648,260, U.S. Pat. No. 6,165,745, U.S. Pat. No. 5,834,597).
[0526] Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced with a different residue. Targeted sites for substitution mutagenesis include hypervariable regions, although modifications of FRs are also contemplated. Conservative substitutions are shown in Table 2 under the heading of "preferred substitutions." If such substitutions result in desirable changes in biological activity, larger substitution changes can be introduced and the products screened, as indicated in Table 2 under "exemplary substitutions," or as detailed below for classes of amino acids. [Table 11]
[0527] Substitutional modifications in the biological properties of antibodies are achieved by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the region of the substitution, e.g., as a sheet or helical conformation, (b) the charge or hydrophobicity of the target site molecule, or (c) the bulk of the side chain. Amino acids can be grouped according to the similarity of their side chain properties (A.L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) Non-polar: Ala(A), Val(V), Leu(L), Iie(I), Pro(P), Phe(F), Trp(W), Met(M) (2) Uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (Q) (3) Acidic: Asp(D), Glu(E) (4) Basic: Lys(K), Arg(R), His(H) Alternatively, the naturally occurring residues can be divided into groups based on the following general side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, he; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that influence chain directionality: Gly, Pro; (6) Aromatics: Trp, Tyr, Phe. Non-conservative substitutions involve exchanging a member of one of these classes for another. Such substituted residues also may be introduced into the conservative substitution sites or into the remaining (non-conserved) sites.
[0528] Another type of substitution variant involves substituting a natural amino acid residue with a non-natural amino acid residue, which may be incorporated, for example, via tRNA recoding or via any of the methods described in WO2016154675A1, which is incorporated herein by reference.
[0529] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variants selected for further development have modified (e.g., improved) biological properties relative to the parent antibody from which they were generated. A convenient method for generating such substitutional variants involves affinity maturation using phage display, yeast display, or mammalian display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino acid substitutions at each site. The antibodies thus generated are displayed from filamentous phage particles as fusions to at least a portion of a phage coat protein (e.g., the gene III product of M13) packaged within each particle. Phage-displayed variants are then screened for their biological activity (e.g., binding affinity). To identify potential hypervariable region sites for modification, scanning mutagenesis (e.g., alanine scanning) can be performed to identify hypervariable region residues that significantly contribute to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and adjacent residues are candidates for substitution by techniques known in the art, including those detailed herein. Once such variants are generated, the panel of variants can be screened using techniques known in the art, including those described herein, and antibodies with superior properties in one or more relevant assays can be selected for further development.
[0530] Nucleic acid molecules encoding amino acid sequence variants of masked cytokines are prepared by a variety of methods known in the art, including, but not limited to, isolation from natural sources (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of variant or non-variant versions of previously prepared antibodies.
[0531] It may be desirable to introduce one or more amino acid modifications into the Fc region of an antibody of the invention, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) containing an amino acid modification (e.g., substitution) at one or more amino acid positions, including the hinge cysteine amino acid position.
[0532] In some embodiments, the masked cytokines provided herein comprise antibodies or fragments thereof having an IgG1, IgG2, IgG3, or IgG4 isotype with enhanced effector function. In some embodiments, the masked cytokines provided herein comprise antibodies or fragments thereof having an IgG1 isotype with enhanced effector function. In some embodiments, the masked cytokines provided herein have an IgG1 isotype with enhanced effector function. In some embodiments, the masked cytokines are nonfucosylated. In some embodiments, the masked cytokines have increased levels of mannose moieties. In some embodiments, the masked cytokines have increased levels of bisecting glycan moieties. In some embodiments, the IgG1 comprises an amino acid mutation.
[0533] In some embodiments, the masked cytokines provided herein comprise antibodies having an IgG1 isotype (e.g., a human IgG1 isotype). In some embodiments, the IgG1 comprises one or more amino acid substitutions that enhance effector function. In one embodiment, the IgG1 comprises amino acid substitutions S298A, E333A, and K334A, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises amino acid substitutions S239D and I332E, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises amino acid substitutions S239D, A330L, and I332E, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises amino acid substitutions P247I and A339D or A339Q, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises the amino acid substitutions D280H, K290S with or without S298D, or S298V, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises the amino acid substitutions F243L, R292P, and Y300L, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises the amino acid substitutions F243L, R292P, Y300L, and P396L, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises the amino acid substitutions F243L, R292P, Y300L, V305I, and P396L, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises the amino acid substitutions G236A, S239D, and I332E, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K326A and E333A, where the amino acid residues are numbered according to the EU index as in Kabat.In one embodiment, IgG1 comprises amino acid substitutions K326W and E333S, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions K290E, S298G, T299A, with or without K326E, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions K290N, S298G, T299A, with or without K326E, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions K334V, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions L235S, S239D, and K334V, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions K334V and Q331M, S239D, F243V, E294L, or S298T, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions E233L, Q311M, and K334V, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions L234I, Q311M, and K334V, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions K334V and S298T, A330M, or A330F, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions K334V, Q311M, and either A330M or A330F, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions K334V, S298T, and either A330M or A330F, where amino acid residues are numbered according to the EU index as in Kabat.In one embodiment, IgG1 comprises amino acid substitutions K334V, S239D, and either A330M or S298T, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions L234Y, Y296W, and K290Y, F243V, or E294L, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions Y296W and either L234Y or K290Y, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, IgG1 comprises amino acid substitutions S239D, A330S, and I332E, where the amino acid residues are numbered according to the EU index as in Kabat.
[0534] In some embodiments, the IgG1 comprises one or more amino acid substitutions that reduce or inhibit effector function. In one embodiment, the IgG1 comprises the amino acid substitution N297A, N297G, or N297Q, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitution L234A or L235A, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions C220S, C226S, C229S, and P238S, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions C226S, C229S, E233P, L234V, and L235A, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions L234F, L235E, and P331S, where the amino acid residues are numbered according to the EU index as in Kabat. In one embodiment, the IgG1 comprises the amino acid substitutions S267E and L328F, where the amino acid residues are numbered according to the EU index as in Kabat.
[0535] In accordance with this description and teachings of the art, it is contemplated that in some embodiments, a masked cytokine antibody or fragment thereof may contain one or more modifications, for example, in the Fc region, compared to a wild-type corresponding antibody. For example, certain modifications may be made in the Fc region that will result in altered (i.e., either improved or reduced) C1q binding and / or complement-dependent cytotoxicity (CDC), as described, for example, in WO99 / 51642. For other examples of Fc region variants, see Duncan & Winter Nature 322:738-40 (1988), U.S. Patent No. 5,648,260, U.S. Patent No. 5,624,821, and WO94 / 29351. WO00 / 42072 (Presta) and WO2004 / 056312 (Lowman) describe antibody variants with improved or reduced binding to FcR. The contents of these patent publications are specifically incorporated herein by reference. See also Shields et al. J. Biol. Chem. 9(2): 6591-6604 (2001). Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), are described in US2005 / 0014934A1 (Hinton et al.). These antibodies comprise an Fc region with one or more substitutions therein that improve binding of the Fc region to FcRn. Polypeptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding ability are described in U.S. Patent No. 6,194,551B1 and WO99 / 51642. The contents of these patent publications are specifically incorporated herein by reference. See also Idusogie et al. J Immunol. 164: 4178-4184 (2000).
[0536] 4.2 Masked cytokine-drug conjugates The present invention also provides masked cytokine-drug conjugates (MCDCs) comprising the masked cytokines provided herein, which can be any masked cytokine disclosed herein conjugated to one or more agents. In some embodiments, the one or more agents are cytotoxic agents such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins,
[0537] an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof, or a radioactive isotope. In some embodiments, the one or more agents are immunostimulants.
[0538] In some embodiments, the one or more drugs conjugated to the masked cytokine include, but are not limited to, maytansinoids (see U.S. Pat. Nos. 5,208,020, 5,416,064, and European Patent EP 0425235 B1); auristatins, such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483, 5,780,588, and 7,498,298); dolastatins; calicheamicin or a derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., Cancer Res. 53:3336-3342 (1993), and Lode et al., Cancer Res. 58:2925-2928 (1998); anthracyclines such as daunomycin or doxorubicin (Kratz et al., Current Med. Chem. 13:477-523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et al., Bioconj. Chem. 16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000); Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2002), King et al., J. Med. Chem. 45:4336-4343 (2002), and U.S. Patent No. 6,630,579); methotrexate; vindesine; taxanes such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; and CC1065.
[0539] In another embodiment, the one or more drugs conjugated to the masked cytokine include, but are not limited to, inhibitors of tubulin polymerization (e.g., maytansinoids and auristatins), DNA damaging agents (e.g., pyrrolobenzodiazepine (PBD) dimers, calicheamicins, duocarmycins, and indolinobenzodiazepine dimers), and DNA synthesis inhibitors (e.g., exatecan derivatives Dxd).
[0540] In another embodiment, the masked cytokine-drug conjugate comprises a masked cytokine described herein conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, unbound active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii protein, dianthin protein, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogenin, restrictocin, phenomycin, enomycin, and the trichothecenes.
[0541] In another embodiment, the masked cytokine-drug conjugate comprises a masked cytokine described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for producing the radioconjugate. Examples include At211, 1131, 1125, Y90, Rel86, Rel88, Sml53, B1212, P32, Pb212, and radioactive isotopes of Lu. When a radioconjugate is used for detection, the radioconjugate may contain a radioactive atom for scintigraphy studies, such as tc99m or 1123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron.
[0542] In some embodiments, the masked cytokine-drug conjugate comprises a masked cytokine described herein conjugated to one or more immunostimulatory agents, which in some embodiments are stimulators of interferon genes (STING) agonists or toll-like receptor (TER) agonists.
[0543] The STING agonist may be any agonist of STING. In some embodiments, the STING agonist is a cyclic dinucleotide (CDN). The CDN may be any CDN or a derivative or variant thereof. In some embodiments, the STING agonist is a CDN selected from the group consisting of cGAMP, c-di-AMP, c-di-GMP, cAIMP, and c-di-IMP. In some embodiments, the STING agonist is a derivative or variant of a CDN selected from the group consisting of cGAMP, c-di-AMP, c-di-GMP, cAIMP, and c-di-IMP. In some embodiments, the STING agonist is 4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][l,4]thiazine-6-carboxamide, or a derivative or variant thereof. See, for example, Sali et al. (2015) PloS Pathog., 11(12): e!005324.
[0544] The TLR agonist may be an agonist of any TLR, such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, or TLR10. In some embodiments, the TLR agonist is an agonist of a TLR expressed on the cell surface, such as TLR1, TLR2, TLR4, or TLR5. In some embodiments, the TLR agonist is an agonist of a TLR expressed intracellularly, such as TLR3, TLR7, TLR8, TLR9, or TLR10.
[0545] Conjugates of masked cytokines and cytotoxic agents can be made using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14-labeled l-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See WO94 / 11026. The linker may be a "cleavable linker" that facilitates the release of the cytotoxic drug in cells. For example, acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers, or disulfide-containing linkers (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Patent No. 5,208,020) may be used.
[0546] The MCDC herein may be commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL, USA), such as BMPS, EMCS, GMBS, HBVS, LC-SMCC,
[0547] Expressly contemplated are, but are not limited to, such conjugates prepared with crosslinker reagents including, but not limited to, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate).
[0548] 4.3 Vectors, host cells, and recombinant methods For recombinant production of a masked cytokine of the present invention, the nucleic acid(s) encoding it are isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression.
[0549] The DNA encoding the masked cytokine, including its components, is easily isolated and sequenced using conventional procedures. Many vectors are available. The choice of vector depends in part on the host cell to be used. Generally, the host cell is either prokaryotic or eukaryotic (generally mammalian) in origin. It will be understood that the constant region of any isotype of antibody or fragment thereof, including IgG, IgM, IgA, IgD, and IgE constant regions, where applicable, can be used for this purpose, and that such constant regions can be obtained from any human or animal species. In some embodiments, one vector is used to encode the masked cytokine. In some embodiments, multiple vectors are used to encode the masked cytokine.
[0550] 1. Produce masked cytokines using prokaryotic host cells a. Vector construction Polynucleotide sequences encoding polypeptide components of the masked cytokines of the present invention can be obtained using standard recombinant techniques. The desired polynucleotide sequence of an antibody or antibody fragment thereof may be isolated and sequenced from antibody-producing cells, such as hybridoma cells. Alternatively, polynucleotides can be synthesized using a nucleotide synthesizer or PCR technology, or obtained from other sources. Once obtained, the sequences encoding the masked cytokine components are inserted into a recombinant vector capable of replicating and expressing heterologous polynucleotides in a prokaryotic host. Many vectors available and known in the art can be used for the purposes of the present invention. The selection of an appropriate vector depends primarily on the size of the nucleic acid to be inserted into the vector and the specific host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification or expression of the heterologous polynucleotide, or both) and its compatibility with the specific host cell in which it resides. Vector components generally include, but are not limited to, an origin of replication, a selectable marker gene, a promoter, a ribosome binding site (RBS), a signal sequence, the heterologous nucleic acid insert, and a transcription termination sequence.
[0551] Generally, plasmid vectors containing replicons and control sequences derived from species compatible with the host cell are used in connection with these hosts. The vectors usually carry a replication site and marking sequences capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR322, a plasmid derived from the E. coli species. pBR322 contains genes encoding ampicillin (Amp) and tetracycline (Tet) resistance, thus providing an easy means for identifying transformed cells. pBR322, its derivatives, or other microbial plasmids or bacteriophages may also contain, or be modified to contain, promoters that can be used by the microorganism for expression of endogenous proteins. Examples of pBR322 derivatives used to express specific antibodies are described in detail in Carter et al., U.S. Patent No. 5,648,237.
[0552] Additionally, phage vectors containing replicons and control sequences compatible with host microorganisms can be used as transformation vectors in connection with these hosts. For example, bacteriophages such as 7GEM.TM.-11 can be utilized to generate recombinant vectors that can be used to transform susceptible host cells such as E. coli LE392.
[0553] The expression vector of the present invention may contain two or more promoter-cistron pairs, each encoding a polypeptide component. A promoter is a non-translated regulatory sequence located upstream (5') of a cistron that controls its expression. Prokaryotic promoters are typically divided into two classes: inducible and constitutive. An inducible promoter is a promoter that initiates an increased level of transcription of the cistron under its control in response to a change in culture conditions, such as the presence or absence of a nutrient or a change in temperature.
[0554] Many promoters recognized by various potential host cells are well known. The selected promoter can be operably linked to the cistron DNA encoding any chain of the masked cytokine by removing the promoter from the source DNA through restriction enzyme digestion and inserting the isolated promoter sequence into the vector of the present invention. Both the native promoter sequence and many heterologous promoters can be used to direct the amplification and / or expression of the target gene.
[0555] In some embodiments, heterologous promoters are utilized because they generally allow for greater transcriptional yields and higher yields of the expressed target gene compared to the native target polypeptide promoter.
[0556] Suitable promoters for use with prokaryotic hosts include the PhoA promoter, the β-galactamase and lactose promoter system, the tryptophan (trp) promoter system, and hybrid promoters such as the tac or trc promoter. However, other promoters that function in bacteria (such as other known bacterial or phage promoters) are also suitable. Their nucleotide sequences have been published, allowing those skilled in the art to operably ligate them into the cistron encoding the target light and heavy chains of a masked cytokine, for example, using linkers or adapters to provide any necessary restriction sites (Siebenlist et al. (1980) Cell 20:269).
[0557] In one aspect of the present invention, each cistron in a recombinant vector contains a secretory signal sequence component that directs translocation of the expressed polypeptide across a membrane. Generally, the signal sequence may be a component of the vector or may be part of the target polypeptide DNA inserted into the vector. The signal sequence selected for purposes of the present invention should be one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the native signal sequence for a heterologous polypeptide, the signal sequence is replaced by a prokaryotic signal sequence selected from the group consisting of, for example, alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II (STII) leaders, LamB, PhoE, PelB, OmpA, and MBP. In one embodiment of the present invention, the signal sequences used in both cistrons of the expression system are STII signal sequences or variants thereof.
[0558] In another aspect, production of the polypeptide components according to the present invention can occur within the cytoplasm of the host cell, and therefore does not require the presence of a secretory signal sequence within each cistron. In this regard, for embodiments including immunoglobulin light and heavy chains, for example, the heavy and light chains can be expressed, folded, and assembled to form functional immunoglobulins within the cytoplasm, with or without sequences such as masking moieties, linker sequences, etc. Certain host strains (e.g., E. coli trxB strains) provide cytoplasmic conditions favorable for disulfide bond formation, thereby enabling proper folding and assembly of the expressed protein subunits. Proba and Pluckthun Gene, 159:203 (1995).
[0559] The masked cytokines of the present invention can also be produced by using an expression system that allows for the quantitative ratio of expressed polypeptide components to be adjusted to maximize the yield of secreted and properly assembled antibodies of the present invention, such adjustment being achieved at least in part by simultaneously adjusting the translational strength of the polypeptide components.
[0560] Suitable prokaryotic host cells for expressing the masked cytokines of the present invention include, for example, archaebacteria and eubacteria, such as gram-negative or gram-positive organisms. Examples of useful bacteria include Escherichia (e.g., E. coli), Bacilli (e.g., B. subtilis), Enterobacteria, Pseudomonas species (e.g., P. aeruginosa), Salmonella typhimurium, Serratia marcescans, Klebsiella, Proteus, Shigella, Rhizobia, Vitreoscilla, or Paracoccus. In one embodiment, gram-negative cells are used. In one embodiment, E. coli cells are used as hosts in the present invention. Examples of E. coli strains include the W3110 strain (Bachmann, Cellular and Molecular Biology, vol. 2 (Washington, DC: American Society for Microbiology, 1987), pp. 1190-1219; ATCC Deposit No. 27,325), including the 33D3 strain with the genotype W3110 AfhuA (AtonA) ptr3 lac Iq lacL8 AompTA (nmpc-fepE) degP41 kanR (U.S. Pat. No. 5,639,635). Other strains and their derivatives, such as E. coli 294 (ATCC 31,446), E. coli B, E. coli 1776 (ATCC 31,537), and E. coli RV308 (ATCC 31,608), are also suitable. These examples are illustrative rather than limiting. Methods for constructing derivatives of any of the above-mentioned bacteria with defined genotypes are known in the art and are described, for example, in Bass et al., Proteins, 8:309-314 (1990). It is generally necessary to select an appropriate bacterium taking into account the replicability of the replicon within the bacterial cell.For example, E. coli, Serratia, or Salmonella species are suitable for use as hosts when well-known plasmids such as pBR322, pBR325, pACYC177, or pKN410 are used to supply the replicon. Typically, the host cell should secrete minimal amounts of proteolytic enzymes, and additional protease inhibitors may desirably be incorporated into the cell culture.
[0561] B. Masked cytokine production Host cells are transformed with the above-described expression vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
[0562] Transformation refers to the introduction of DNA into a prokaryotic host so that the DNA is replicable either as an extrachromosomal element or by chromosomal integration. Depending on the host cell used, transformation is carried out using standard techniques appropriate for such cells. Calcium treatment using calcium chloride is commonly used for bacterial cells that contain substantial cell wall barriers. Another method for transformation uses polyethylene glycol / DMSO. Yet another technique that can be used is electroporation.
[0563] Prokaryotic cells used to produce the masked cytokines of the present invention are grown in media known in the art and suitable for culturing the selected host cells. Examples of suitable media include Luria Broth (LB) plus necessary nutrient supplements. In some embodiments, the media also contains a selection agent selected based on the construction of the expression vector, selectively allowing the growth of prokaryotic cells containing the expression vector. For example, ampicillin is added to the media for the growth of cells expressing an ampicillin resistance gene.
[0564] Any necessary supplements other than carbon, nitrogen, and inorganic phosphate sources may also be introduced at appropriate concentrations, either alone or in mixture with the medium, such as another supplement or a complex nitrogen source. Optionally, the culture medium may contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolate, dithioerythritol, and dithiothreitol.
[0565] Prokaryotic host cells are cultured at a suitable temperature. In certain embodiments, for growth of E. coli, the growth temperature ranges from about 20°C to about 39°C, from about 25°C to about 37°C, or about 30°C. The pH of the medium can be any pH ranging from about 5 to about 9, depending primarily on the host organism. In certain embodiments, for E. coli, the pH is about 6.8 to about 7.4, or about 7.0.
[0566] When an inducible promoter is used in the expression vector of the present invention, protein expression is induced under the conditions suitable for promoter activation.In one aspect of the present invention, PhoA promoter is used to control the transcription of polypeptide.Therefore, transformed host cells are cultured in phosphate-limited medium for induction.In certain embodiments, phosphate-limited medium is CRAP medium (see, for example, Simmons et al., J.Immunol.Methods(2002),263:133-147).As known in the art, various other inducers can also be used according to the vector construction used.
[0567] In one embodiment, the expressed masked cytokine of the present invention is secreted into the periplasm of the host cell and recovered from the periplasm of the host cell. Protein recovery typically involves disrupting the microorganism, generally by such means as osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris or whole cells can be removed by centrifugation or filtration. The protein can be further purified, for example, by affinity resin chromatography. Alternatively, the protein can be transported into the culture medium and isolated therein. The cells can be removed from the culture, and the culture supernatant can be filtered and concentrated for further purification of the produced protein. The expressed polypeptide can be further isolated and characterized using commonly known methods such as polyacrylamide gel electrophoresis (PAGE) and Western blot assay.
[0568] In one aspect of the present invention, masked cytokine production is carried out on a large scale by a fermentation process. A variety of large-scale fed-batch fermentation procedures are available for recombinant protein production. Large-scale fermentations have a volume of at least 1000 liters, and in certain embodiments, a volume of about 1,000 to 100,000 liters. These fermenters use agitator impellers to distribute oxygen and nutrients, particularly glucose. Small-scale fermentation generally refers to fermentation in fermentors with a volumetric capacity of about 100 liters or less, and can range from about 1 liter to about 100 liters.
[0569] In fermentation processes, induction of protein expression typically begins after cells have grown under suitable conditions to a desired density, approximately 180-220 OD550, at which point the cells are in early stationary phase. Various inducers are known in the art and may be used according to the vector construct used, as described above. Cells may be grown for a shorter period before induction. Cells are usually induced for approximately 12-50 hours, although longer or shorter induction times may be used.
[0570] Various fermentation conditions can be modified to improve the production yield and quality of the polypeptides of the present invention. For example, to improve the proper assembly and folding of secreted antibody polypeptides, prokaryotic host cells can be co-transformed with an additional vector overexpressing a chaperone protein, such as a Dsb protein (DsbA, DsbB, DsbC, DsbD, and / or DsbG) or FkpA (a peptidyl prolyl cis, trans-isomerase with chaperone activity). Chaperone proteins have been demonstrated to promote the proper folding and solubility of heterologous proteins produced in bacterial host cells. Chen et al. (1999) J. Biol. Chem. 274:19601-19605; Georgiou et ak, U.S. Patent No. 6,083,715, Georgiou et ak, U.S. Patent No. 6,027,888, Bothmann and Pluckthun (2000) J. Biol. Chem. 275:17100-17105; Ramm and Pluckthun (2000) J. Biol. Chem. 275:17106-17113; Arie et ak (2001) Mol. Microbiol. 39:199-210.
[0571] To minimize proteolysis of expressed heterologous proteins (especially proteolytically sensitive proteins), certain host strains deficient in proteolytic enzymes can be used in the present invention. For example, host cell strains can be modified to affect genetic mutations in genes encoding known bacterial proteases, such as protease III, OmpT, DegP, Tsp, protease I, protease Mi, protease V, protease VI, and combinations thereof. Several E. coli protease-deficient strains are available and are described, for example, in Joly et al. (1998), supra; Georgiou et al., U.S. Pat. No. 5,264,365; Georgiou et al., U.S. Pat. No. 5,508,192; and Kara et al., Microbial Drug Resistance, 2:63-72 (1996).
[0572] In some embodiments, E. coli strains that are deficient in proteolytic enzymes and transformed with a plasmid that overexpresses one or more chaperone proteins are used as host cells in the expression systems of the present invention.
[0573] c. Masked cytokine purification In some embodiments, the masked cytokines produced herein are further purified to obtain substantially homogeneous preparations for further assays and uses. Standard protein purification methods known in the art can be used. The following procedures are examples of suitable purification procedures: fractionation on an immunoaffinity or ion exchange column, ethanol precipitation, reverse-phase HPLC, chromatography on silica or on a cation exchange resin such as DEAE, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, and gel filtration using, for example, Sephadex G-75.
[0574] In some embodiments, Protein A immobilized on a solid phase is used for immunoaffinity purification of the masked cytokines of the present invention. Protein A is a 41 kD cell wall protein from Staphylococcus aureus that binds with high affinity to the Fc region of antibodies. Lindmark et al. (1983) J. Immunol. Meth. 62:1-13. The solid phase to which Protein A is immobilized can be a glass or silica surface, or a column, including a controlled pore glass column or a silicic acid column. In some applications, the column may be coated with a reagent such as glycerol to prevent nonspecific adhesion of contaminants.
[0575] As a first step in purification, the preparation from the cell culture described above can be applied to a Protein A-immobilized solid phase to allow specific binding of the masked cytokine of interest to Protein A. The solid phase is then washed to remove contaminants nonspecifically bound to the solid phase. Finally, the masked cytokine of interest is recovered from the solid phase by elution.
[0576] Other purification methods that provide high affinity binding to components of the masked cytokine can be used according to standard protein purification methods known in the art.
[0577] 2. Using eukaryotic host cells to produce masked cytokines Vectors for use in eukaryotic host cells generally include one or more of the following, but are not limited to, a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
[0578] a. Signal sequence component Vectors for use in eukaryotic host cells may also contain a signal sequence or other polypeptide with a specific cleavage site at the N-terminus of the mature protein or polypeptide of interest. The heterologous signal sequence selected may be one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. In mammalian cell expression, mammalian signal sequences as well as viral secretory leaders, such as the herpes simplex gD signal, are available.
[0579] The DNA for such precursor region is ligated in reading frame to DNA encoding the masked cytokine.
[0580] b. Origin of replication Generally, the origin of replication component is not needed for mammalian expression vectors. For example, the SV40 origin may typically be used only because it contains the early promoter.
[0581] c. Selective gene components Expression and cloning vectors may contain a selection gene, also referred to as a selection marker. Typical selection genes encode (a) a protein that confers resistance to antibiotics or other toxins, such as ampicillin, neomycin, methotrexate, or tetracycline, (b) a protein that complements an auxotrophic deficiency, if relevant, or (c) a protein that supplies a critical nutrient not available from complex media.
[0582] One example of a selection scheme utilizes drugs to arrest the growth of host cells. Those cells that are successfully transformed with the heterologous gene produce proteins that confer drug resistance and therefore survive the selection regimen. Examples of such dominant selection use the drugs neomycin, mycophenolic acid, and hygromycin.
[0583] Other examples of suitable selectable markers for mammalian cells are those that enable the identification of cells capable of producing masked cytokine encoding nucleic acids, such as DHFR, thymidine kinase, metallothionein-I and -II, primate metallothionein genes, adenosine deaminase, ornithine decarboxylase, and the like.
[0584] For example, in some embodiments, cells transformed with the DHFR selection gene are first identified by culturing all transformants in a culture medium containing methotrexate (Mtx), a competitive antagonist of DHFR. In some embodiments, when wild-type DHFR is used, a suitable host cell is a Chinese hamster ovary (CHO) cell line deficient in DHFR activity (e.g., ATCC CRL-9096).
[0585] Alternatively, host cells transformed or co-transformed with DNA sequences encoding a masked cytokine, wild-type DHFR protein, and another selectable marker, such as aminoglycoside 3'-phosphotransferase (APH), particularly wild-type hosts containing endogenous DHFR, can be selected by growing the cells in medium containing an aminoglycoside antibiotic, e.g., kanamycin, neomycin, or a selection agent for the selectable marker, such as G418. See U.S. Pat. No. 4,965,199. Host cells may also include NS0, including cell lines deficient in glutamine synthetase (GS). Methods for using GS as a selectable marker for mammalian cells are described in U.S. Pat. Nos. 5,122,464 and 5,891,693.
[0586] d. Promoter Components Expression and cloning vectors usually contain a promoter recognized by the host organism and operably linked to a nucleic acid encoding a masked cytokine of interest, which may be any of the masked cytokines described herein. Promoter sequences are known for eukaryotic organisms. For example, nearly all eukaryotic genes have an AT-rich region located approximately 25-30 bases upstream from the site where transcription begins. Another sequence found 70-80 bases upstream from the start of transcription of many genes is a CNCAAT region, where N can be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence, which may signal the addition of a polyA tail to the 3' end of the coding sequence. In certain embodiments, any or all of these sequences may be suitably inserted into a eukaryotic expression vector.
[0587] Transcription from vectors in mammalian host cells is controlled by promoters derived from the genomes of viruses such as polyoma virus, fowlpox virus, adenovirus (such as adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, retroviruses, hepatitis B virus, and simian virus 40 (SV40), from heterologous mammalian promoters, such as the actin promoter or immunoglobulin promoters, or heat shock promoters, provided that such promoters are compatible with the host cell system.
[0588] The early and late promoters of SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. The immediate early promoter of human cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment. A system for expressing DNA in mammalian hosts using bovine papillomavirus as a vector is disclosed in U.S. Pat. No. 4,419,446. A modification of this system is described in U.S. Pat. No. 4,601,978. See also Reyes et al., Nature 297:598-601 (1982), which describes the expression of human β-interferon cDNA in mouse cells under the control of the thymidine kinase promoter from herpes simplex virus. Alternatively, the Rous sarcoma virus long terminal repeat can be used as a promoter.
[0589] e. Enhancer Element Components Transcription of DNA encoding the masked cytokine of the present invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α-fetoprotein, and insulin). However, typically, one uses an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the human cytomegalovirus early promoter enhancer, the mouse cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, Nature 297:17-18 (1982), which describes enhancer elements for the activation of eukaryotic promoters. Enhancers can be
[0590] The masked cytokine coding sequence may be spliced into the vector at a position 5' or 3' to the promoter, but will generally be located at a site 5' from the promoter.
[0591] f. Transcription termination component Expression vectors used in eukaryotic host cells may also contain sequences necessary for the termination of transcription and stabilization of mRNA. Such sequences are commonly available from the 5' and, occasionally, 3' untranslated regions of eukaryotic or viral DNA or cDNA. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the masked cytokine. One useful transcription termination component is the bovine growth hormone polyadenylation region. See WO94 / 11026 and the expression vector disclosed therein.
[0592] g. Host Cell Selection and Transformation Suitable host cells for cloning or expressing the DNA in the vectors herein include the higher eukaryotic cells described herein, including vertebrate host cells. Propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines include monkey kidney CV1 transformed with SV40 (COS-7, ATCC CRL 1651); human embryonic kidney (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells / -DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL2); canine kidney cells (MDCK, ATCC CCL34); buffalo rat liver cells (BEL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary carcinoma tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals NY Acad. Sci. 383:44-68 (1982)); MRC5 cells; FS4 cells; and a human hepatoma line (Hep G2).
[0593] Host cells are transformed with the above-described expression or cloning vectors for masked cytokine production and cultured in conventional nutrient media modified as appropriate to induce promoters, select transformants, or amplify the genes encoding the desired sequences.
[0594] h. Host cell culture The host cells used to produce the masked cytokines of the present invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), minimal essential medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's modified Eagle's medium ((DMEM), Sigma) are suitable for culturing the host cells. Further, see Ham et al., Meth. Enz. 58:44 (1979); Barnes et al., Anal. Biochem. 102:255 (1980); U.S. Patent Nos. 4,767,704 and 4,657,866;
[0595] Any of the media described in US Pat. Nos. A, 921,162, 4,560,655, or 5,122,469, WO 90 / 03430, WO 87 / 00195, or U.S. Patent No. Re. 30,985 can be used as a culture medium for host cells. Any of these media may be supplemented, if necessary, with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as the drug GENTAMYCIN™), trace elements (usually defined as inorganic compounds present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other supplements may also be included at appropriate concentrations that would be known to those skilled in the art. Culture conditions, such as temperature and pH, will be those previously used with the host cell selected for expression and will be apparent to those of ordinary skill in the art.
[0596] i. Purification of masked cytokines When using recombinant technology, masked cytokines can be produced intracellularly or directly secreted into the culture medium. If the masked cytokine is produced intracellularly as a first step, particulate debris, either host cells or lysed fragments, can be removed, for example, by centrifugation or ultrafiltration. If the masked cytokine is secreted into the culture medium, the supernatant from such an expression system can first be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF can be included in any of the above steps to inhibit proteolysis, and antibiotics can be included to prevent the growth of adventitious contaminants.
[0597] Masked cytokine compositions prepared from cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being a convenient technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domains present in the masked cytokine, if any. Protein A can be used to purify antibodies based on human IgG1, IgG2, or IgG4 heavy chains (Lindmark et al., J. Immunol. Methods 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and human y3 (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached can be agarose, although other matrices are available. Mechanically stable matrices, such as controlled pore glass or poly(styrenedivinyl)benzene, allow for faster flow rates and shorter processing times than can be achieved with agarose. If the masked cytokine contains a CH3 domain, Bakerbond ABX™ resin (JT Baker, Phillipsburg, NJ) is useful for purification.
[0598] Other techniques for protein purification, such as fractionation on ion exchange columns, ethanol precipitation, reverse-phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™, chromatography on anion or cation exchange resins (such as polyaspartic acid columns), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation, are also available depending on the masked cytokine to be recovered.
[0599] Following any preliminary purification steps, the mixture containing the masked cytokine of interest and contaminants may be subjected to further purification, for example, by low pH hydrophobic interaction chromatography using an elution buffer at a pH of about 2.5 to 4.5, performed at a low salt concentration (e.g., about 0 to 0.25 M salt).
[0600] Generally, various methodologies for preparing masked cytokines for use in research, testing, and clinical use are well established in the art, consistent with those described above and / or as deemed appropriate by those skilled in the art for a particular masked cytokine of interest.
[0601] 5. Composition In some aspects, compositions comprising any of the masked cytokines described herein are also provided herein. In some embodiments, the composition comprises any of the exemplary embodiments of the masked cytokines described herein. In some embodiments, the composition comprises a dimer of any of the masked cytokines described herein. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a masked cytokine and further comprises one or more of the components described in detail below. For example, in some embodiments, the composition comprises one or more pharmaceutically acceptable carriers, excipients, stabilizers, buffers, preservatives, tonicity agents, non-ionic surfactants or detergents, or other therapeutic agents or active compounds, or combinations thereof. Various embodiments of compositions may be referred to herein as formulations.
[0602] Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired purity with any pharmaceutically acceptable carrier, excipient, or stabilizer (Remington: The Science and Practice of Pharmacy, 20th Ed., Lippincott Williams & Wiklins, Pub., Gennaro Ed., Philadelphia, Pa. 2000). Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed and include buffers; antioxidants including ascorbic acid, methionine, vitamin E, and sodium metabisulfite; preservatives, isotonicity agents, stabilizers, metal complexes (e.g., Zn-protein complexes); and chelating agents such as EDTA and / or nonionic surfactants.
[0603] Buffers can be used to adjust the pH within a range that optimizes therapeutic efficacy, particularly when stability is pH-dependent. Buffers can be present at concentrations ranging from about 50 mM to about 250 mM. Suitable buffers for use with the present invention include both organic and inorganic acids and their salts, such as citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, and acetate. Additionally, buffers may consist of histidine and trimethylamine salts, such as Tris.
[0604] Preservatives may be added to prevent microbial growth and are typically present in the range of about 0.2% to 1.0% (w / v). Examples of suitable preservatives commonly used with therapeutic agents include octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium halides (e.g., chloride, bromide, iodide), benzethonium chloride; thimerosal, phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol, 3-pentanol, m-cresol, o-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, ethanol, chlorobutanol, thiomerosal, bronopol, benzoic acid, imidurea, chlorhexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, and chlorphenesin (3p-chlorophenoxypropane-l,2-diol).
[0605] Isotonicity agents, sometimes known as "stabilizers," may be present to adjust or maintain the isotonicity of the liquid in the composition. When used with large charged biomolecules such as proteins and antibodies, they are often referred to as "stabilizers" because they can interact with the charged groups of amino acid side chains, thereby reducing the likelihood of intermolecular and intramolecular interactions.
[0606] The tonicity agent may be present in any amount from about 0.1% to about 25% by weight, or from about 1% to about 5% by weight, taking into account the relative amounts of other ingredients. In some embodiments, the tonicity agent includes polyhydric sugar alcohols, trihydric or higher hydric sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol.
[0607] Additional excipients include agents that can act as one or more of: (1) bulking agents, (2) solubility enhancers, (3) stabilizers, and (4) agents that prevent denaturation or adhesion to the container wall. Such excipients include polyhydric sugar alcohols (listed above); amino acids such as alanine, glycine, glutamine, asparagine, histidine, arginine, lysine, ornithine, leucine, 2-phenylalanine, glutamic acid, and threonine; organic sugars or sugar alcohols such as sucrose, lactose, lactitol, trehalose, stachyose, mannose, sorbose, xylose, ribose, ribitol, myo-inisitose, myo-inisitol, galactose, galactitol, glycerol, cyclitols (e.g., inositol), and polyethylene glycol. sulfur-containing reducing agents such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol, and sodium thiosulfate; low molecular weight proteins such as human serum albumin, bovine serum albumin, gelatin, or other immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides (e.g., xylose, mannose, fructose, glucose); disaccharides (e.g., lactose, maltose, sucrose); trisaccharides such as raffinose; and polysaccharides such as dextrin or dextran.
[0608] A non-ionic surfactant or detergent (also known as a "wetting agent") can be present to help solubilize the therapeutic agent and protect the therapeutic protein from agitation-induced aggregation, which also allows the formulation to be exposed to shear surface stresses without denaturing the active therapeutic protein or antibody. The non-ionic surfactant is present in a range of about 0.05 mg / ml to about 1.0 mg / ml, or about 0.07 mg / ml to about 0.2 mg / ml. In some embodiments, the non-ionic surfactant is present in a range of about 0.001% to about 0.1% w / v, or about 0.01% to about 0.1% w / v, or about 0.01% to about 0.025% w / v.
[0609] Suitable nonionic surfactants include polysorbates (e.g., 20, 40, 60, 65, 80), poloxamers (e.g., 184, 188), PLURONIC® polyols, TRITON®, polyoxyethylene sorbitan monoethers (e.g., TWEEN®-20, TWEEN®-80), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50, and 60, glycerol monostearate, sucrose fatty acid esters, methylcellulose, and carboxymethylcellulose. Anionic detergents that can be used include sodium lauryl sulfate, sodium dioctyl sulfosuccinate, and sodium dioctyl sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.
[0610] For the preparation to be used for in vivo administration, the preparation must be sterile.The preparation can be sterilized by filtration through a sterile filtration membrane.The therapeutic composition herein is generally placed into a container with a sterile access port, for example, an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle.
[0611] The route of administration will be in accordance with known and accepted methods, for example, by subcutaneous, intravenous, intraperitoneal, intramuscular, intraarterial, intralesional, or intraarticular route, topical administration, by inhalation, or by slow or sustained release means, in a suitable manner such as injection or infusion, as single or multiple boluses, or as infusion over an extended period of time.
[0612] Any of the masked cytokines described herein can be used alone or in combination with other therapeutic agents as in the methods described herein. The term "in combination with" encompasses two or more therapeutic agents (e.g., a masked cytokine and a therapeutic agent) in the same or separate formulations. In some embodiments, "in combination with" refers to "simultaneous" administration, where administration of a masked cytokine of the present invention occurs simultaneously with administration of one or more additional therapeutic agents (e.g., simultaneously with or within one hour between administration of the masked cytokine and administration of one or more additional therapeutic agents). In some embodiments, "in combination with" refers to sequential administration, where administration of a masked cytokine of the present invention occurs before and / or after administration of one or more additional therapeutic agents (e.g., more than one hour between administration of the masked cytokine and administration of one or more additional therapeutic agents). Agents contemplated herein include, but are not limited to, cytotoxic agents, cytokines, agents targeting immune checkpoint molecules, agents targeting immune stimulatory molecules, growth inhibitory agents, immunostimulatory agents, anti-inflammatory agents, or anti-cancer agents.
[0613] The formulations herein may also contain multiple active compounds as needed for the particular indication being treated, preferably with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may include a cytotoxic agent, a cytokine, an agent that targets an immune checkpoint or stimulatory molecule, a growth inhibitory agent, an immunostimulatory agent, an anti-inflammatory agent, or an anti-cancer agent. Such molecules are suitably present in combination in amounts effective for the intended purpose.
[0614] The formulations may be presented in any suitable form, such as a liquid formulation, a solid (lyophilized) formulation, or a frozen formulation, etc. Approaches for preparing each of these types of formulations for therapeutic use are well known in the art.
[0615] 6. Treatment method Provided herein are methods for treating or preventing disease in a subject, comprising administering to the subject an effective amount of any masked cytokine or composition thereof described herein. In some embodiments, provided are methods for treating or preventing disease in a subject, comprising administering to the subject any composition described herein. In some embodiments, the subject (e.g., a human patient) has been diagnosed with cancer or is at risk of developing such a disorder. In some embodiments, provided are methods for treating or preventing disease in a subject, comprising administering to the subject an effective amount of any masked cytokine or composition thereof described herein, wherein the masked cytokine is activated upon enzymatic cleavage. In some embodiments, the masked cytokine is activated in the tumor microenvironment. The masked cytokine is therapeutically active after cleavage. Thus, in some embodiments, the active agent is a cleavage product.
[0616] For the prevention or treatment of disease, the appropriate dosage of the active agent will depend on the type of disease being treated, as defined herein, the severity and course of the disease, whether the agent is being administered for prophylactic or therapeutic purposes, previous treatments, the subject's clinical history and response to the agent, and the discretion of the treating physician. The agent is suitably administered to the subject at one time or over a series of treatments.
[0617] In some embodiments, the protease that acts to cleave the proteolytically cleavable peptide is an MMP.
[0618] In some embodiments of the methods described herein, the interval between administrations of the masked cytokine is about one week or more. In some embodiments of the methods described herein, the interval between administrations of the masked cytokine described herein is about two days or more, about three days or more, about four days or more, about five days or more, or about six days or more. In some embodiments of the methods described herein, the interval between administrations of the masked cytokine described herein is about one week or more, about two weeks or more, about three weeks or more, or about four weeks or more. In some embodiments of the methods described herein, the interval between administrations of the masked cytokine described herein is about one month or more, about two months or more, or about three months or more. As used herein, the interval between administrations refers to the period between one administration of the masked cytokine and the next administration of the masked cytokine. As used herein, an interval of about one month includes four weeks. In some embodiments, the treatment includes multiple administrations of the masked cytokine, and the interval between administrations can vary. For example, in some embodiments, the interval between the first administration and the second administration is about one week, and the interval between subsequent administrations is about two weeks. In some embodiments, the interval between the first and second administration is about 2, 3, 4, or 5, or 6 days, and thereafter the interval between administrations is about 1 week.
[0619] In some embodiments, the masked cytokine is administered multiple times over a period of time. In some embodiments, the multiple doses administered to a subject may be the same for each administration, or in some embodiments, the masked cytokine may be administered to a subject in two or more different doses. For example, in some embodiments, the masked cytokine is initially administered one or more times in one dose, and then at a later time point, one or more times in two doses.
[0620] In some embodiments, the masked polypeptides described herein are administered in a fixed dose, hi some embodiments, the masked polypeptides described herein are administered to a subject in a dose of about 25 mg to about 500 mg per dose. In some embodiments, the masked polypeptide is administered to a subject at a dose of about 25 mg to about 50 mg, about 50 mg to about 75 mg, about 75 mg to about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, about 200 mg to about 225 mg, about 225 mg to about 250 mg, about 250 mg to about 275 mg, about 275 mg to about 300 mg, about 300 mg to about 325 mg, about 325 mg to about 350 mg, about 350 mg to about 375 mg, about 375 mg to about 400 mg, about 400 mg to about 425 mg, about 425 mg to about 450 mg, about 450 mg to about 475 mg, or about 475 mg to about 500 mg per dose.
[0621] In some embodiments, the masked polypeptides described herein are administered to a subject at a dosage based on the subject's body weight or body surface area (BSA). Depending on the type and severity of the disease, a masked polypeptide of about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg to 10 mg / kg) may be an initial candidate dosage for administration to a patient, whether by one or more separate administrations or by continuous infusion. A typical daily dosage may range from about 1 μg / kg to about 100 mg / kg or more, depending on the factors discussed above. For repeated administration over several days or longer, treatment would generally be maintained until a desired suppression of disease symptoms occurs, depending on the condition. An exemplary dosage of a masked polypeptide would be in the range of about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, about 2.0 mg / kg, about 4.0 mg / kg, or about 10 mg / kg (or any combination thereof) may be administered to a patient. In some embodiments, the masked polypeptides described herein are administered to a subject at a dose of about 0.1 mg / kg to about 10 mg / kg or about 1.0 mg / kg to about 10 mg / kg. In some embodiments, the masked polypeptides described herein are administered to a subject at any of the following doses: about 0.1 mg / kg, about 0.5 mg / kg, about 1.0 mg / kg, about 1.5 mg / kg, about 2.0 mg / kg, about 2.5 mg / kg, about 3.0 mg / kg, about 3.5 mg / kg, about 4.0 mg / kg, about 4.5 mg / kg, about 5.0 mg / kg, about 5.5 mg / kg, about 6.0 mg / kg, about 6.5 mg / kg, about 7.0 mg / kg, about 7.5 mg / kg, about 8.0 mg / kg, about 8.5 mg / kg, about 9.0 mg / kg, about 9.5 mg / kg, or about 10.0 mg / kg.In some embodiments, the masked polypeptides described herein have a concentration of about or at least about 0.1 mg / kg, about or at least about 0.5 mg / kg, about or at least about 1.0 mg / kg, about or at least about 1.5 mg / kg, about or at least about 2.0 mg / kg, about or at least about 2.5 mg / kg, about or at least about 3.0 mg / kg, about or at least about 3.5 mg / kg, about or at least about 4.0 mg / kg, about or at least about The subject is administered a dose of at least about 4.5 mg / kg, about or at least about 5.0 mg / kg, about or at least about 5.5 mg / kg, about or at least about 6.0 mg / kg, about or at least about 6.5 mg / kg, about or at least about 7.0 mg / kg, about or at least about 7.5 mg / kg, about or at least about 8.0 mg / kg, about or at least about 8.5 mg / kg, about or at least about 9.0 mg / kg, about or at least about 9.5 mg / kg, about or at least about 10.0 mg / kg, about or at least about 15.0 mg / kg, about or at least about 20 mg / kg, about or at least about 30 mg / kg, about or at least about 40 mg / kg, about or at least about 50 mg / kg, about or at least about 60 mg / kg, about or at least about 70 mg / kg, about or at least about 80 mg / kg, about or at least about 90 mg / kg, or about or at least about 100 mg / kg. Any of the above-mentioned dosing frequencies may be used.
[0622] Therapeutic methods contemplated herein are the treatment of disorders or diseases, such as cancer, with any of the masked cytokines or compositions described herein. Disorders or diseases treatable with the formulations of the present invention include leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, spleen cancer, melanoma, breast cancer, neuroblastoma, lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), or testicular cancer.
[0623] In some embodiments, provided herein are methods for treating or preventing cancer by administering any of the masked cytokines or compositions described herein. In some embodiments, provided herein are methods for treating or preventing cancer by administering any of the masked cytokines or compositions described herein in combination with an anti-cancer agent. The anti-cancer agent can be any agent that can reduce cancer growth, inhibit cancer cell replication, directly or indirectly kill cancer cells, reduce metastasis, reduce tumor blood supply, or reduce cell survival. In some embodiments, the anti-cancer agent is a PD-1 inhibitor, an EGFR inhibitor, a HER2 inhibitor, a VEGFR inhibitor, a CTLA-4 inhibitor, a BTLA inhibitor, a B7H4 inhibitor, a B7H3 inhibitor, a CSFIR inhibitor, an HVEM inhibitor, a CD27 inhibitor, a KIR inhibitor, an NKG2A inhibitor, an NKG2D agonist, a TWEAK inhibitor, an ALK inhibitor, a CD52-targeting antibody, a CCR4-targeting antibody, a PD-L1 inhibitor, a KIT inhibitor, a PDGFR inhibitor, a BAFF inhibitor, a HDL1 inhibitor, a PDGFR inhibitor, a BAFF inhibitor, a PD-L1 inhibitor, a PDGFR inhibitor, a BAFF inhibitor, a HDL1 ... AC inhibitor, VEGF ligand inhibitor, CD19 targeting molecule, FOFR1 targeting molecule, DFF3 targeting molecule, DKK1 targeting molecule, MUC1 targeting molecule, MUG16 targeting molecule, PSMA targeting molecule, MSFN targeting molecule child, NY-ES0-1 targeting molecule, B7H3 targeting molecule, B7H4 targeting molecule, BCMA targeting molecule, CD29 targeting molecule, CD151 targeting molecule, CD123 targeting molecule, CD33 targeting molecule, CD37 targeting molecule, CDH19 targeting molecule, CEA targeting molecule, claudin 18.2 targeting molecule, CFEC12A targeting molecule, EGFRVIII targeting molecule, EPCAM targeting molecule, EPHA2 targeting molecule, FCRH5 targeting molecule, FLT3 targeting molecule, GD2 targeting molecule, glypican 3 targeting molecule, gpA33 targeting molecule, GPRC5D targeting molecule, IL-23R targeting molecule, IL-1RAP targeting molecule, MCSP targeting molecule, RON targeting molecule, ROR1 targeting molecule, STEAP2 targeting molecule, TfR targeting molecule, CD166 targeting molecule, TPBG targeting molecule, TROP2 targeting molecule, proteasome inhibitor, ABE inhibitor, CD30 inhibitor, FLT3 inhibitor, MET inhibitor, RET inhibitor, IL-1β inhibitor, MEK inhibitor, ROS1 inhibitor, BRAE inhibitor, CD38 inhibitor, RANKE inhibitor, B4GALNT1 inhibitor, SLAMF7 inhibitor, IDH2 inhibitor, The inhibitor is selected from the group consisting of an mTOR inhibitor, a CD20-targeting antibody, a BTK inhibitor, a PI3K inhibitor, a FLT3 inhibitor, a PARP inhibitor, a CDK4 inhibitor, a CDK6 inhibitor, an EGFR inhibitor, a RAF inhibitor, a JAK1 inhibitor, a JAK2 inhibitor, a JAK3 inhibitor, an IL-6 inhibitor, an IL-17 inhibitor, a smoothened inhibitor, an IL-6R inhibitor, a BCL2 inhibitor, a PTCH inhibitor, a PIGF inhibitor, a TGFB inhibitor, a CD28 agonist, a CD3 agonist, a CD40 agonist, a GITR agonist, an OX40 agonist, a VISTA agonist, a CD137 agonist, a LAG3 inhibitor, a TIM3 inhibitor, a TIGIT inhibitor, and an IL-2R inhibitor.
[0624] In some embodiments, provided herein are methods for treating or preventing cancer by administering any of the masked cytokines described herein in combination with an anti-inflammatory agent. The anti-inflammatory agent can be any agent that can prevent, antagonize, inhibit, or otherwise reduce inflammation.
[0625] In some embodiments, the anti-inflammatory agent is a cyclooxygenase (COX) inhibitor. The COX inhibitor can be any agent that inhibits the activity of COX-1 and / or COX-2. In some embodiments, the COX inhibitor selectively inhibits COX-1 (i.e., the COX inhibitor inhibits the activity of COX-1 more than it inhibits the activity of COX-2). In some embodiments, the COX inhibitor selectively inhibits COX-2 (i.e., the COX inhibitor inhibits the activity of COX-2 more than it inhibits the activity of COX-1). In some embodiments, the COX inhibitor inhibits both COX-1 and COX-2.
[0626] In some embodiments, the COX inhibitor is a selective COX-1 inhibitor and is selected from the group consisting of SC-560, FR122047, P6, mofezolac, TFAP, flurbiprofen, and ketoprofen. In some embodiments, the COX inhibitor is a selective COX-2 inhibitor, and is selected from the group consisting of celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, chromene derivatives, chroman derivatives, N-(2-cyclohexyloxynitrophenyl)methanesulfonamide, parecoxib, lumiracoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, dalbuferon, CS-502, LAS-34475, LAS- 34555, S-33516, diclofenac, mefenamic acid, and SD-8381. In some embodiments, the COX inhibitor is selected from the group consisting of ibuprofen, naproxen, ketorolac, indomethacin, aspirin, naproxen, tolmetin, piroxicam, and meclofenamic acid.In some embodiments, the COX inhibitor is SC-560, FR122047, P6, mofezolac, TFAP, flurbiprofen, ketoprofen, celecoxib, rofecoxib, meloxicam, piroxicam, deracoxib, parecoxib, valdecoxib, etoricoxib, chromene derivatives, chroman derivatives, N-(2-cyclohexyloxynitrophenyl)methanesulfonamide, parecoxib, lumiracoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, dalbuferon, CS-502, LAS-34475, LAS-34555, S-33516, diclofenac, mefenamic acid, SD-8381, ibuprofen, naproxen, ketorolac, indomethacin, aspirin, naproxen, tolmetin, piroxicam, and meclofenamic acid.
[0627] In some embodiments, the anti-inflammatory agent is an NF-kB inhibitor.The NF-kB inhibitor can be any agent that inhibits the activity of the NF-kB pathway.In some embodiments, the NF-kB inhibitor is selected from the group consisting of an IKK complex inhibitor, an IkB degradation inhibitor, an NF-kB nuclear translocation inhibitor, a p65 acetylation inhibitor, an NF-kB DNA binding inhibitor, an NF-kB transactivation inhibitor, and a p53 induction inhibitor.
[0628] In some embodiments, the IKK complex inhibitor is selected from the group consisting of TPCA-1, NF-kB activation inhibitor VI (BOT-64), BMS-345541, amlexanox, SC-514 (GK-01140), IMD-0354, and IKK-16. In some embodiments, the IkB degradation inhibitor is selected from the group consisting of BAY-11-7082, MG-115, MG-132, lactacystin, epoxomicin, parthenolide, carfilzomib, and MLN-4924 (pevonedistat). In some embodiments, the NF-kB nuclear translocation inhibitor is selected from the group consisting of JSH-23 and rolipram. In some embodiments, the p65 acetylation inhibitor is selected from the group consisting of gallic acid and anacardic acid. In some embodiments, the NF-kB DNA binding inhibitor is selected from the group consisting of GYY-4137, p-XSC, CV-3988, and prostaglandin E2 (PGE2). In some embodiments, the NF-kB transactivation inhibitor is selected from the group consisting of LY-294002, wortmannin, and mesalamine. In some embodiments, the p53 induction inhibitor is selected from the group consisting of quinacrine and flavopiridol. In some embodiments, the NF-kB inhibitor is selected from the group consisting of TPCA-1, NF-kB activation inhibitor VI (BOT-64), BMS-345541, amlexanox, SC-514 (GK-01140), IMD-0354, IKK-16, BAY-11-7082, MG-115, MG-132, lactacystin, epoxomicin, parthenolide, carfilzomib, MLN-4924 (pevonedistat), JSH-23 rolipram, gallic acid, anacardic acid, GYY-4137, p-XSC, CV-3988, prostaglandin E2 (PGE2), LY-294002, wortmannin, mesalamine, quinacrine, and flavopiridol.
[0629] In some embodiments, provided herein are methods for treating or preventing cancer by administering any of the masked cytokines or compositions described herein in combination with an anti-cancer therapeutic protein. The anti-cancer therapeutic protein can be any therapeutic protein that can reduce cancer growth, inhibit cancer cell replication, directly or indirectly kill cancer cells, reduce metastasis, reduce tumor blood supply, or reduce cell survival. Exemplary anti-cancer therapeutic proteins can be in the form of an antibody or fragment thereof, an antibody derivative, a bispecific antibody, a chimeric antigen receptor (CAR) T cell, a fusion protein, or a bispecific T cell derivative (BiTE). In some embodiments, provided herein are methods for treating or preventing cancer by administering any of the masked cytokines or compositions described herein in combination with CAR-NK (natural killer) cells.
[0630] 7. Manufactured articles or kits In another aspect, an article of manufacture or kit is provided that includes any of the masked cytokines described herein. The article of manufacture or kit may further include instructions for using the cytokine in the methods of the invention. Thus, in certain embodiments, the article of manufacture or kit includes instructions for using the masked cytokine in a method for treating or preventing a disorder (e.g., cancer) in an individual, comprising administering an effective amount of the masked cytokine to the individual. For example, in certain embodiments, the article of manufacture or kit includes instructions for using the masked polypeptide in a method for treating or preventing a disorder (e.g., cancer) in an individual, comprising administering an effective amount of the masked polypeptide to the individual. In certain embodiments, the individual is human. In some embodiments, the individual has a disease selected from the group consisting of leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, spleen cancer, melanoma, breast cancer, neuroblastoma, lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer, or testicular cancer.
[0631] The article of manufacture or kit may further comprise a container. Suitable containers include, for example, bottles, vials (e.g., dual-chamber vials), syringes (such as single-chamber or dual-chamber syringes), test tubes, and intravenous (IV) bags. The container may be formed from a variety of materials, such as glass or plastic. The container holds the formulation. In some embodiments, the formulation is a lyophilized formulation. In some embodiments, the formulation is a frozen formulation. In some embodiments, the formulation is a liquid formulation.
[0632] The article of manufacture or kit may further include a label or package insert on or associated with the container, which may indicate instructions for reconstitution and / or use of the formulation. The label or package insert may further indicate that the formulation is useful or intended for subcutaneous, intravenous, or other administration for treating or preventing a disorder (e.g., cancer) in an individual. The container holding the formulation may be a single-use or multi-use vial, which allows for repeated administration of the reconstituted formulation. The article of manufacture or kit may further include a second container containing a suitable diluent. The article of manufacture or kit may further include other materials desirable from commercial, therapeutic, and user standpoints, including other buffers, diluents, filters, needles, syringes, and package inserts containing instructions for use.
[0633] In certain embodiments, the present invention provides a kit for single-dose administration units. Such kits include a container of an aqueous formulation of a therapeutic cytokine, and include both single- and multi-chamber pre-filled syringes. Exemplary pre-filled syringes are available from Vetter GmbH (Ravensburg, Germany).
[0634] The article of manufacture or kit herein optionally further comprises a container containing a second agent, wherein the masked cytokine is the first agent, and the article or kit further comprises instructions on a label or package insert for treating a subject with the second agent in an effective amount.
[0635] In another embodiment, provided herein is an article of manufacture or kit comprising the formulations described herein for administration in an automatic injector. Automatic injectors can be described as injection devices that, upon activation, deliver their contents without any additional action required from the patient or the administering person. They are particularly suitable for self-medication of therapeutic formulations when the delivery rate must be constant and the delivery time is longer than a few moments.
[0636] 8. Definition Unless otherwise defined, all technical terms, notations, and other technical and scientific or terminology used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some instances, terms having commonly understood meanings are defined herein for clarity and / or ready reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial departure from what is commonly understood in the art.
[0637] It is to be understood that this invention is not limited to particular compositions or biological systems, which can, of course, vary. Also, it is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.
[0638] As used herein, the term "about" refers to a normal range of error for the respective value, readily known to one of ordinary skill in the art. Reference herein to "about" a value or parameter includes (and describes) embodiments that are inherently directed to that value or parameter.
[0639] It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.
[0640] As used herein, the term "and / or" refers to any one of the items, any combination of the items, or all of the items with which the term is associated. For example, the phrase "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or B; A or C; B or C; A and B; A and C; B and C; A and B or C; B and A or C; C and A or B; A alone; B alone; and C alone.
[0641] The term "antibody" includes polyclonal antibodies, monoclonal antibodies (including full-length antibodies having an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules), and antibody fragments (e.g., Fab, F(ab'), and Fv). The term "immunoglobulin (Ig)" is used interchangeably with "antibody" herein.
[0642] The term "bispecific antibody" refers to a small antibody fragment having two antigen-binding sites comprising a heavy-chain variable (VH) domain connected to a light-chain variable (VL) domain in the same polypeptide chain (VH-VL).
[0643] The basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. IgM antibodies, along with an additional polypeptide called the J chain, consist of five basic heterotetrameric units and contain ten antigen-binding sites, whereas IgA antibodies consist of two to five basic four-chain units that can polymerize to form multivalent aggregates with the J chain. In the case of IgG, the four-chain unit is generally approximately 150,000 daltons. Each L chain is linked to an H chain by a single covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds, depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at the N-terminus, followed by three constant domains (CH) for each a- and y-chain, and four CH domains for the p- and s-isotypes. Each L chain has a variable domain (VL) at its N-terminus followed by a constant domain at its other end. The VL aligns with the VH, and the CL aligns with the first constant domain of the heavy chain (CHI). Certain amino acid residues are thought to form an interface between the light and heavy chain variable domains. The pairing of VH and VL together forms a single antigen-binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology, 8th Edition, Daniel P. Sties, Abba I. Terr and Tristram G. Parsolw (eds), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.
[0644] Light chains from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequence of their constant domains. Depending on the amino acid sequence of their heavy chain constant domains (CH), i...
Claims
1. A polypeptide drug construct comprising: (i) a therapeutic moiety; (ii) a carrier moiety; and (iii) a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS or DLLAVVAAS.
2. The proteolytically cleavable peptide (CP) has the formula: As shown in FIG. 1, the ribosome is flanked on both sides by spacer domains (SD1 and SD2), Optionally, a) the proteolytically cleavable peptide linker is 9 to 25 amino acids in length; b) said spacer domain is rich in the amino acid residues G, S and P, and further optionally said spacer domain comprises only amino acid residue types selected from the group consisting of G, S and P; c) the first spacer domain (SD1) is 3 to 6 amino acids in length; d) the second spacer domain (SD2) is 3 to 6 amino acids in length; and / or e) the second spacer domain (SD2) has the amino acid sequence SGP; The polypeptide drug construct of claim 1.
3. the proteolytically cleavable peptide linker a) directly covalently attached to said therapeutic moiety; and / or b) located within the polypeptide drug construct between the therapeutic moiety and the carrier moiety, or located within the carrier moiety; A polypeptide drug construct according to claim 1 or 2.
4. The polypeptide drug construct of any one of claims 1 to 3, wherein the polypeptide drug construct comprises two or more polypeptide chains and the proteolytically cleavable peptide linker is present in the same or different polypeptide chains as the therapeutic moiety.
5. The polypeptide drug construct of any one of claims 1 to 4, further comprising a masking moiety, said masking moiety being present on the same or a different polypeptide chain as said therapeutic moiety.
6. The polypeptide drug construct of any one of claims 1 to 5, wherein said polypeptide drug construct comprises a half-life extending moiety, optionally said half-life extending moiety comprises an antibody or a fragment thereof.
7. The polypeptide drug construct comprising a masked cytokine, a) a first polypeptide chain comprising a masking moiety linked to a first half-life extending moiety via a first linker; b) a second polypeptide chain comprising the cytokine portion linked to a second half-life extending moiety via a second linker; said first half-life extending moiety is associated with said second half-life extending moiety; at least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS or DLLAVVAAS; Optionally, the first polypeptide chain comprises: Including, The second polypeptide chain Including, wherein HL1 is the first half-life prolonging domain, L1 is the first linker, MM is the masking moiety, HL2 is the second half-life prolonging domain, L2 is the second linker, and C is the cytokine moiety; said first half-life extending moiety is associated with said second half-life extending moiety; At least the first linker or the second linker is a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS or DLLAVVAAS; A polypeptide drug construct according to any one of claims 1 to 6.
8. A polypeptide drug construct comprising: a) Formula: and a polypeptide chain comprising a masked cytokine, wherein HL is the half-life prolonging domain, L1 is the first linker, MM is the masking moiety, L2 is the second linker, and C is the cytokine moiety, wherein at least the first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence ISSGLLSGRS or DLLAVVAAS, and optionally the second linker is a non-cleavable linker; or b) Formula: and a polypeptide chain comprising a masked cytokine, wherein HL is a half-life prolonging domain, L1 is said first linker, MM is said masking moiety, L2 is a second linker, and C is said cytokine portion thereof, wherein at least said first linker comprises a proteolytically cleavable peptide linker comprising a proteolytically cleavable peptide (CP) consisting of the amino acid sequence DLLAVVAAS or ISSGLLSGRS, and optionally said second linker is a non-cleavable linker; The polypeptide drug construct according to any one of claims 1 to 7,
9. The polypeptide drug construct of claim 7 or 8, wherein the cytokine portion comprises an IL-12, IL-2, or IL-15 cytokine or a fragment thereof.
10. A cleavage product comprising an active therapeutic moiety, preparable by proteolytic cleavage of the proteolytically cleavable linker in the polypeptide drug construct of any one of claims 1 to 9.
11. A nucleic acid encoding a polypeptide drug construct according to any one of claims 1 to 9 or a cleavage product according to claim 10.
12. 12. A vector or host cell comprising the nucleic acid of claim 11, optionally wherein the host cell is a HEK cell or a CHO cell.
13. A pharmaceutical composition comprising a polypeptide drug construct according to any one of claims 1 to 9 or a cleavage product according to claim 10 and a pharma- ceutically acceptable carrier, optionally wherein said pharmaceutical composition is liquid and in a single unit dosage form.
14. A medicament comprising a polypeptide drug construct according to any one of claims 1 to 9, or a cleavage product according to claim 10, or a pharmaceutical composition according to claim 13.
15. A pharmaceutical for treating or preventing cancer, comprising a polypeptide drug construct described in any one of claims 1 to 9, or a cleavage product described in claim 10, or a pharmaceutical composition described in claim 13, optionally wherein the cancer is a solid tumor.
